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1  Introduction 
INTRODUCTION 
 
1. Cholesterol 
 
1.1 Cholesterol structure 
 
Cholesterol (Chol) was 
discovered  in 1815 by the French 
chemist M.E. Chevreul  (Figure 1a) but 
its structure was determined only in 
1932 by Heinrich Wieland (figure 1b).  
The molecule consists of three main 
functional elements (figure 2): 
I. The steroid ring 
II. The hydrophilic 3β-
hydroxyl group 
III. The hydrocarbon 
chain 
Any modification of these 
structural elements decreases 
effects of cholesterol on lipid 
bilayers.  
I. The steroid ring: 
Cholesterol steroid ring 
system consist in four rings 
of which three have six 
carbons and one has five. 
These rings are trans 
connected and create a flat 
and rigid structure which 
characterizes cholesterol and 
most of its analogues. Two 
Figure 1: a) M.E. Chevreul  the French chemist that discovered
cholesterol in 1815 picture from Vance and Bosch 2000 b) Heinrich
Wieland Nobel Prize 1927 picture from Vaupel 2007  
Figure 2: Cholesterol molecule: chemical structure with numbering of carbon 
atoms and rings (labeled A, B, C, and D). Image from Róg et al. 2009 
Figure 3 Cholesterol CPK representation, the smooth α-face and rough β-face 
are labeled. Image from Róg  et al 2009. 
a 
a
a
b 
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methyl substituents, C18 and C19, are attached at positions 10 and 13, in relative cis orientations. 
Due to the above, the cholesterol ring system is asymmetric: one side is flat  without any 
substituents, while the other is rough characterized by the presence of the two methyl substituents. 
The flat face of cholesterol is called the α-face, and all substituents located on this face (in trans 
conformation relative to C19) are called α, while the substituents located on the rough β-face (in cis 
conformation relative to C19) are called β (figure 3). In cholesterol there is only one double bond 
between C5 and C6 in ring B, in other sterols the number and positions of the double bonds vary to 
some extent. 
II. The hydrophilic 3β-hydroxyl group: 
The only additional group in cholesterol molecule is the polar 3β-hydroxyl group, while in other 
sterols there are many possible α and β substituents. Due to the presence of this hydroxyl group 
cholesterol is a steroid alcohol. 
III. The hydrocarbon chain: 
The hydrocarbon chain is composed by 8 C molecule and is attached to the steroid ring at the 
position 17. 
[1-3] 
 
1.2 Double origin of cholesterol: 
 
Human Chol concentration mainly depends on de novo endogenous biosynthesis and on 
dietary intake, with a ratio estimated as ~70:30. 
Such as fatty acid (FA), cholesterol is a primary component of cellular membranes. Cells, 
according to their growth demand, need to synthesize both cholesterol and FA. Chol biosynthetic 
pathway is linked to synthesis of bile acids and steroid hormones in liver and endocrine organs 
respectively.  
The synthesis for fatty acids and triglycerides (TG), lipogenesis, is an energy storage system 
specialized to lipogenic organs such as liver and adipose tissues. In contrast to cholesterol synthesis, 
which is tightly regulated by a feedback system to maintain cellular cholesterol levels, fatty acid 
synthesis is driven primarily by the availability of carbohydrates and the actions of hormones such 
as insulin. Both pathways are nutritionally controlled at the transcriptional level.  
[4, 5] 
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1.2.1 Cholesterol adsorption by the diet. 
 
Cholesterol dietary intake is not a complete adsorption, but only the 40–60% is assimilated. 
Most of the cholesterol mass escape intestinal absorption, is degraded to coprostanol through 
reduction of the double bond at C:5 by colonic bacteria, and is excreted in feces. 
Early lipid digestion, from the oral cavity to the duodenum sub-layer of the intestine, 
produce crude emulsions consisting of free 
cholesterol, triglycerides, free fatty acids, and 
phospholipids. Ones in the intestine these 
emulsions are mixed with bile salt micelles 
emulsified triglycerides and cholesteryl esters; 
then they are hydrolyzed by pancreatic lipase 
(PL) and carboxyl ester lipase respectively. It is 
important to note that only non-esterified 
cholesterol can be incorporated into bile acid 
micelles and absorbed by enterocytes. Most 
dietary cholesterol exists in the form of the free 
sterol, with only 10–15% existing as the 
cholesteryl ester (Chol-E). The latter must be 
hydrolyzed by cholesterol esterase to release free-
Chol for absorption. So micelle acts as carrier and 
solubilizer for cholesterol, assisting in 
overcoming the resistance of the unstirred water 
layer adjacent to the brush border of enterocytes, 
and maintaining a high concentration gradient for 
the passage of cholesterol into the aqueous phase, 
from which uptake occurs into the cellular 
membrane. In particular uptake is facilitated by 
the NPC1L1 (Niemann–Pick C1-like-1) protein 
located at the apical membrane of enterocytes. 
Once dissociated from mixed micelles at the 
aqueous phase, and by virtue of their insolubility, 
cholesterol monomers are taken up by intestinal 
cells at a slower rate than that of the more soluble 
Figure 4: Micellar solubilization of dietary sterols by
bile acids allows them to move through the diffusion
barrier overlying the luminal surface of enterocytes. The
NPC1L1 (Niemann–Pick C1-like-1) protein (dark red) is
located at the apical membrane of enterocytes and
facilitates the uptake of cholesterol across the brush
border membrane. This is blocked by the cholesterol
absorption inhibitor ezetimibe. Acyl CoA cholesterol
acyltransferase isoform-2 (ACAT2) esterifies the
absorbed cholesterol, which becomes incorporated into
nascent chylomicron particles. How the absorbed
cholesterol reaches ACAT2 is not known. Chylomicrons
are synthesized around the APOB48 apoprotein in the
endoplasmic reticulum (ER). Dietary fatty acids are used
for triglyceride synthesis in the smooth ER and MTP
(microsomal triglyceride transfer protein) transfers
triglycerides and cholesteryl esters to APOB48. The
nascent chylomicrons leave the ER in COPII-coated
vesicles, are secreted through the Golgi complex to the
basolateral side of the enterocyte, and reach the venous
circulation through lymphatic vessels. Image from
Ikonen Nature 2008. 
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protonated fatty acids. This explains in part the inefficiency of intestinal cholesterol absorption 
(figure 4).  
Once inside enterocytes, dietary cholesterol is packaged into chylomicrons (CM) and placed 
into circulation. This process starts with the esterification of large amounts of free cholesterol by the 
acylCoA-cholesterol acyltransferase isoform-2 (ACAT2). In the endoplasmic reticulum (ER), 
cholesteryl esters, phospholipids and triglycerides are amalgamated together with ApoB-48 by the 
microsomal triglyceride transfer protein (MTP). The action of MTP1 is not localized to enterocytes, 
or even to chylomicron synthesis (§2.1), instead it is nearly ubiquitously expressed and a crucial 
element of very low density lipoprotein (VLDL) synthesis(§2.1). As well as nascent chylomicron 
synthesis nears completion, the particles are transported to the Golgi apparatus where additional 
triglycerides are recruited, and then the particles are transported via vesicular structures to clatherin-
coated pits and exocytosed.  
Apolipoprotein B (ApoB) is the major protein component of all lipoproteins except high 
density lipoprotein (HDL). During chylomicron synthesis in the intestine, ApoB mRNA sequence is 
altered by (APOBEC1)2 (apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 protein), 
so that the 6666th nucleotide is changed from a cytosine to a uracil . This unique process leads to a 
premature UAA stop codon and production of a truncated ApoB peptide only 48% the length of full 
ApoB. Considering that ApoB is a direct measurement of potentially atherogenic particles, the 
ApoB levels in circulation are considered a more appropriate trait to measure risk of cardiovascular 
disease than low density lipoprotein (LDL). However LDL level remains more clinically utilized.  
While the digestion and packaging of dietary lipids into chylomicrons takes about one hour, 
lipids half-life in chylomicrons is only 4.5 minutes. Upon exiting enterocytes, the only protein 
component of chylomicrons is ApoB-48. After passage through the thoracic duct and into the 
bloodstream, nascent chylomicrons accept ApoC2 and ApoE from HDL, a process that yields 
mature chylomicrons. As mature chylomicrons circulate, the newly acquired ApoC2 on the particle 
surface activates lipoprotein lipase (LPL), which is bound to epithelial surfaces of capillaries in 
adipose and muscle tissue, where it is differentially expressed according to fed/fasting conditions. 
Into chylomicrons, LPL3 catalyzes the hydrolysis of triglycerides, a crucial process that distributes 
fatty acids to tissues, generates non-esterified FA in plasma, and remodels chylomicrons into 
                                                            
1 Inactivating mutations in MTP result in abetalipoproteinemia, in which chylomicrons and VLDL are not synthesized, 
ApoB containing particles in general are absent, and lipids accumulate in the intestine. 
2 APOBEC1 inactivated mice demonstrate a complete lack of ApoB-48, 178% more ApoB-100, and decreased HDL 
cholesterol. Mutations in the ApoB gene itself are an important source of phenotypic variation in humans. In a recent 
review, 132 genetic variants in the ApoB gene are listed including one in the promoter region, one in the 5’ untranslated 
region, 85 in the coding region (22 synonymous), 44 in the various introns, and one in the 3’ UTR. Notably, genotypes 
of the very common T2488T and E4154K mutations have crucial implications to LDL homeostasis. 
3 The absence of LPL causes familial LPL deficiency, which is characterized by hypertriglyceridemia, decreased HDL 
and LDL, and massive accumulation of chylomicrons in plasma. 
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chylomicrons remnant (CRs). As CM shed triglycerides to epithelial cells, ApoC2 is lost (ApoE is 
retained). As a result, CR loses further lipase activation.  
As CRs lose TG, they become enriched in ApoE and consequently are destined for the liver. 
ApoE peptides are essential for particle uptake into hepatocytes, as demonstrated by ApoE  
inactivated mice, which demonstrate tiny CR clearance. The model for hepatic clearance involves 
ApoE interaction with hepatocytes cell surface molecules followed by an endocytosis step mediated 
by a complex of low density lipoprotein receptor (LDLR) and the low density lipoprotein related 1 
protein (LRP1). Another factor influencing CR uptake is cholesterol content of the macromolecule. 
Chylomicron-like particles, created without cholesterol, undergo triglyceride hydrolysis by LPL but 
are not taken up by hepatocytes. This result has been interpreted as a failure of ApoE to attain the 
necessary conformation to achieve receptor binding with LRP1. After delivery to the liver, CR 
lipids are hydrolyzed once again into free fatty acids and free cholesterol for eventual synthesis of 
VLDL.  
[4-7] 
 
1.2.2 Cholesterol biosynthesis  
 
Cholesterol biosynthesis could be divided in 4 step. The first one take place with two acetyl 
coenzyme A (Ac-CoA) molecules condensation and finish with the mevalonate generation. The 
second part is the activated isoprenoid production. The third reaction set consist in squalene 
assembly and the last one generate cholesterol molecule by squalene cyclization. 
I. Mevalonate generation 
The first part of cholesterol biosynthesis (Figure 5)  take place in cell cytoplasm and 
reactions starts when two acetyl-CoA molecules are condensed to acetoacetyl-CoA by a thiolase 
(Acetyl-CoA C-acetyltransferase). The acetoacetyl-CoA is further combined by 
hydroxymethylglutaryl-CoA synthase  with a third acetyl-CoA to form the six carbon (C6) 
Figure 5: From Acetyl-Coa to mevalonate. The first step of cholesterol biosynthesis 
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intermediate beta-hydroxy-beta-methylglutaryl-CoA (HMG-CoA). HMG-CoA synthase is the 
principal regulatory enzyme for the isoprenoids biosynthesis. 
HMG-CoA4 is transported to the endoplasmatic reticulum membranes where is reduced to 
mevalonate (C6 ) by HMG-CoA reductase using 2 molecules of NADPH as reductant. Mevalonate 
is the immediate sterol synthesis precursor leading to the formation of the cholesterol ring structure, 
and HMG-CoA reductase is the key limiting enzyme of cholesterol production.  
 
II. Activated isoprenoid generation 
In this second reaction set, mevalonate is decarboxylated to form the C5 intermediate 
isoprene or isopentenyl pyrophosphate (figure 6). Isoprene is a key intermediate for different 
pathways including biosynthesis and degradation of glycoproteins and synthesis of coenzyme Q 
(ubiquinone), vitamin K and carotenoids.  
Three reaction requiring ATP idrolisis occours in sequence: At first mevalonate (C6) 
generates 5-phospho-mevalonate (C6) through mevalonate kinase enzyme action. Then the enzyme 
phosphomevalonate chinase generates 5-pyrophospho-mevalonate (C6). The decarboxilase enzyme 
pyrophospho-mevalonate decarboxylase, using ATP and discarting CO2 and Pi, generates 
isopentenylpyrophosphate (C5), that could be isomerizated in dimetihylallyl-pyrophosphate (C5). 
This two structure are in equilibrium one with the oter. 
 
 
 
 
 
 
 
                                                            
4 HMG-CoA could be also employed in mitochondria as cheton precursor 
Figure 6: The generation of isoprene. From mevalonate to dimetihylallyl-pyrophosphate reaction set. 
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III. Squalene generation 
This third reaction set begins with C5 molecule that condensates to generate in sequences 
C10, C15 and C30 molecule (figure 7). The two C5 molecules: isopentenyl-pyrophosphate and its 
isomer dimetihylallyl-pyrophosphate condensate to generate geranyl-pyrophosphate (C10). A 
subsequent condensation occours between the geranyl-pyrophosphate and a second molecule of 
isopentenyl-pyrophosphate to produce farnesyl-pyrophosphate (C15). The riductive condensation of 
two farnesyl-pyrophosphate molecules generate Squalene (C30). 
 
 
IV. Squalene  cyclization and cholesterol production 
The last reaction set requires molecular oxygen (O2) and takes place to cyclizate squalene, 
generating cholesterol. Only the main step of this complex pathway are schematically shown in 
figure 8.  
Squalene is first oxidized by a squalene monooxygenase to squalene 2,3-epoxide, which 
undergoes cyclization catalysed by the enzyme squalene epoxide lanosterol-cyclase to form the first 
steroidal intermediate, lanosterol (C30). In this reaction there is a succession of concerted 1,2-
methyl group and hydride shifts along the chain of the squalene molecule to bring about the 
formation of the four rings. This reaction takes place in the endoplasmic reticulum, but a cytosolic 
protein, sterol carrier protein 1, in the presence of the cofactors phosphatidylserine and flavin 
adenine dinucleotide (FAD), is required to bind squalene in an appropriate orientation. Finally, 
lanosterol is converted to cholesterol (C27) by multiple reactions that involve the removal of three 
Figure 7: Condensation reactions that produce squalene from isopentenyl-pyrophosphate and dimetihylallyl-pyrophosphate. 
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methyl groups, hydrogenation of the double bond in the side-chain, and a shift of the double bond 
from position 8,9 to 5,6 in ring B. A second cytosolic protein, sterol carrier protein 2, is required to 
bind 7-dehydrocholesterol, one of the intermediates of the process [8]. 
 
 
 
 
 
Figure 8: Main intermediates of squalene ciclyzation pathway that leads to cholesterol production. 
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2. Cholesterol transport 
 
2.1 The cholesterol transporters.  
 
Lipoproteins are aggregates of lipids and proteins, synthesized mainly in the liver and 
intestines, that allow lipids transport trough the aqueous environment of body fluids. Within the 
circulation, these aggregates are in a state of constant flux, changing in composition and physical 
structure as the peripheral tissues take up the various components before the remnants return to the 
liver. The most abundant lipid constituents are triacylglycerols, free cholesterol, cholesterol esters 
and phospholipids (phosphatidylcholine and sphingomyelin especially). Fat-soluble vitamins and 
anti-oxidants are also transported in this way.  
Ideally lipoproteins should be classified via different apolipoproteins contents, as these 
determine the overall structures, metabolism and the interactions with receptor molecules in liver 
and peripheral tissues. However, the practical methods that have been used to segregate different 
lipoprotein classes, based on the relative densities of the aggregates on ultracentrifugation, have 
determined the nomenclature. Thus, the main groups are classified as chylomicrons (CM), very-
low-density lipoproteins (VLDL), low-density lipoproteins (LDL) and high-density lipoproteins 
(HDL). However, these classes can be further refined by improved separation procedures, and 
intermediate-density lipoproteins (IDL) and subdivisions of the HDL (e.g. HDL1, HDL2, HDL3 and 
so forth) are often defined. Density is determined largely by the relative concentrations of 
triacylglycerols and proteins and by the diameters of the broadly spherical particles, which vary 
from about 6000Å in CM to 100Å or less in the smallest HDL.  
 
I. Chylomicrons 
Before having CM, prechylomicrons biosynthesis is needed. This process take place in the 
ER lumen and then lipoprotein molecules move along the secretory pathway to the Golgi. 
Prechylomicrons ER egress is defined as the rate-limiting step in their overall secretion from the 
enterocytes. Because of their very large size (average diameter 250 nm) how prechylomicrons 
traverse the ER and Golgi membranes is unclear. Prechylomicrons are processed into mature CM in 
the Golgi and then transported to the basolateral membrane via a separate vesicular system for 
exocytosis into the intestinal lamina propria. Fatty acids and monoacylglycerols entering the 
enterocyte via the basolateral membrane are also incorporated into triacylglycerol, but the 
basolaterally entering lipid is much more likely to enter the triacylglycerol storage pool than the 
lipid entering via the apical membrane (figure 9). 
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II. LDL/VLDL 
Hepatic VLDL are lipid emulsion particles composed of a triglyceride-rich core and a 
surface monolayer of phospholipid. They transport 
endogenously synthesized lipids, particularly 
cholesteryl esters and triglyceride, from the liver to 
peripheral tissues. Their assemblage is a process 
consisting in two steps: first, during its translocation 
across the ER membrane, nascent apolipoprotein 
B100 (apoB) associates with lipids provided by 
microsomal triglyceride transfer protein. This results 
in the formation of incompletely lipidated 
“primordial” pre-VLDL particles. In the second step, 
additional lipid (primarily triglyceride) and other 
apolipoproteins (e.g. apoE) are added, resulting in the 
formation of mature, fully lipidated VLDL particles.  
The circulating VLDL particles become 
progressively smaller as their core is removed by 
lipolysis and surface materials are transferred to 
HDL. In healthy individuals, most of the VLDL is 
converted to smaller LDL particles through an 
intermediary lipoprotein known as intermediate 
density lipoprotein (IDL). This has a density of 1006-
1019 g/L, and possesses Apo E (which in the latter 
respect is similar to chylomicron remnants).  
Low density lipoproteins (figure 10) are the main cholesterol carriers in the human 
circulation, and are thus key players in its transfer and metabolism. They have an average diameter 
of 22 nm, the core consisting of about 170 triglyceride and 1600 cholesteryl ester and the surface 
monolayer comprising about 700 phospholipid molecules and a single copy of apoB-100. In 
addition, the particles contain about 600 molecules of unesterified cholesterol (UC), of which about 
one-third is located in the core and two-thirds in the surface. It should also be noted that a few 
percent of the TG and CE molecules penetrate toward the surface. The main phospholipid 
components are phosphatidylcholine (PC) (about 450 molecules/LDL particle) and sphingomyelin 
(SM) (about 185 molecules/LDL particle). The LDL particles also contain lysophosphatidylcholine 
Figure 9: Intracellular prechylomicron transport.
The assembly of prechylomicrons occurs in the
lumen of ER. They are packaged into specialized
vesicles known as prechylomicron transport
vesicles (PCTVs) that bud off the ER membrane
and move to and fuse with the cis-Golgi, delivering
their prechylomicron cargo to the Golgi lumen.
Nascent proteins are transported from the ER to the
Golgi in coat protein complex II (COPII) vesicles.
PCTVs bud from the ER membrane in the absence
of COPII proteins, whereas the protein vesicles
require the COPII machinery for their budding.
After processing in the Golgi, mature chylomicrons
are transported to the basolateral membrane via a
separate vesicular system. Image from Mansbach et
al. 2010 
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(lyso-PC) (about 80 molecules/LDL particle), 
phosphatidylethanolamine (PE) (about 10 
molecules/LDL particle), diacylglycerol 
(DAG) (about 7 molecules/LDL particle), 
ceramide (CER) (about 2 molecules/LDL 
particle), and some phosphatidylinositol (PI) . 
In addition to lipids, LDL particles also carry 
lipophilic vitamins and antioxidants, such as α-
tocopherol (about 6 molecules/LDL particle) 
and minute amounts of γ-tocopherol, 
carotenoids, oxycarotenoids and ubiquinol-10. 
The particles are in a dynamic state, their 
structure and physical properties being 
dependent on their lipid composition as well as 
on the conformation of apoB-100. 
The endocytic uptake of lipoproteins 
such as low-density lipoprotein represents the 
major source of cholesterol in not-
steroidogenic cells (see 2.2) 
A characteristic phenomenon of early 
atherogenesis is extracellular accumulation of 
LDL-derived lipids in the form of small lipid droplets and vesicles, which can lead to the 
development of atherosclerotic lesions in the arterial intima. Modifications in the structure of native 
LDL, that are capable of inducing aggregation and/or fusion of the particles, are currently 
recognized to be a prerequisite for the initiation of lipid accumulation.  
ApoB-100 is the major protein component of very low, intermediate, and low density 
lipoproteins. These particles are linked in a delipidation cascade in which triglyceride-rich VLDL, 
released from the liver, is converted to cholesterol-rich LDL which is in turn catabolized by specific 
cell-membrane receptors throughout the body. Abnormalities in the metabolism of apoB-containing 
lipoproteins are responsible for the generation of hyperlipidemia and the associated increased risk 
of developing coronary heart disease.  
 
 
 
Figure 10: Schematic molecular model of an LDL particle.
The depicted particle has a diameter of 20 nm, including a
surface monolayer of 2 nm (yellowish background), and an
average composition of 20% protein, 20% phospholipids,
40% CEs, 10% UC, and 5% TGs. The molecular components
of the particle are drawn in both the correct percentages and
size ratios. Note the different domains illustrated at the
particle surface and the interpenetration of core and surface
lipids. The individual molecules were built using Cerius2
software (MSI Molecular Simulations Inc.). The chain
compositions are illustrated as follows: SM (16:0); PC
(16:0/18:2Δ9,12); TG (16:0/18:2Δ9,12/14:0); CE (18:2Δ9,12).
Image from Hevonoja et al. 2000. 
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III. HDL 
High density lipoproteins are a 
heterogeneous group of particles whose principal 
physiological role is that of reverse cholesterol 
transport, but they also exert important anti-
inflammatory and antithrombotic effects. They can 
be classified according to their chemical and 
physical characteristics, including hydrated density 
(1.063–1.210 kg/l), flotation rate (0–9 Svedbergs), 
diameter (7–12 nm), and electrophoretic mobility.   
Small particles of discoid shape, named pre-
HDL, are synthesized in liver and small intestine, or result from hydrolysis of triglyceride-rich 
particles. These pre-HDL uptake cholesterol from peripheral cells, and their shape change to 
spherical particles, named HDL3 then HDL2. The transformation of HDL3 into HDL2 is related to 
their enrichment in esterified cholesterol (via an esterifying enzyme, lecithin cholesterol-acyl-
transferase (LCAT) associated with pre-HDL particles) and phospholipids. The final uptake of 
HDL2 by the liver involves a selective receptor, named scavenger receptor B1 (SR-B1) (figure 
11)[9-17]. 
 
2.2 Cholesterol endocytosis 
 
Endocytic uptake of lipoproteins such as low-density lipoprotein, and hydrolysis of their 
cholesterol esters in late endosomes and lysosomes (figure 12), represents a fundamental source of 
cell cholesterol.  
LDL bind LDL receptors (LDLR) on cell surface and the complex is internalized via clathrin-
coated pits5. These vesicles enter the clathrin-mediated endocytic pathway, drop their coats and fuse 
with early endosomes. The lower pH in early endosomes promotes dissociation of LDL from 
LDLR. The LDLR and other recycling proteins localize to early endosomal tubular extensions, 
which bud off of vesicles that fuse with the endocytic recycling compartment (ERC). They recycle 
back to the PM after approximately 10 minutes to be reutilized for many more rounds of LDL 
delivery. Eventually, the LDLRs enter the late endosomes en route to being degraded in the 
lysosomes. Some amount of early endosomal membrane free cholesterol, from both LDL and 
endocytosed PM, may also sort to the ERC via the same vesicles that carry recycling proteins.  
                                                            
5 The coated pits are composed of clathrin and other accessory proteins. The complex is build to invaginate, pinch off 
from the PM, and form coated vesicles. 
Figure 11:  Schematic illustration of reverse
cholesterol transport. Image from Fredenrich et al
2003 
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Cholesterol seems also traffics in the opposite direction from PM to ERC in non-vesicular, 
rapid and ATP-independent manner (figure 12 and 13). 
Hydrolysis of LDL-chol esters to free cholesterol is widely thought to occur in late 
endosomes and lysosomes, but the acid lipase enzyme was recently localized to an earlier acidic 
compartment, so LDL cholesterol ester-derived free cholesterol may be generated soon after 
endocytosis..  
The non-recycled contents of early endosomes proceed to late endosomes, by a process 
perhaps involving vesicular transport or the evolution of early to late endosomes. Late endosomes 
deliver the endocytosed materials to the trans-Golgi network (TGN) en route to the PMs. Late 
endosomes also receive various hydrolases and other protein components from the TGN, in this 
manner undergo successive maturation processes and become lysosomes. The materials not 
Figure 12: Intracellular cholesterol transport: LDL (yellow circles) carrying cholesterol and cholesterol esters
bound to LDL receptors (light blue Y-shape) is internalized and transported to sorting endosomes and to late
endosomes and lysosomes from which cholesterol can efflux to cellular compartments including the plasma
membrane or the endoplasmic reticulum (ER). The LDL receptor recycles to the plasma membrane via the
endocytic recycling compartment (ERC). Efflux from late endosomes and lysosomes is poorly characterized
as indicated by the dashed lines. Cholesterol can move from the plasma membrane to the ERC by a non-
vesicular, ATPindependent process. Recycling of cholesterol back to the plasma membrane occurs by
nonvesicular transport and in membrane-recycling vesicles carrying other recycling membrane components.
Newly synthesized cholesterol in the ER is mostly transported from the ER directly to the plasma membrane,
bypassing the Golgi, but some follows the biosynthetic secretory pathway from the ER to the Golgi. Excess
cholesterol in the ER becomes esterified by ACAT and stored in cytoplasmic lipid droplets. TGN, trans-Golgi
network. Picture from Maxfield and Tabas 2005. 
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retrieved/sorted in the endosomes end up in the lysosomes for degradation. It is unclear where 
cholesterol normally leaves the endosomal pathway and how it effluxes and redistributes to other 
sites. Studies of Niemann-Pick disease type C (NPC), an inherited lysosomal storage disorder that 
leads to accumulation of cholesterol and other lipids, have shown that a luminal protein (NPC2) and 
a transmembrane protein (NPC1) in late endosomes are required for efflux of cholesterol from these 
organelles, but the details of how these proteins work remain to be determined. In normal non-NPC 
cells, LDL-derived cholesterol leave late endosomes to reach other compartments like ER and PM. 
LDL-Chol also arrives at the endoplasmic reticulum and becomes available for esterification  by the 
resident ER enzyme acyl-coenzyme A: cholesterol acyltransferase (ACAT). 
Cholesterol that move to ER seem to use almost two pathways: the major one involves the PM 
as an intermediate and it has been divided into 2 steps:  
I. From the proximal endosome to PM  
II. From the distal PM to ER 
Figure 13: The plasma membranes (PMs) contain the highest concentration of cholesterol (yellow circles). The
cholesterol-sensing membrane proteins are located in the ER:HMG-CoA reductase (HMGR), SREBP cleavage–
activating protein (SCAP), and acyl-coenzyme A cholesterol acyltransferase 1 (ACAT1); or in the late
endosomes Niemann-Pick type C1 (NPC1). The translocation of cholesterol between various compartments may
involve both vesicular and non-vesicular mechanisms. The dotted lines represent cholesterol trafficking steps that
are not well documented. Figure abbreviations : AL, acid lipase; CEH, cholesteryl ester hydrolase; EE, early
endosome; ERC, endocytic recycling compartment; LE, late endosome; NPC2, Niemann-Pick type C2; SREBP,
sterol-regulatory element–binding protein; TGN, trans-Golgi network. Image from Chang et al. 2006 
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Time-course studies in CHO cells show that it takes approximately 30 min for the LDL-CHOL to 
become available for efflux at the PM, but it takes approximately 60 min to 90 min before it 
becomes esterified at the ER (Cruz & Chang 2000, Sugii et al. 2003). Thus, LDL-CHOL may first 
arrive at the PM before it moves back to the ER. Alternatively, LDL-CHOL may move to the PM 
and ER by two separate transport mechanisms. 
 
2.3 Intracellular cholesterol transport 
 
Cholesterol that is synthesized in the ER need to be delivered to other compartments. The 
transport take place through a combination of vesicular and non-vesicular transport processes: 
 
I. Vesicular transport 
Cholesterol is present in the membranes of intracellular vesicles that shuttle among 
compartments. This kind of transfer typically requires an intact cytoskeleton, the tracks along which 
vesicles move, and ATP, providing energy for motor proteins. 
 
II. Non-vesicular transport  
This mechanisms is only partially understood but it seems to be the major way for cholesterol 
movement between organelles. Since cholesterol is extremely insoluble in water, it must be shuttled 
by diffusible carrier proteins, which have hydrophobic cavities to bind cholesterol and transport it 
across the aqueous cytosol. The best-documented example is the steroidogenic acute regulatory 
protein (StAR), which is the prototype for the StAR-related lipid transfer (START) family of 
transport proteins. This protein is essential for the delivery of cholesterol to mitochondria, where it 
is used in steroid hormone synthesis. Other members of this family can bind cholesterol or other 
lipids and facilitate their intracellular, non-vesicular transport.  
Another form of non-vesicular transport may involve spontaneous desorption of cholesterol 
from one membrane and diffusion to another closely juxtaposed membrane, perhaps brought 
together at contact sites by specialized proteins. 
The ER is the primary site of cholesterol synthesis but it is a cholesterol-poor organelle. 65% to 
80% of total cellular cholesterol is in plasmatic membrane (PM), whereas only 0.1% to 2% is in ER. 
So, Chol leaving ER to rich PM moves against concentration gradient. Vesicular transport along the 
protein secretory pathway through the Golgi is one route from ER to PM but it is not the major 
pathway. Sites of close physical membrane apposition between ER and PM could facilitate this 
transport. Once biosynthesized, most of the endo-CHOL is rapidly (10–20 minutes ) transported to 
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the cholesterol-rich, sphingolipid-rich domains (i.e., lipid rafts/caveolae) of the PM by an energy 
dependent non-vescicular trafficking process (figure 13). The molecular nature of this process is not 
well understood and some data support roles for SCP-2 and caveolin. Studies have identified two 
distinct cytosolic complexes of caveolin-1 and various chaperone proteins, one containing nascent 
cholesterol and another cholesterol esters. It has been proposed that these caveolin-cholesterol-
chaperone complexes represent novel intracellular lipid particles analogous to plasma lipoproteins. 
Excess cellular cholesterol from other compartments returns to the ER for esterification. PM 
cholesterol is thought to follow at least 2 paths to the ER (figure 13):  
1) vesicular route via endosomes and/or Golgi; 
2) non-vesicular alternative route.  
However involved mechanism are not well understood 
 
The principal steroidogenic organs in the body are the gonads, adrenal glands and the brain. 
De novo synthesis of steroid hormones from cholesterol is catalyzed by the cholesterol side-chain 
cleavage enzyme P450, which resides in the inner mitochondrial membrane. For this reason it is 
significant the mitochondrial capitation of cellular cholesterol in this tissue. In general mitochondria 
are considered cholesterol-poor organelles and outer mitochondrial membrane contains more 
cholesterol than the inner6. The steroidogenic acute regulatory element, a protein with a cholesterol-
binding pocket, acts on the mitochondrial outer membrane to facilitate cholesterol transfer to the 
inner membrane (non vescicular transport). It is estimated that 400 molecules of cholesterol per 
minute are transferred into the mitochondria by each molecule of newly synthesized StAR. The 
transfer activity requires a conformational change in StAR. Spectroscopic and simulation studies 
suggest that the protein undergoes a molten globule transition in which the tertiary structure is 
altered and the secondary structure is preserved to open the sterol-binding pocket. However, 
according to other simulations, less distorting changes in protein conformation may be sufficient for 
cholesterol uptake and release. 
                                                            
6 Two important cholesterol-metabolizing P450 enzymes reside on the matrix side of the inner mitochondrial 
membrane: 
I. The P450 side chain cleavage system (P450scc/Cyp11A1) 
II. The sterol 27-hydroxylase (Cyp27) 
both are expressed only in steroid hormone-producing cells. P450scc converts cholesterol to pregnenolone, which is 
modified by other enzymes to generate steroid hormones. The widely expressed Cyp27 converts cholesterol to 27-
hydroxycholesterol, the most abundant oxysterol in plasma. This important oxysterol serves at least 4 functions 
I. first intermediate in the alternative pathway of bile acid synthesis from cholesterol 
II. a more soluble transport form of cholesterol in plasma 
III. a potent repressor of SREBP processing 
IV. a partial LXR agonist  
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Other proteins with StAR-related lipid-transfer domains that lack evident targeting sequences, 
such as STARD4, may be responsible for cytoplasmic delivery of cholesterol to the outer 
mitochondrial membrane. The peripheral benzodiazepine receptor (PBR) is an outer mitochondrial 
membrane protein that is also involved in the mitochondrial import of cholesterol for 
steroidogenesis. Increasing evidence points to a functional interaction between PBR and StAR. One 
possibility is that the cholesterol recognition domain of PBR contains a reservoir of labile 
cholesterol that StAR can mobilize for steroidogenesis. Recently, additional proteins that participate 
in the formation of a signalling complex were identified. In addition to PBR, this complex includes 
the PBR-associated protein PAP7, PKARIα (the PAP7-binding regulatory subunit of cyclic-AMP-
dependent protein kinase) and StAR81. It was proposed that this complex forms a scaffold in the 
outer mitochondrial membrane and mediates the effects of hormones through cAMP on 
mitochondrial cholesterol transport [5, 18-22]. 
 
2.4 Cellular cholesterol efflux 
 
Peripheral tissues cells can store but not degrade cholesterol, that need to be transported to the 
liver for reutilization and excretion.  
High-density lipoproteins (§2.1) are the main acceptors for cholesterol released from the extra-
hepatic cells. Mature HDLs transport CEs to the liver, the adrenals and other steroidogenic tissues. 
On surface of the liver cells and steroidogenic cells HDL are recognized by the HDL receptor: 
scavenger receptor type B class I. This receptor is also important for cholesterol efflux in the vessel 
wall, and it mediates uptake of CE by a selective  process.  
Once in the liver the HDL-derived cholesterol serves as an important precursor for bile acid 
synthesis. It can enter the bile duct to be excreted from the body. In steroidogenic tissues, the HDL-
derived cholesterol is utilized for hormone synthesis.  
For this retrograde transport of CHOL excess, HDL is recognized as an antiatherogenic 
lipoprotein. Raising plasma HDL is a potential therapeutic goal for treating atherosclerotic 
cardiovascular disease. 
Cellular cholesterol effluxes occur by two distinct mechanisms: 
 
I. Passive diffusion: driven by the cholesterol gradient between the cell surface and the 
HDLs in contact with the cell surface 
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II. Apolipoprotein-mediated pathway (figure 14). It consists in the production of the disk-
like nascent HDL particles, using mainly the lipid-poor apoA-I (synthesized mainly in 
the liver), phospholipids and cholesterol (both donated from peripheral tissues cells) as 
substrates. The ABC protein ABCA1, located mainly in the PMs of various peripheral 
cells, plays an essential role in this process. Tangier Disease, a rare disease that lead to 
familial HDL deficiency, is caused by defective mutations within the coding regions of 
the Abca1 gene. How ABCA1 mediates cholesterol efflux is under intense investigation. 
Cellular ABCA1 gene expression is mainly controlled by transcription and by protein 
degradation. For transcriptional control, the liver X receptors (LXRs) bind to oxidized 
derivatives of cholesterol called oxysterols and forms heterodimers with the retinoid X 
receptors, which use 9-cis retinoic acid as natural ligand. The heterodimeric complex 
Figure 14:  Summarizing scheme for cholesterol efflux. Cellular cholesterol efflux mediated by
ABCA1 and ABCG1 and the dynamic relationship between the cholesterol pools for efflux and for
esterification by acyl-coenzyme A:cholesterol acyltransferase 1 (ACAT1) within the cells of the
peripheral tissues. ABCA1 facilitates apolipoprotein-mediated cholesterol and phospholipid efflux to
generate nascent, disk-like high-density lipoprotein (HDL). Lecithin:cholesterol acyltransferase
(LCAT), an enzyme present in the plasma, then uses phospholipids and cholesterol in the nascent HDL
to esterify cholesterol and to produce mature, globular-shaped HDL. Mature HDL removes cholesterol
from cells, facilitated by ABCG1. ABCA1 is widely distributed in various tissues. ABCG1 is highly
expressed in macrophages. Other abbreviations used in figure: apoA-I, apolipoprotein A-I; CE,
cholesteryl ester; CEH, cholesteryl ester hydrolase; CHOL, cholesterol; PL, phospholipid; SR-BI,
scavenger receptor type B class I. Picture fromChang et al. 2006 
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then becomes active in stimulating expression of the Abca1 gene  as well as of several 
other genes involved in cellular sterol efflux. Protein degradation regulation consist in 
ABCA1 binding with apolipoproteins that, in intact cells, stabilizes ABCA1 against 
degradation. The removal of cellular cholesterol by apoA-I mobilizes certain 
intracellular cholesterol pools and causes a decrease in ACAT1 activity. Conversely, 
blocking ACAT activity with ACAT inhibitors expands the cellular cholesterol pool 
available for apoA-I-mediated cholesterol efflux. In macrophages, in addition to 
ABCA1, another ABC transporter called ABCG1 mediates cellular cholesterol efflux to 
mature HDL by passive diffusion. This results in a huge reduction in cellular cholesterol. 
[20, 23] 
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3. Regulation of cholesterol homeostasis. 
 
  Later in 1950s and 1960s it was 
well established that dietary cholesterol 
inhibits its biosynthesis and in the 1970s it 
was shown that this regulation was 
primarily due to the inhibition of the rate 
limiting step in the pathway catalyzed by 
HMGCoA reductase. Various mechanisms 
by which this occurs have been reviewed.  
In the last quarter of the 20th century, 
Michael Brown and Joseph Goldstein (figure 
15), working on hypercholesterolemia, elucidated the regulation of cholesterol biosynthesis and 
discovered the low density lipoprotein (LDL) receptor. For this work, in 1985 this two researcher 
were awarded the Nobel Prize in Physiology and Medicine. Once Brown and Goldstein had 
discovered the LDL receptor pathway, they addressed the mechanism by which cholesterol 
suppressed the expression of the genes encoding HMG-CoA reductase and the LDL receptor. Their 
work led to the discovery of the sterol regulatory element in the proximal promoter of these genes. 
Sterol regulatory element binding protein (SREBP) was subsequently found to bind to this element 
and promotes the expression of these and other genes involved in cholesterol and fatty acid 
biosynthesis.   
Further research showed that cholesterol interacts with a protein on the endoplasmic reticulum 
and Golgi named SREBP  cleavage activating protein (SCAP), which in turn governs the activity of 
a protease that cleaves a precursor of SREBP. When cholesterol levels are adequate, the protease is 
not activated and therefore SREBP is not released and does not migrate to the nucleus. As a result, 
expression of the genes for HMG-CoA reductase and LDL receptor is not induced. When 
cholesterol levels are insufficient, the SREBP precursor is cleaved, SREBP migrates to the nucleus 
and the expression of these genes is promoted. Thus, cholesterol levels in a cell are sensed by the 
SCAP-SREBP pathway to feedback regulate the biosynthesis of cholesterol (§3.2). 
[2, 24, 25] 
 
 
 
 
Figure 15:  a) Michael S. Brown . b) Joseph L. Goldstein the 
Nobel Prize in Physiology and Medicine
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3.1 The SREBP family: structure and functions 
SREBPs are basic-helix-loop-helix-leucine zipper (bHLHLZ) transcription factors 
synthetized as 1150 amino acid (AA) inactive precursors bound to the membranes of the 
endoplasmic reticulum. Both amino and carboxyl terminal project into the cytoplasm. 
Each SREBP precursor is organized into three domains: 
1. NH2-terminal domain ~ 480 AA that contains: 
a. the transactivation domain, a region rich in serine and proline  
b. the bHLH-LZ region for DNA binding and dimerization. This region contains the 
nuclear localization signal, which binds directly to importin (figure16), allowing 
the transport of nSREBPs into the nucleus. 
2. two hydrophobic transmembrane spanning segments interrupted by a short loop of about 30 
AA that projects into the lumen of the ER 
3. COOH-terminal segment regulatory domain ~ 590 AA 
Figure 16: A schematic drawing of the 19 heat 
repeats of importin-b and the SREBP-2 HLHZ 
dimer. The importin-b molecule has a twofold 
symmetric arrangement of heat repeats 5 to 19, 
with heat repeat 12 in the center. In the 
importin-b molecule, the characteristic four 
long helices (heat repeats 7, 11, 13, and 17) are 
present. Major interactions occur between heat 
repeats 7 and 17 of importin-b and helix 2 of 
SREBP-2 (black). Importin-b uses the 
characteristic long helices 7 and 17 as a pair of 
chopsticks to pick up SREBP-2. Image 
modified from et Lee al 2003. 
 
Three members of the SREBP family have been described in several mammalian species: 
SREBP-1a and 1c produced from a single gene (srebf-1) located on human chromosome 17p11.2  
and SREBP-2 from a separate gene (srebf-2) located on human chromosome 22q13. SREBP1 and 
SREBP2 share ~47% sequence identity  (figure 17).  
SREBP-1a and 1c transcripts are produced through the use of alternative transcription start sites 
and differ in their first exon (exon 1a and exon 1c). The other exons are common to both isoforms. 
In humans, alternative splicing in the 3′ end has also been described (exon 18a and 19a or exon 18c 
and 19c). SREBP-1a is a more potent transcriptional activator than SREBP-1c due to its longer 
NH2-terminal transactivation domain. However, SREBP-1c is the predominant isoform expressed in 
most of the tissues of mice and humans, with especially high levels in the liver, white adipose tissue 
(WAT), skeletal muscle, adrenal gland and brain. In contrast, SREBP-1a is highly expressed in cell 
lines and tissues with a high capacity for cell proliferation, such as spleen and intestine  
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Experimental data from mouse liver demonstrated that over-expression of: 
• SREBP-1a  markedly increases the expression of genes involved in cholesterol synthesis 
(HMG-CoA synthase and reductase, squalene synthase) and in FA synthesis (acetyl-CoA 
carboxylase (ACC), fatty acid synthase (FAS) and stearoyl-CoA desaturase-1 (SCD-1).  
• SREBP-1c isoform causes a selective induction of lipogenic genes, with no effect on genes 
of cholesterol synthesis. 
• SREBP-2 isoform (figure 18) results in a preferential induction of genes involved in 
cholesterol biosynthesis, although a moderate induction of genes involved in FA synthesis 
is also observed.  
The observed selectivity of the SREBP isoforms for cholesterogenic and/or lipogenic genes is 
at least partly due to their different affinities for the various consensus sequences in the target gene 
(Amemiya-kudo et al).  
The active form of the transcription factors is the amino terminal portion of the protein. 
SREBPs must be proteolytically cleaved to release the NH2-terminal segment that can enter the 
nucleus [26-33]. 
 
 
Figure 18: Domain structure of human SREBP-2. Ser Gly Pro, serine-glycine-proline rich domain; bHLH Zip, basic helix-
loop-helix leucine zipper domain (transcriptionally active domain); TM 1, first transmembrane domain; TM 2, second
transmembrane domain.Immage from Muller et al 2001 
Figure 17: (a) Schematic illustrations of the
membrane-associated (top) and nuclear
(bottom) forms of SREBPs. The nuclear
forms are generated by cleavage of the
precursor forms in response to cholesterol
depletion. There are three SREBP proteins:
SREBP1a, SREBP1c and SREBP2. The
amino acid numbers refer to human
SREBP1a. Transcriptional co-activators that
interact with the N-terminal trans-activation
domains of nuclear SREBPs are indicated.
(b) SREBP1a and SREBP1c originate from a
single gene and only differ in the length of
their N-terminal trans-activation domains,
which makes SREBP1a a stronger activator.
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3.2 SREBP activation mechanism 
 
Four proteins required for SREBP processing have been delineated (figure 19):  
 
I. SREBP cleavage–activating protein (SCAP): 
SCAP is a 1276 amino acid polytopic membrane protein that is both an escort for SREBPs and a 
sensor of sterols.  It is required for movement of SREBPs from ER to Golgi.  The NH2-terminal 
domain of SCAP consists of 730 amino acids organized into eight membranespanning segments. 
Within this segment, there are three N-linked oligosaccharide chains attached to the lumenal loops. 
The COOH-terminal cytoplasmic domain consists of 546 amino acids and includes five copies of a 
WD repeat (tryptophan–aspartate repeat), which represents a protein–protein interaction motif 
required for SCAP  binding to the COOH-terminal domain of SREBP. SCAP/SREBP trafficking is 
regulated by cholesterol. 
 
II. Insulin-induced gene (INSIG) 
Two INSIG isoforms, designated 
INSIG1 and INSIG2, are known. Both 
the isoforms are expressed in most 
tissues, with especially high expression 
in the liver. Insigs are almost 
exclusively localized to the ER 
irrespective of sterol levels, suggesting 
that there might be an additional ER 
protein associated with them. Analysis 
of the Insig-1 sequence predicts a 
hydrophobic protein with multiple 
membrane-associated domains. 
Immunofluorescence data show that 
epitope-tagged Insig-1 is located in the 
ER membrane in both the presence and 
the absence of sterols. The two human 
INSIG proteins are 59% identical and both bind SREBP cleavage-activating protein in a sterol-de-
pendent fashion. The major differences between these two proteins relate to the regulation of their 
expression. Thus, INSIG1 is itself an obligatory SREBP target gene, whereas INSIG2 is expressed 
Figure 19: Domain Structures of Membrane Proteins that Regulate 
CholesterolAmino acid numbers refer to human proteins. Vertical 
bars denote transmembrane domains identified by hydropathy plots 
and verified by topology mapping (see text for references). SSD 
denotes sterol-sensing domain. Pro in Site-1 protease denotes 
propeptide sequence. The catalytic triad in Site-1 protease is the 
hallmark of a serine protease. The HExxH motif in Site-2 protease 
is the hallmark of a Zn2+ metalloprotease. Picture modified from 
Goldstein et al 2005 
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at a low but constitutive level, at least in cultured cells, and is not regulated by SREBPs.  Yabe et al. 
[34]  reported the existence of a liver-specific transcript of Insig2 in rodents, designated Insig2a, 
which differs from the ubiquitous transcript, called Insig2b, in the noncoding first exons that splice 
into a common second exon through the use of different promoters. Although both transcripts 
encode identical proteins, they differ in terms of regulation patterns.  
 
III. Site-1 protease (S1P)  
S1P is a 1,052-amino-acid serine protease, also known as subtilisin/kexin isozyme-1, SKI-1 (figure 
20). It is anchored to the membrane by a single membrane-spanning helix, the bulk of the protease 
faces the lumen of the ER. The carboxy terminus is a short stretch of basic amino acids that face the 
cytoplasm, which makes S1P a type-1 membrane protein. S1P is synthesized as a proenzyme that 
undergoes autocatalytic cleavage of its prosegment to yield the active enzyme. 
 
IV. Site-2 protease (S2P) 
S2P, one of the most hydrophobic protease known (figure 20), contains an HEXXH zinc-binding 
motif, which is characteristic of the active site of many families of metalloproteinases. The unusual 
location of this motif within an otherwise hydrophobic region of the protein might be due to the 
nature of its substrates, as hydrophobic membrane-spanning helices are thought to lie within the 
plane of the lipid bilayer. S2P is sufficiently different from all other metalloproteinases to be 
included in its own family, M50, which consists of at least 68 proteins found in bacteria, archaea, 
plants and animals. S2P was identified using human genomic DNA to complement mutant cells that 
were unable to cleave SREBPs at site-2. Moreover a distal aspartate residue, Asp467, is believed to 
provide an additional coordinating ligand for the active-site metal atom. It is found in the sequence 
LDG that is highly conserved among homologues of S2P. 
Figure 20: S1P is a subtilisin-like serine protease and the 
Asp-Ser-His (DSH) residues of the catalytic triad are 
necessary for S1P function32. S2P is an exceptionally 
hydrophobic metalloproteinase containing an HEXXH 
active-site motif in an otherwise hydrophobic portion of the 
protein (where H is histidine, E is glutamate and X can be 
any amino acid). Both histidine residues and the glutamate 
residue of the active site (indicated in bold) are necessary 
for S2P function43, as is a distal aspartate residue (D; bold), 
found within the LDG motif. This residue, which also lies 
within a hydrophobic portion of the protein, is believed to 
provide an additional ligand for the active-site metal 
atom47. N, amino-terminal. Picture modified from Rawson 
et al. 2003 
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Newly synthesized SREBP is inserted into the ER membranes, where its COOH-terminal 
regulatory domain binds the COOH-terminal domain of SCAP (figure 21). Integral-membrane 
proteins insulin induced Insig have been identified as ER proteins that bind SCAP and cause ER 
retention of the SCAP/SREBP complex when a certain amount of sterols is present. Cholesterol 
addition to the ER membranes causes a conformational change in the cytoplasmic loop between the 
sixth and seventh membrane-spanning segments of SCAP. The amount of cholesterol required to 
produce this conformational change is reduced in the presence of Insig proteins, thus facilitating the 
retention of SCAP/SREBP complexes in the ER. Sterol-insensitive SCAP mutants do not undergo 
this sterol-induced conformational change. As demonstrated by Goldstein in 2002 [35], SCAPs with 
Figure 21: Model for the sterol regulation of SREBP trafficking and proteolysis. SCAP contains a ~170 amino 
acid putative sterol-sensing domain (helices 2–6). SCAP forms a tight complex with SREBP via the C-terminal 
domains of both proteins, consisting of five WD repeats in SCAP and the regulatory domain of SREBP. In the 
presence of high concentrations of cholesterol in the ER, SCAP undergoes a conformational change. This 
increases the affinity of SCAP for Insig-1 and -2. The Insig/SCAP/SREBP complex is thus retained in the ER. 
Excess cellular cholesterol also leads to the production of oxysterols, which increases SREBP-1a gene 
expression, yielding oleic acid for formation of cholesteryl esters. This provides a feed-forward mechanism to 
prevent the production or uptake of unesterified cholesterol. In the absence of cholesterol, the affinity of SCAP 
for Insig-1 is decreased. This allows the SCAP/SREBP complex to interact with the COPII proteins Sec23/24 and 
move into the transitional ER, eventually budding into COPII-coated vesicles for transport to the Golgi. In the 
Golgi, the SREBP undergoes two sequential proteolytic cleavages from the Golgi-resident S1P and S2P 
proteases. These cleavages are required for release of the transcriptionally active NH2 fragment, which can then 
enter the nucleus and regulate the transcription of a variety of sterol response genes. Insig-1 is itself regulated by 
SREBP and it can bind to SCAP under high protein concentrations independent of the cholesterol-dependent 
conformation of SCAP. Thus, under cholesterol-depleted conditions, there exists a feedback mechanism to 
prevent the overaccumulation of cholesterol. Picture from McPherson and Gauthier (2004) 
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point mutations at any positions within the cholesterol-sensing domain cannot bind Insig proteins. 
This fact facilitate SREBP processing also in the presence of elevated sterol levels. 
The mechanism that Insigs play in the retention of SCAP/SREBP complexes is still not fully 
understood. It is possible that the binding of Insigs to SCAP in the presence of sterols, when SCAP 
conformation is changed, simply prevents the binding of the COPII proteins Sec23/24 and the 
formation of SCAP/SREBP-containing COPII vesicles. This implies that the binding of Sec23/24 is 
itself not regulated by the conformation of SCAP, and this is supported by evidence that over-
expression of SCAP results in SREBP processing irrespective of sterol concentration. Additionally, 
Insig-1 has been shown to enhance the degradation of HMG-CoA reductase when sterol levels are 
high by binding to its sterol-sensing domain. This suggests a dual role for Insigs in the 
SCAP/SREBP pathway and in the regulation of cholesterol metabolism. 
When cholesterol level drops down it is sensed by SCAP sterol sensor domain. The complex 
leaves the ER and moves to the Golgi apparatus membranes, where the two proteases S1P and S2P 
reside. Cleavage takes place in two steps: at first S1P cleaves the SREBP in the luminal loop 
between its two membrane-spanning segments, dividing the SREBP molecule in half. This cleavage 
allows a second protease S2P to clip the proteins at site 2 in the middle of the first membrane-
spanning segment, and the NH2-terminal bHLHZip domain is released from the membrane. The 
NH2-terminal domain, designated nuclear SREBP (nSREBP), translocates to the nucleus, where it 
activates transcription by binding to non-palindromic sterol response elements (SREs) in the 
promoter/enhancer regions of multiple target genes [35-39]. 
 
3.3 Regulation of SREBP genes 
 
SREBPs regulation occurs not only in posttranscriptional manner (S1P and S2P cleavage) 
but also transcriptionally.  In this way SREBP-1c and SREBP-2 are subject to distinct forms of 
regulation, whereas SREBP-1a appears to be constitutively expressed at low levels in liver and most 
other tissues of adult animals.  
One mechanism of regulation shared by SREBP-1c and SREBP-2 involves a feed-forward 
regulation mediated by SREs present in the enhancer/promoters of each gene. Through this feed-
forward loop, nSREBPs activate the transcription of their own genes. In contrast, when nSREBPs 
decline (as in Scap or S1p knockout mice), there is a secondary decline in the mRNAs encoding 
SREBP-1c and SREBP-2.  
Three factors selectively regulate the transcription of SREBP-1c: 
I) liver X-activated receptors (LXRs) 
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II) insulin 
III) glucagon  
 
I. Liver X-activated receptors (LXRs) 
LXRα and LXRβ are nuclear receptors that form heterodimers with retinoid X receptors. They are 
activated by a variety of sterols, including oxysterol intermediates that form during cholesterol 
biosynthesis. An LXR-binding site in the SREBP-1c promoter activates SREBP-1c transcription in 
the presence of LXR agonists. The functional significance of LXR-mediated SREBP-1c regulation 
has been confirmed in two animal models. Mice lacking both LXRα and LXRβ express reduced 
liver levels of SREBP-1c and its lipogenic target enzymes, and respond relatively weakly to 
treatment with a synthetic LXR agonist. Because a similar blunted response is found in mice that 
lack SREBP-1c, it appears that LXR increases fatty acid synthesis largely by inducing SREBP-1c. 
LXR-mediated activation of SREBP-1c transcription provides a mechanism for the cell to induce 
the synthesis of oleate when sterols are in excess. Oleate is the preferred fatty acid for the synthesis 
of cholesteryl esters, which are necessary for both the transport and the storage of cholesterol. LXR-
mediated regulation of SREBP-1c appears also to be one mechanism by which unsaturated fatty 
acids suppress SREBP-1c transcription and thus fatty acid synthesis. Rodents fed diets enriched in 
polyunsaturated fatty acids manifest reduced SREBP-1c mRNA expression and low rates of 
lipogenesis in liver. In vitro, unsaturated fatty acids competitively block LXR activation by 
antagonizing with its endogenous ligands, and so decreasing LXR mediated SREBP-1c expression. 
In addition to LXR-mediated transcriptional inhibition, polyunsaturated fatty acids lower SREBP-
1c levels by accelerating degradation of its mRNA. These combined effects may contribute to the 
long recognized ability of polyunsaturated fatty acids to lower plasma triglyceride levels.  
 
   II III.      Insulin and glucagon 
Transcription of some hepatic genes such as glucokinase (GK) are exclusively dependent on insulin. 
The mechanism is partially unknown but is clear that it involves SREBP-1c activation. It is 
established that insulin stimulates SREBP-1c gene transcription in the liver and in adipose tissue. 
Insulin-stimulated SREBP-1c gene transcription should logically result in an increased abundance 
of the precursor form of SREBP-1c in membranes of the hepatic endoplasmic reticulum. In 
hepatocytes insulin increases SREBP-1c mRNA levels concomitant with its ability to elevate 
mRNA levels for fatty acid biosynthetic genes. A dominant-negative form of SREBP-1c blocks the 
insulin effect on the fatty acid biosynthetic genes. The insulin effect on SREBP-1c mRNA is 
blocked when cAMP levels are elevated by glucagon, and this block is associated with a decline in 
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acetyl-CoA carboxylase and fatty acid synthetase, the two key enzymes of fatty acid biosynthesis. 
In the livers of living rodents, SREBP-1c mRNA levels have been shown to decline when insulin 
falls as a result of fasting or treatment with streptozotocin, and this fall is paralleled by decreases in 
lipogenic mRNAs. The opposite result has been observed when insulin is administered to  
streptozotocin-treated rats. In livers of lipodystrophic and ob/ob mice, SREBP-1c mRNA levels are 
elevated as a result of hyperinsulinemia secondary to leptin deficiency. Leptin treatment normalizes 
plasma insulin. As a result, SREBP-1c mRNA levels fall down, the mRNAs for lipogenic genes 
decline, and the fatty liver resolve. 
 
SREBPs are also subject to regulation by rapid degradation via the ubiquitin-proteasome 
pathway (Hampton 2002), as it is shown in figure 22. In particular, nuclear SREBPs are targeted by 
various post-translational modifications, including phosphorylation, acetylation, sumoylation and 
ubiquitination. Nuclear SREBP1c was found to be phosphorylated and negatively regulated by 
GSK-3β7. Phosphorylation of these residues created a docking site for Fbw7, the substrate 
recognition component of a specific SCF ubiquitin ligase. Ubiquitinated SREBP is then degradated 
via proteasome. Knockdown of Fbw7 prevented the degradation of SREBP1 and enhanced SREBP-
dependent transcription. Interestingly, the GSK-3-dependent phosphorylation of Thr426 and Ser430 
in nuclear SREBP1 was enhanced in response to DNA binding. Accordingly, GSK-3β and Fbw7 
were recruited to the promoters of SREBP target genes in vivo and DNA binding promoted Fbw7-
dependent ubiquitination of SREBP1.  
SREBPs are also modified by another protein, small ubiquitin-like modifier (SUMO). 
SUMO-1 is a 101 amino acid protein having 18% identity with ubiquitin, but with a remarkably 
similar secondary structure.  Sumoylation of transcription factors, including SREBPs, is prone to 
result in attenuation of their transcriptional activities. The process requires a multistep reaction 
similar to that of ubiquitination, but the specific enzymes are distinct from those involved in 
ubiquitination. Ubc9 is a SUMO-conjugating enzyme (E2) that directly interacts with most 
sumoylated proteins, including SREBPs. In some cases, ubc9 itself plays, to a certain extent, a 
SUMO E3-like role in the absence of any E3 ligases. Unlike ubiquitination, which requires 
phosphorylation near the ubiquitination site, sumoylation competes with the phosphorylation close 
to the sumoylation site, which occurs in response to growth factor stimuli. This implies that growth 
factor stimuli interfere with sumoylation, thereby enhancing SREBP transcriptional activities, and 
lipid synthesis required for cell growth. Sumoylated SREBPs recruit a co-repressor complex 
containing histone deacetylase 3 to suppress their transcriptional activities [21]. Histone deacetylase 
                                                            
7  Two  of  the  residues  targeted  by  GSK‐3:  Thr426  and  Ser430;  were  mapped  to  the  C  terminus  of  nuclear 
SREBP1(Thr402 and Ser406 in SREBP1c) 
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3 is unable to directly interact with SREBPs, but a certain subunit in the co-repressor complex, 
which is not yet identified, is considered to be involved in the interaction  
[36, 40-46]. 
 
 
3.4 SREBPs are master regulator of gene expression 
 
SREBPs are master regulator of a large number of genes (some genes are shown in table 1) 
involved in cholesterol biosynthesis, transport and esterification. The mechanism trough they act 
involves consensus sequence recognized on DNA and the interaction with co-activators factors. 
SREBP-1a and -2 promote gene expression by interacting with two large ubiquitous 
transcriptional co-activators, CBP and P300. SREBP-1c, which has a much shorter activation 
domain, does not interact with CBP and P300.  
SREBPs have recently been shown to be stabilized via acetylation by the intrinsic 
acetyltransferase activity of P300 and CBP. Independently of CBP and P300, the amino terminal of 
 
Figure 22: Phosphorylation-dependent degradation of active sterol regulatory element-binding protein 1 (SREBP1). 
Once in the nucleus, dimeric SREBP1 functions as a transcription factor by binding to specific DNA sequences in
the promoters of its target genes. DNA binding enhances the interaction between SREBP1 and GSK-3β, resulting in 
the phosphorylation of Thr426 and Ser430 in the C terminus of nuclear SREBP1. As a result, the ubiquitin ligase 
SCFFbw7 is recruited to SREBP target promoters and induces the ubiquitination and degradation of SREBP1. Most
probably, both subunits of the SREBP dimer become phosphorylated and ubiquitinated in response to DNA binding. 
Only the substrate recognition component of the SCF complex is included in the figure. Figure from Bengoechea-
Alonso and Ericsson 2007. 
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SREBP-1a also interacts with the vitamin D receptor interacting protein (DRIP), also known as 
activator recruited cofactor (ARC).  
Like all members of the bHLH-Zip family of transcription factors, SREBPs recognize the 
inverted E-box repeat 5′- CAXXTG-3′. Similar to Myc/Max and USF, the preferred SREBP E-box 
is 5′-CACGTC-3′. However, in contrast with other bHLH-Zip transcription factors, SREBPs 
contain a tyrosine residue in their basic domain in place of an arginine residue. This tyrosine residue 
confers flexibility, which allows SREBPs to bind also to the direct repeat sterol regulatory element 
(SRE) 5′- TCACNCCAC-3′. 
All cholesterol-responsive promoters, including genes that regulate fatty acid as well as 
cholesterol metabolism, contain a direct repeat SRE site that is not accessible to other bHLH-Zip 
proteins, thus ensuring highly regulated cholesterol-dependent transcription. The functional 
importance of SREBPs in controlling transcription of sterol-regulated genes is well established. 
However, in all SREBP-regulated promoters studied to date, additional co-regulatory transcription 
factors are required.  
SREBPs are inherently weak activators by themselves and function synergistically with 
ubiquitous factors such as nuclear factor-Y, CREB/ATF, and Sp1, that bind in proximity to achieve 
a high level of promoter activation. Sp1 has been shown to be a SREBP-1a coactivating factor for  
low-density lipoprotein receptor, and NF-Y has been shown to be a SREBP-1a coactivating 
factorfor steroidogenic acute regulatory protein (StAR), farnesyl diphosphate synthase, and HMG-
CoA synthase. There is a requirement for both Sp1 and NF-Y in sterol regulation of the human fatty 
acid synthase promoter. Yin yang-1 (YY1) is a unique transcription factor that has the capability of 
acting as repressor, activator, or initiator of gene transcription via multiple mechanisms, including 
YY1 binding to an activator to occlude its recognition site. In binding to a promoter, YY1 may also 
bend the DNA and impair activator interaction. YY1 may also recruit histone deacetylases that 
confer transcriptional silencing. YY1 has been shown to repress in a dose-dependent manner the 
transcription of LDL receptor gene, by specifically targeting SREBP-1a interaction with Sp1. YYI 
has been shown to inhibit SREBP-1a/NF-Y enhancement of StAR activation by decreasing SREBP-
1a binding to an SRE in the presence or absence of NF-Y.  
[36, 47] 
 
31  Introduction 
 
 
 
 
 
 
 
 
 
  
Table 1: Gene recognized to have SRE consensus sequence. Table modified from
Hitoshi  and Shimano 2001. 
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4. Cholesterol and disease 
Changes in the organization of membrane lipids can have profound effects on cellular functions 
such as signal transduction and membrane trafficking. These membrane effects can cause disease in 
humans as a result of genetic alterations or environmental effects (such as diet), or both. Cholesterol 
is one of the most important regulators of lipid organization, and mammals have developed 
sophisticated and complex mechanisms to maintain cellular cholesterol levels in membranes within 
a narrow range (as is shown in previous chapters). When these homeostatic mechanisms are 
overwhelmed, outcomes or progression of pathological conditions under cardiovascular system are 
facilitate. 
4.1 Hypercholesterolemia  
 
LDL excess is the major cause of injury to the vessels endothelium and underlying smooth 
muscle. When LDL particles become trapped in an artery, they can undergo progressive oxidation 
and be internalized by macrophages by means of the scavenger receptors on the surfaces of these 
cells. The internalization leads to the formation of lipid peroxides and facilitates the accumulation 
of cholesterol esters resulting in the formation of foam cells. The degree to which LDLs are 
modified can vary greatly. Once modified and taken up by macrophages, LDLs activate the foam 
cells. Removal and sequestration of modified LDLs are important parts of the protective role of the 
macrophage in the inflammatory response, and minimize the effects of modified LDLs on 
endothelial and smooth-muscle cells. Antioxidants such as vitamin E can reduce free-radical 
formation by modified LDLs. Modified LDLs are chemotactic for other monocytes, and can up-
regulate the expression of genes for macrophage colony-stimulating factor and monocyte 
chemotactic protein derived from endothelial cells. Thus, it may help expand the inflammatory 
response by stimulating the replication of monocyte-derived macrophages and the entry of new 
monocytes into lesions. 
The inflammatory response itself can have a profound effect on lipoprotein movement 
within the artery. Specifically, mediators of inflammation such as tumor necrosis factor α, 
interleukin-1, and macrophage colony-stimulating factor, increase binding of LDLs to endothelium 
and smooth muscle and increase the transcription of the LDL-receptor gene. After binding to 
scavenger receptors in vitro, modified LDL initiates a series of intracellular events that include the 
induction of urokinase and inflammatory cytokines, such as interleukin-1. Thus, a vicious circle of 
inflammation, modification of lipoproteins, and further inflammation can be maintained in the 
artery by the presence of these lipids. 
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Oxidized LDLs are present in 
atherosclerotic lesions in humans. In 
animals with hypercholesterolemia, 
antioxidants can reduce the size of 
lesions, and they reduce fatty streaks in 
non human primates [18, 48].  
  
4.2 Atherosclerosis 
 
Atherosclerosis is the major 
human disease associated with 
cholesterol and lipid metabolism. The 
earliest event in atherogenesis (Figure 23 
and 24) is the atheromas formation, that 
consists in the accumulation of plasma 
lipoproteins in the sub-endothelium, or 
intima, of focal areas of the arterial tree. 
The lipoproteins are retained owing to a 
combination of proteoglycan binding and 
lipoprotein aggregation. This leads to the 
increasing in particle size, that blocks 
egress from the arterial wall. These 
retained lipoproteins, particularly those 
that are modified by oxidation, 
aggregation and other means, stimulate 
atherogenesis trough the promotion of 
inflammation. Monocytes and T cells, but 
not neutrophils, infiltrate the arterial wall. 
More specifically, certain types of 
oxidized phospholipid derived from 
modified lipoproteins can activate the overlying endothelium to secrete chemokines, and express 
adhesion molecules for monocytes and T cells. These leukocytes migrate through an otherwise 
intact endothelial layer, and the monocytes eventually differentiate into macrophages in the intima.  
Figure 23:a) Monocytes are attracted to focal areas of the arterial
wall in which atherogenic lipoproteins have been retained on the
extracellular matrix. These retained lipoproteins signal to the
endothelium to express chemokines and adhesion molecules.
b) The monocytes migrate through the endothelial layer and
differentiate into macrophages. c) The macrophages ingest the
retained lipoproteins by endocytic and phagocytic mechanisms and
thus acquire a large load of lipoprotein-derived cholesterol.
d) In early lesions, the cholesterol is stored as ACAT-derived
cholesteryl esters and thus acquire a foamy appearance.
e) In advanced lesions, unesterified or 'free' cholesterol (FC)
accumulates f)  leading to macrophage apoptosis g) and necrosis.
Image from Maxfieeld and Tabas (2005) 
Figure 24: Endothelial Dysfunction in Atherosclerosis. Image
from Ross 1999 
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Once embedded in the intima, the macrophages, through a process that is only partly 
understood, ingest the lipoprotein particles8 bound to the matrix. Interestingly, just as cholesterol 
depletion inhibits signal-dependent actin assembly. In some cells, loading of macrophages with 
cholesterol through uptake of modified lipoproteins or through a cyclodextrin carrier (that is, 
without a lipoprotein) can lead to increased actin assembly and protrusion of membrane processes 
in macrophages. It seems likely that these cholesterol-dependent effects are mediated by changes in 
lipid organization, which can affect activation of the small GTPase Rac17. In the blood vessel wall, 
the initial contact with lipoproteins could lead to cholesterol transfer to the macrophages, leading to 
actin-dependent protrusions. This would enhance the further uptake of cholesterol into the cells. 
Most of the cholesterol in lipoproteins is in the form CE. These esters are hydrolyzed to 
cholesterol and fatty acids in acidic degradative organelles such as late endosomes, and then free 
cholesterol is transported to other sites in the macrophage: 
- transport to the plasma membrane is important for cholesterol efflux;  
- transport to the ER is necessary for intracellular cholesterol homeostasis (through SREBP) 
and for re-esterification by ACAT; 
- transport to the mitochondria leads to the formation of oxysterols, which, in turn, may have 
roles in LXR activation and sterol efflux.  
ACAT-mediated re-esterification is a major fate of lipoprotein-derived cholesterol in intimal 
macrophages. The resulting cholesteryl ester molecules coalesce into membrane-bound neutral lipid 
droplets in the cytoplasm, a feature 
that has given rise to the term 'foam 
cell' (figure 25). 
Receptor-mediated uptake by 
means of the LDL receptor is usually 
limited because of its homeostatic 
down-regulation by cholesterol. 
However, aggregated LDL can deliver 
enormous amounts of cholesterol to 
macrophages and cause foam-cell 
formation. The likely explanation is 
that one or more receptors other than 
LDL receptors are involved and/or that 
                                                            
8 In a cell‐culture model of the initial interaction of macrophages with retained and aggregated lipoproteins, significant 
rearrangement of the actin cytoskeleton and protrusion of membrane processes  is seen, and this  is required for the 
continued uptake of cholesterol into the cells 
Figure 25. Atherosclerosis progression: Plaque formation. Image
from Ross 1999 
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LDL receptor down-regulation is not complete in these macrophages. Foam cells seems to be 
formed mostly, if not exclusively, by the uptake of oxidized LDL and may also participate in other 
early atherogenic processes, such as smooth-muscle-cell migration and T-cell-mediated 
inflammatory and immune responses. Moreover, remnant lipoproteins are avidly internalized by 
cultured macrophages and are potent inducers of ACAT activation and foam-cell formation. They 
are abundant in the intima of atherosclerotic lesions, and their levels in plasma are strongly 
associated with the presence of foam cells and the incidence of atherosclerotic vascular disease in 
animal models and humans. 
Foam-cell secretion of inflammatory cytokines and matrix metalloproteinases contributes to 
atherosclerosis. Macrophage foam cells may also participate in other early atherogenic processes, 
such as smooth-muscle-cell migration and T-cell-mediated inflammatory and immune responses. 
Early atherosclerotic lesions are not symptomatic because arterial lumen occlusion is not 
great enough to compromise blood flow. This lack of occlusion is aided by outward remodelling of 
the affected region of the arterial wall. After years of gradual lesion development, foam cells, 
smooth muscle cells, extracellular matrix material and smooth-muscle-cell-derived scar tissue can 
lead to slowly progressive lumen occlusion. Symptoms are usually absent because organ blood flow 
is restored by compensatory, hypoxia-driven neo-vascularization. If this compensatory process 
becomes compromised, the patient may experience stable, exercise-induced compromise of blood 
flow (for example, exercise-induced angina), but not acute cardiovascular events. Importantly, the 
smooth-muscle-cell-derived scar tissue forms a fibrous cap that covers and essentially 'protects' the 
underlying lesion, and these lesions tend to be relatively stable. 
Some lesions progress leading to acute vascular events, including sudden death, acute 
myocardial infarction, unstable 
angina or ischemic stroke (figure 26). 
These events are caused by acute, 
occlusive luminal thrombosis, which 
leads to organ damage because of the 
suddenness of lumen occlusion. This 
process occurs over minutes, so there 
is not enough time for compensatory 
responses. Pathological observations 
of affected arteries in patients 
suffering from acute events led to the 
plaque-disruption theory of acute Figure 26: Formation of advanced lesion of Atherosclerosis.
Image from Ross 1999 
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athero-thrombosis. According to this theory, a minority of plaques become necrotic and highly 
inflammatory, which eventually leads to breakdown of the protective fibrous cap or to erosion of 
the endothelial cell layer. These events, in turn, expose the luminal blood to underlying plaque 
material, which promotes coagulation and thrombosis. Of interest, these rare events do not 
necessarily occur in the largest plaques, but rather those that have large areas of necrosis.  
[7, 18, 48, 49] 
 
4.3 Alzheimer's disease. 
 
The role of cholesterol and lipids in Alzheimer's disease has been actively studied for over a 
decade, on the basis of the observation that there is a genetic linkage between age of onset of 
Alzheimer's disease and the presence of the ε4 allele of ApoE. Polymorphisms in other proteins 
involved in cholesterol metabolism may also have a genetic linkage with this disease. 
 ApoE is one of the main carriers of cholesterol in the brain, and it seems possible that 
alterations in cholesterol distribution or levels have a role in formation of amyloid deposits. The 
amyloid in Alzheimer's disease is formed by aggregation of a 39–42-residue peptide, the Aβ 
peptide, which is formed by two proteolytic cleavages of a transmembrane protein, the amyloid 
precursor protein (APP). These cleavages take place in intracellular organelles. In tissue culture 
studies, severe lowering of cellular cholesterol (more than 35% reduction) partly inhibited the 
formation of the Aβ peptide, but moderate reduction in cellular cholesterol increased the formation 
of Aβ peptide. Furthermore, rodents treated with statins can have increased amyloid production, and 
recent studies indicate that treatment with statins does not reduce the amyloid burden in humans. 
Nevertheless, statins may be neuroprotective, perhaps because of their pleiotropic effects on 
endothelial cell function and as suppressors of inflammation. There is still not a good mechanistic 
explanation for the association of the ε4 allele of ApoE with age of onset of Alzheimer's disease. 
Studies using animal models of AD9 show a strong connection between plasma cholesterol 
levels and Aβ generation. In a study done by Refolo, L.M. et al et al, is shown that high fat/high 
cholesterol diet raises cholesterol levels in plasma and CNS of transgenic mice expressing the FAD 
mutants APPK670N,M671L and PS1M146V. Because both β-APP C-terminal fragment (CTF) and Aβ 
levels are increased in the brain of these animals, it may be possible that cholesterol levels can 
regulate APP processing and Aβ generation in vivo. Neuropathological analysis showed that a high 
cholesterol diet also increases the deposition of amyloid plaques. Additionally, cholesterol-lowering 
agents reverses the effect of high fat/high cholesterol diet on Aβ accumulation and cholesterol 
                                                            
9 Rabbits, transgenic mice and guinea pigs 
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levels in the plasma and CNS. In a study on mice harboring a different APP FAD mutation 
(Swedish mutant) (Howland, D.S. et al, anno) a high-cholesterol diet elevated cholesterol levels in 
plasma and CNS, but had an opposite effect on Aβ generation. In this model mice, the levels of 
both Aβ40 and Aβ42 were reduced in the brain. The reason for the apparent discrepancy may reside 
in either the genetic background of the mice or, more likely, in the different transgene introduced. 
Species differences in mice may affect cholesterol generation, and therefore the choice of APP 
transgenic mouse model used becomes extremely important for the outcome of studies in which 
cholesterol levels are manipulated. A recent study in guinea pigs has strengthened the role of lipid-
lowering drugs in the regulation of A  generation, as simvastatin reduced cholesterol and both 
Aβ40 and Aβ42 levels in guinea pig plasma. 
All this evidence underline that there are multiple strands of research pointing at an 
important role for cholesterol in the pathogenesis of AD, but the process is however far from a clear 
explanation. AD is a complex multifactorial disease, and cholesterol metabolism is subject to a 
complex regulation at many different levels and in different compartments, so that increase or 
decrease in cholesterol levels bring about re-adjustments of the system in way that may not be 
immediately evident. Certainly more research is needed in this rapidly evolving and promising 
field.  
[18, 50-53] 
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NUTRITIONAL REGULATION OF 
CHOLESTEROL HOMEOSTASIS 
 
Cardiovascular diseases (CVDs) are the major cause of death in industrialized country and has 
been strongly linked to an excessive dietary intake of saturated fatty acids and cholesterol, over 
production of endogenous cholesterol, and chronic inflammation due to oxidative stress. The 
combination of these conditions causes accumulation and oxidation of plasma low-density 
lipoprotein–cholesterol (LDL-c), vascular inflammation, and endothelial dysfunction.   
Dietary and pharmacologic reduction in total and LDL cholesterol decreases the risk of 
coronary events, and dietary intervention is the first-line approach. Many nutritional compounds can 
act on cholesterol absorption, metabolism, and biosynthesis. 
There is a large amount of evidence suggesting that a high consumption of fruits, vegetables and 
fish can help reduce the risk of CVD. Certain phytochemicals, including flavonoids and 
phytosterols  are the food components to which the protective effect is ascribed. A considerable 
amount of epidemiological data suggests that phytochemicals contained in plant derived foods are 
able to reduce the risk of age-related chronic illness such as CVD. The initial ideas about how these 
compounds provide protection following ingestion, centred upon their direct antioxidant activity. 
However, recent research propose that many of these compounds do not act as direct antioxidants 
but through more subtle effects on a variety of cell signalling pathways, and by modulating gene 
expression. Now it appears clear that phytochemicals act not only as direct anti-oxidants but also 
through more subtle routes such as interaction with cell signalling pathways, or modulation of gene 
expression.  
Other important nutrients that possess a recognized protective effect in CVD are n-3 
polyunsaturated fatty acids (PUFAs). Even in this case, the mechanism of action appears multiple, 
also involving cell signalling and molecular events.  
n-3 PUFAs and some phytochemicals such as Epigallocatechingallate from green tea and 
phytosterols from soybeans, share the characteristic of regulating both inflammation and cholesterol 
biosynthesis, so influencing two of the main risk factors for CVD.  
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5. Poly Unsaturated Fatty Acid (PUFA) 
 
5.1 Structure and metabolism. 
 
Fatty acids are composed by a hydrocarbon chain with a carboxyl group at one end and a 
methyl group at the other. The most abundant fatty acids have straight chains of an even number of 
carbon atoms and the length of this chain varies from 2 to 30 or more, and may contain double 
bonds. If double bonds are present in the acyl chain the fatty acid is called unsaturated (UFA). A 
fatty acid containing two or more double bonds is called a poly unsaturated fatty acid (PUFA). 
  Unsaturated fatty acids are named by identifying the number of double bonds and the 
position of the first double bond counted from the methyl terminus (with the methyl, or ω, carbon as 
number 1) of the acyl chain. The 18-carbon fatty acid with two double bonds in the acyl chain with 
the first double bond on carbon number six from the methyl terminus is notated as 18:2ω–6, or 
18:2n–6. It is commonly named linoleic acid and it is the first member of the n–6 family. α-
linolenic acid (18:3n–3) is the simplest member of the ω –3 or n–3 family. Mammals, but not 
plants, lack the desaturase enzymes necessary to synthesize linoleic and α-linolenic acids, which are 
essential fatty acids (EFAs) and must be introduced with food. Since EFAs are widely distributed in 
foods their deficiency is rare in humans. 
Once introduced by diet, linoleic acid can be converted in longer and more unsaturated ω-3 
PUFAs, while α‐linolenic acid is the precursor of ω-3 PUFAs (figure 27).  Thus linoleic acid can be 
converted into γ-linolenic acid (18:3n–6), and dihomo-γ-linolenic acid (20:3n–6) into arachidonic 
acid (20:4n–6). Using the same series of enzymes, α-linolenic acid is converted into EPA 
(eicosapentaenoic acid; 20:5n–3). Further conversion of EPA into DHA (docosahexaenoic acid; 
22:6n–3) involves the addition of two carbons to form docosapentaenoic acid (22:5n–3), the 
addition of two more carbons to produce 24:5n–3, desaturation to form 24:6n–3 and removal of two 
carbons by limited β-oxidation to yield DHA. Arachidonic acid can also be metabolized by the 
same series of enzymes. In mammals, the pathway of desaturation and elongation occurs mainly in 
the liver. 
It is important to note that a competition exist between the metabolism of n–6 and n–3 fatty 
acids. Δ6-desaturase preferred substrate is α-linolenic acid, but linoleic acid is much more prevalent 
in the human diet, so the metabolism of n–6 fatty acids is quantitatively more important. 
Plant seed oils are rich in PUFAs. Corn, sunflower, safflower and soya-bean oils are rich in 
linoleic acid, which may comprise as much as 75% of the fatty acids present. Thus these oils and 
foods made from them are important dietary sources of linoleic acid. Some plant oils (e.g. soya-
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bean oil) also contain α-linolenic acid in smaller amounts; green plant tissues are also a source of 
this fatty acid. Data from U.K. indicate that the typical intakes of linoleic and α-linolenic acid are in 
the range of 10–15 and 0.75–1.5 g/day respectively. As to longer chain PUFAs, they are consumed 
in smaller amounts than linoleic and α-linolenic acids. Estimates of the intake of arachidonic acid in 
Western populations vary between 50 and 300 mg/day for adults. Fish, especially oily fish (salmon, 
herring, tuna and mackerel) and fish oils are a rich source of EPA and DHA. In the absence of oily 
fish or fish oil consumption, α-linolenic acid is by far the principal dietary n–3 PUFA. Average 
intake of the long-chain n–3 PUFAs in the U.K. is estimated at <250 mg/day. [1, 2] 
 
5.2 Occurrence in food 
 
 Omega-3 fatty acids have ever been a part of the human diet and it has been estimated that 
the ratio n-6 /n-3 in the diet of early humans was 1:1. Nowadays the ratio calculated in the United 
Figure 27: Structure and metabolism of n-6 and n-3 PUFAs. Image from Calder 2005. 
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States has risen to ~10:1 because of the combination of reduced omega-3 fatty acid intake and the 
widespread use of vegetable oils rich in linoleic acid. Because of the  competition between the 
linolenic acid and the α-linoleic acid for metabolic conversion to longer-chain, physiologically 
active metabolites, reducing the former while increasing the latter (or simply increasing the latter) is 
a strategy for increasing tissue levels of n-3 fatty acids. Another obvious strategy is to simply 
consume more EPA and DHA, an approach that minimizes the significance of the ratio. 
 The major food sources of α-linolenic acid are 
vegetable oils, principally canola and soybean oils 
(Table 2). Although some α-linolenic acid is 
converted to the longer-chain omega-3 fatty acids, the 
extent of this conversion is modest and controversial 
(0,2-15%) and the conversion to DHA is much less 
than that to EPA. This is the reason why it is better to 
favour the assumption of food in which EPA and 
DHA are already present. The primary source of very 
long chain n−3 PUFA in the diet is derived from the 
consumption of cold-water fatty fish such as salmon 
and tuna (table 3).  
 A number of countries (Canada, Sweden, United Kingdom, Australia, Japan) as well as the 
World Health Organization and North Atlantic Treaty Organisation have made formal population-
based dietary recommendations for omega-3 fatty acids. Typical recommendations are 0.3 to 0.5 
g/die of EPA DHA and 0.8 to 1.1 g/die of α-linolenic acid. Recently, the Food and Nutrition Board, 
Institute of Medicine, and The National Academies, in collaboration with Health Canada, released 
the Dietary Reference Intakes for Energy and Macronutrients. The Acceptable Macronutrient 
Distribution Range (AMDR) for α-linolenic acid is estimated to be 0.6% to 1.2% of energy, or 1.3 
to 2.7 g/die on the basis of a 2000-calorie diet. This is ~10 times the current intake of EPA and 
DHA. The lower boundary of the range is based on an Adequate Intake set for α-linolenic acid, 
which represents median intake levels that prevent an essential fatty acid deficiency. The upper 
boundary corresponds to the highest α-linolenic acid intakes from foods consumed by individuals in 
the United States and Canada. Thus, the intent of the AMDR range for n-3 fatty acids is to provide 
guidance for healthy people, not to prevent chronic disease. These recommendations can easily be  
 
Linolenic Acid 
Content 
   g/tbsp 
Olive oil  0.01 
Walnuts, English  0.07 
Soybean oil  0.09 
Canola oil  1.03 
Walnut oil  1.04 
Flaxseeds  2.02 
Flaxseed (linseed) 
oil 
8.05 
Adapted from USDA Nutrient Data 
Laboratory 
Table 2: α-Linolenic Acid Content of Selected
Vegetable Oils, Nuts, and Seeds. Table modified
from Kris-Etherton et al 2003. 
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Table 3: Fish rich in PUFA. Amounts of EPA_DHA in Fish and Fish Oils and the Amount  
of Fish Consumption Required to Provide ~1 g of EPA+DHA per Day. Table modified  
from Kris-Etherton et al 2003. 
 
 
EPA+DHA Content Amount Required to Provide
Fish g/3-oz Serving Fish (Edible Portion) 1 g of EPA+DHA per Day
or g/g oil oz (Fish) or g (Oil)
    Tuna
        Light, canned in water, drained 0.26 12
        White, canned in water, drained 0,051 4
        Fresh 0.24–1.28 2.5–12
    Sardines 0.98–1.70 2–3
    Salmon
        Chum 0,047 4.05
        Sockeye 0,047 4.05
        Pink 1.09 2.05
        Chinook 1.48 2
        Atlantic, farmed 1.09–1.83 1.5–2.5
        Atlantic, wild 0.9–1.56 2–3.5
    Mackerel 0.34–1.57 2–8.5
    Herring
        Pacific 0,098 1.05
        Atlantic 0,091 2
    Trout, rainbow
        Farmed 0,068 3
        Wild 0,058 3.05
    Halibut 0.4–1.0 3–7.5
    Cod
        Pacific 0.13 23
        Atlantic 0.24 12.05
    Haddock 0.02 15
    Catfish
        Farmed 0.15 20
        Wild 0.02 15
    Flounder/Sole 0.42 7
    Oyster
        Pacific 1.17 2.05
        Eastern 0.47 6.05
        Farmed 0.37 8
    Lobster 0.07–0.41 7.5–42.5
    Crab, Alaskan King 0.35 8.05
    Shrimp, mixed species 0.27 11
    Clam 0.24 12.05
    Scallop 0.17 17.05
Capsules
    Cod liver oil* 0.19 5
    Standard fish body oil 0.30 3
    Omega-3 fatty acid concentrate 0.50 2
    Omacor (Pronova Biocare) 0,059 1
Data from the USDA Nutrient Data Laboratory.104The intakes of fish given above are very rough 
stimates because oil content can vary markedly (>300%) with species, season, diet, and packaging
e and cooking methods.
*This intake of cod liver oil would provide approximately the 
Recommended Dietary Allowance of vitamins A and D.
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 met by following the AHA Dietary Guidelines to consume two fish meals per week, with an 
emphasis on fatty fish (for exempla: salmon, herring, and mackerel), and by using liquid vegetable 
oils containing α-linolenic acid. Commercially prepared fried fish (such as fast food establishments, 
as well as many frozen fried fish 
products) should be avoided because 
they are low in omega-3 and high in 
trans-fatty acids. Patients with CHD 
should be encouraged to increase their 
consumption of  EPA and DHA to ~1 
g/die, which is the dose used in the 
GISSI-Prevention Study. Table 3 
presents n-3 fatty acid content of 
various fish and supplements as well 
as the amount required each day to 
provide ~1 g/die of EPA-DHA. 
Although this level of EPA and DHA 
intake potentially can be attained 
through fish consumption, the requisite amount of fish intake may be difficult to achieve and sustain 
over the long term. For those individuals who do not eat fish, have limited access to a variety of 
fish, or cannot afford to purchase fish, a fish oil supplement may be considered. Depending on the 
preparation, up to three 1-g fish oil capsules per day will be necessary to provide ~1 g/d of omega-3 
fatty acids1. 
 In Italy, recommendations on PUFA intake are given by the Italian Society of Human 
Nutrition (SINU- Società Italiana Nutrizione Umana)[3]. They are summarised in table 4.   
[3-7] 
 
5.3 Safety of PUFA intake 
 
The FDA (Food and Drugs Administration) has ruled that intakes of up to 3 g/die of marine 
omega-3 fatty acids are GRAS (Generally Recognized As Safe) for inclusion in the diet. This ruling 
included specific consideration of the reported effects of omega-3 fatty acids on glycemic control in 
patients with diabetes, on bleeding tendencies, and on LDL cholesterol. [4] 
 
                                                            
1 The most common fish oil capsules in the United States today provide 180 mg of EPA and 120 mg DHA per capsule. 
  Age n-6 n-3 
  (years) 
% 
energy g/die 
% 
energy g/die 
Infants 0,5 - 1 4,5 4 0,2-0,5 0,5 
Children 
1 to 3 3 4 0,5 0,7 
4 to 6 2 4 0,5 1 
7 to 10 2 4 0,5 1 
Male 
11 to 14 2 5 0,5 1 
15 to 17 2 6 0,5 1,5 
18 2 6 0,5 1,5 
Female 
11 to 14 2 4 0,5 1 
15 to 17 2 5 0,5 1 
18 2 4,5 0,5 1 
Pregnant   2 5 0,5 1 
Premium   2 5,5 0,5 1 
Table 4: PUFA recommended intake in Italy .  Table modified from
SINU raccomandation. 
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5.4    PUFA biological effects and mechanisms of action 
 
Dietary n-3 PUFA are known to exert positive effects on several physiological processes 
involved in the development of chronic diseases, such as the regulation of plasma lipid levels, 
cardiovascular system, immune function, insulin action, neuronal development and visual function 
(table 5).  
Ingestion of n-3 PUFAs will lead to their distribution in cell with effects on membrane 
composition and function, eicosanoid synthesis, and signalling, as well as the regulation of gene 
expression. Cell-specific lipid metabolism, as well as the expression of fatty acid-regulated 
transcription factors, probable plays an important role in determining how cells respond to changes 
in PUFA composition. 
 
Target System Effect Likely Mechanism 
CNS Improves cognitive functions Membrane composition; RXRα 
Retina Enhances visual acuity Membrane composition 
Immune 
Immunosuppressive Membrane composition/Rafts 
Anti-inflammatory Eicosanoids synthesis/Action; NFkB 
Cardiovascular 
Anti-arrhythmia Membrane composition/Rafts 
Anti-thrombotic Eicosanoids synthesis/Action; NFkB 
Serum Lipids Lowers triglycerides PPARα & γ;SREBP-1c;LXRα & β 
Liver 
Suppresses lipogenesis SREBP-1c;LXRα & b 
Increases fatty acid oxidation PPARα 
Suppresses VLDL synthesis PPARα/HNF4a 
Skeletal Muscle Improves insulin sensitivity Membrane composition 9,10 PPARα & γ; NFkB
Table 5: PUFA effects on humans and mechanism involved. Table modified from Donald B. Jump. 
 
I) Eicosanoids production: relation with inflammation 
The key link between fatty acids and inflammation relates to the fact that the family of 
inflammatory mediators termed eicosanoids is generated from 20-carbon PUFAs liberated from 
cell-membrane phospholipids. Inflammatory cells typically contain a high proportion of the n–6 
PUFA arachidonic acid and low proportions of n–3 PUFAs, especially EPA. Thus arachidonic acid 
is typically the dominant substrate for eicosanoids synthesis.  
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Eicosanoids include PGs (prostaglandins), TXs (thromboxanes), LTs (leukotrienes), HETEs 
(hydroxyeicosatetraenoic acids). Arachidonic acid in cell membranes can be mobilized by various 
phospholipase enzymes, e.g. phospholipase A2. The free acid can subsequently act as a substrate for 
the enzymes that synthesize eicosanoids. Metabolism by COX (cyclo-oxygenase) enzymes gives 
rise to the 2-series PG and TX (figure 28). There are two isoforms of COX: COX-1 is a constitutive 
enzyme, COX-2 is induced in inflammatory cells as a result of stimulation. COX-2 is responsible 
for the markedly increased production of  PG that occurs on cellular activation. PGs are formed in a 
cell-specific manner.  
Increased consumption of fish oil, rich in EPA and DHA, results in increased proportions of 
these fatty acids in inflammatory cell phospholipids, partly at the expense of arachidonic acid. 
Consequently, in view of the fact that there is less substrate available for the synthesis of 
eicosanoids from arachidonic acid, fish oil supplementation has been shown to decrease production 
of PGE2, TXB2 , LTB4 and 5-HETE and LTE4  by inflammatory cells.  
EPA also acts as a substrate for COX and LOX enzymes, giving rise to a different family of 
eicosanoids: the 3-series PGs and TXs, the 5-series LTs and the hydroxy-EPAs. Fish oil 
supplementation results in the increased production of LTB5, LTE5 and 5-hydroxy-EPA by 
inflammatory cells, that are 
believed to be less potent compared 
with those formed from 
arachidonic acid (figure 28).  
Additionally, a novel group of 
mediators, termed E-series 
resolvins, has been identified. They 
are formed from EPA by COX-2, 
and exert anti-inflammatory 
actions. DHA-derived mediators 
(D-series resolvins, docosatrienes 
and neuroprotectins) are also 
produced by COX-2 under some 
conditions, and to be anti-
inflammatory.  
Many of the anti-inflammatory effects of n–3 PUFAs appear to be exerted at the level of altered 
gene expression. However, these effects have been demonstrated only a limited number of times 
and often in in vitro settings, and thus the extent of these effects in vivo is not yet clear. 
Figure 28: Generation of eicosanoids from AA and EPA. Metabolism of
AA and EPA by the COX and 5-LO pathways leads to the 2,4- or 3,5-
series prostanoids and LTs, respectively. The 2,4-series eicosanoids 
produced from AA promote inflammatory and prothrombotic effects,
whereas the corresponding 3,5-series eicosanoids produced from EPA 
have either the opposite effects or possess much lower levels of biological 
activity. Image from Hooman et al.(2009)
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Nevertheless, cell-culture and animal feeding studies indicate potentially very potent effects of n–3 
PUFA on the expression of a range of inflammatory genes. 
The n–3 PUFAs effect on inflammatory gene expression seems to happen through direct actions 
on the intracellular signalling pathways that lead to activation of one or more transcription factors 
such as NF-κB (nuclear factor κB). Previous studies have shown that n–3 PUFAs can down-
regulate the activity of the nuclear transcription factor NF-κB. EPA prevented NF-κB activation by 
TNFα in cultured pancreatic cells, an effect that involved decreased degradation of the inhibitory 
subunit of NF-κB (IκB), perhaps through decreased phosphorylation. Similarly, EPA or fish oil 
decrease endotoxin-induced activation of NF-κB in human monocytes. This is associated with 
decreased IκB phosphorylation, perhaps due to decreased activation of mitogen-activated protein 
kinases. These observations suggest direct effects of long-chain n–3 fatty acids on inflammatory 
gene expression through the inhibition of activation of NF-κB. 
Recently Bordoni et al. (2007) demonstrated in neonatal rat cardiomyocytes that n-3 PUFA 
down-regulate genes related to cardiac remodeling, apoptosis or inflammation. 
 
II) Membranes composition and gene expression 
To understand how PUFAs affect 
membrane composition and gene 
expression is important to introduce lipid 
micro domain called rafts (figure 29 
panel a). Rafts  are  well-studied micro-
domain characterized by a “liquid-
ordered” phase structure in which 
sphingomyelin and cholesterol co-
localize resulting tightly packed. For this 
reason they do not integrate well into the 
fluid phospholipid bilayer, causing them to form micro-domains. This unique environment is 
suitable for signalling protein localization. Caveolae (figure 29 panel b) are specialized rafts 
enriched with the structural protein caveolin-1. This specific kind of raft has several functions 
including cholesterol transport and signal transduction. Several studies showed that hydrolysis of 
plasma membrane SM by bacterial sphingomyelinase (SMase) C (which degrades it to ceramide) 
results in a rapid translocation of plasma membrane cholesterol to endoplasmic reticulum (ER). 
N−3 polyunsaturated fatty acids (PUFA) are able to modulate plasma membrane composition 
and cellular signalling in relation to lipid micro-domains. 
Figure 29: a) Lipid raft enriched with cholesterol and
sphingolipids. b) Caveola enriched with caveolin-1, cholesterol and
sphingolipid. Image modified from Ma et al.(2004). 
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In in vivo model, Ma et al.(2004) have shown that dietary n−3 PUFA markedly alter the lipid 
composition of colonic caveolae/lipid rafts in mice fed with fish oil. The n−3 fatty acids, EPA and 
DHA, from fish oil were incorporated into the fatty acyl groups of caveolae phospholipids and 
decreased the caveolar content of cholesterol and caveolin-1, the major structural component of 
caveolae by ~50%. The effect of diet on caveolar cholesterol content is particularly notable since 
n−3 PUFA, unlike cholesterol-sequestering 
reagents that have been used to perturb micro-
domain integrity in vitro, selectively reduced 
caveolar cholesterol content without affecting total 
cellular cholesterol. 
The intracellular membrane cholesterol 
displacement mechanism may involve the ability 
of fatty acids to cause sphingomyelinase induced 
sphingomyelin hydrolysis. Sphingomyelin 
hydrolysis results in the generation of ceramide, 
which can decrease levels of transcriptionally 
active mSREBP and SRE-mediated gene 
transcription. Cholesterol binds to sphingomyelin 
with higher affinity than to other membrane 
phospholipids. In the presence of cholesterol 
acceptors, sphingomyelin hydrolysis forces 
cholesterol translocation extracellularly. In the 
absence of acceptors, cholesterol is displaced to 
intracellular compartments (figure 30).  
It is also well established that ceramide has 
several signalling effects in cells, including 
activation of ceramide activated protein kinase, 
protein kinase C, and protein phosphatases. 
Moreover, intracellular cholesterol transport has 
been shown to be regulated by protein 
phosphorylation, and the activity of the rate-
limiting enzyme in cholesterol synthesis, HMG-
CoA reductase, is regulated by phosphorylation and dephosphorylation. In a recent study, Papasani 
et al. demonstrated that both exogenous and endogenous ceramide modulate the HMGCR activity 
Figura 30: Dietary n−3 PUFA readily incorporate into
lipid rafts and caveolae. EPA and DHA are acylated to
phospholipids within both rafts and caveolae. The
presence of highly flexible very long chain unsaturated
fatty acids is not compatible with the ordered phase
properties of rafts and caveolae. Consequently, the
localization of microdomain-specific proteins is
perturbed, resulting in the displacement of cholesterol
and ceramide that affect the modulation of downstream
cellular signaling events. Image from Ma et al.(2004). 
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independent of the membrane SM levels. Furthermore, part of the effects of ceramide on the 
enzyme appear unrelated to the increase in ER cholesterol, indicating an independent effect on 
sterol homeostasis. Moreover the depletion of SM alone may not be sufficient to account for the 
substantial translocation of PM cholesterol to ER that occurs following SMase C treatment. 
Ceramide and SMase effects are additive suggesting that the depletion of SM and the generation of 
ceramide have independent effects on cholesterol trafficking, probably affecting different aspects of 
the process. Authors also hypothesize that ceramide increase the phosphorylation of HMGCR, 
inactivating it. 
Ceramide selectively displaces cholesterol from the membrane rafts, possibly by competing 
for association with other raft lipids. This could result in increased availability of cholesterol for 
transport to ER, as well as to exogenous acceptors such as apo AI and phospholipids. The sterol 
regulatory element (SRE)-mediated gene transcription that controls the biosynthesis, cellular uptake 
and catabolism of cholesterol is inhibited by ceramide, independent of cellular cholesterol levels. In 
addition, Gallardo et al. reported that ceramide inhibits the expression of HMGCR in human U-937 
and HL-60 cells, whereas it increases the expression and activity of the enzyme in HepG2 cells, 
apparently by inducing maturation of SRE binding protein. The ceramide degradation product 
sphingosine has also been shown to be an inhibitor of cholesterol esterification by ACAT (by 
Harmala et al., 1993).  
An alternative mechanism to explain PUFA cholesterol lowering effect hypothesizes that 
cholesterol displaced from rafts could be sensed from SCAP as a high intercellular cholesterol 
condition, resulting in the retention of SREBP-SCAP complex into PM.  
In many models PUFAs suppress SREBP-1 but not SREBP-2 expression. The decline in 
SREBP-1 accounts for the PUFA-mediated suppression of de novo lipogenesis. The mechanism for 
the suppression of nSREBP-1 has been attributed to the inhibition of SREBP-1c gene transcription, 
enhanced mRNASREBP-1 degradation, and inhibition of SREBP-1 proteolytic processing. Recently 
Botolino et al. puropsed that PUFA accelerates the nSREBP-1 degradation by a 26S proteasome-
dependent pathway while having little impact on microsomal SREBP-1 or nSREBP-2 [1, 2, 8-20]. 
 
 
5.5     PUFA and CVD 
 
PUFAs reduce inflammation acting on eicosanoids production, and they modulate gene 
expression and membrane composition (§5.4). Other effect ascribed to PUFAs against CVD are the 
reduction of serum triglyceride levels, anti-arrhythmic effects, decreased platelet aggregation, 
plaque stabilization, and/or reduction of blood pressure.  
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I. Reduction of serum triglyceride levels 
Inflammatory response seems to be enhanced by the exposure of endothelium to triglyceride-
rich lipoproteins. One of the most consistent and best recognized anti-atherogenic properties of n-3 
is in the reduction of fasting and postprandial serum triglycerides and free FA (FFA). Such effect 
occurs by a reduction in the synthesis of triglycerides, and hence the secretion rates of hepatic very 
low density lipoproteins (VLDL), through the interference with most of the transcription factors that 
control the expression of enzymes responsible for both triglyceride assembly and FA oxidation.  n-3 
PUFAs reduce the expression of the sterol regulatory element-binding proteins (SREBP), 
transcription factors that regulate cholesterol-, FA-, and triglyceride-synthesizing enzymes (§5.4). 
This effect seems to be due to EPA- and DHA-induced inhibition of liver X receptor alpha/retinoid 
X receptor alpha (LXRα/RXRα) heterodimer binding to the promoter of the SREBP-1c gene. The 
increase by n-3 PUFAs of the mitochondrial and peroxisomal FA β-oxidation rates is well 
documented. This effect is mediated by n-3 FA activation of the peroxisome proliferator-activated 
receptor (PPAR)α, a ligand-activated transcription factor that up-regulates the expression of acyl-
coenzyme A oxidase, the rate-limiting enzyme in the β-oxidation pathway. Finally, a possible effect 
by n-3 FA on the farnesoid X receptor (FXR) activity was also postulated. FXR is a nuclear 
receptor for bile acids that plays a central role in lipid homeostasis.  
 
II. Anti-arrhythmic effects: 
There are several mechanisms able to explain how n-3 PUFAs may prevent arrhythmias. It is 
long known that n-3 PUFAs inhibit voltage-gated sodium channels, resulting in a longer relative 
refractory period and in an increased voltage required for membrane depolarization, which reduces 
heart rate. Furthermore, n-3 PUSAs maintain the integrity of L-type calcium channels, thus 
preventing cytosolic calcium overload during periods of ischemic stress. n-3 PUFA may also 
indirectly contribute to the decrease of heart rate by improving left ventricular efficiency and 
reducing blood pressure. 
 
III. Decrease of platelet aggregation 
PUFA n-6 are precursors for the 2-series eicosanoids (§5.4), which have a wide range of 
potential effects on metabolic pathways relevant to thrombosis. In fact, although the AA derivative 
PGI2 is a potent vasodilator, TXA2 stimulates platelet aggregation and produces vasoconstriction. 5-
LO metabolites, LT, have been linked to inflammation and atherogenesis. EPA and DHA 
consumption lower tissue levels of AA by inhibiting its synthesis and by taking its place in 
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membrane phospholipids. EPA-derived 3-series eicosanoids are typically less vaso-constrictive and 
produce less platelet aggregation than those made from AA. Fish oil could, therefore, be considered 
as “positive conditioners” of the thromboxane–prostaglandin balance. In general, however, the 
reduction in platelet function by EPA and DHA, when measurable, is limited in extent. 
 
IV. Plaque stabilization 
A recent study by Thies et al. has highlighted a potential role of n-3 FA in decreasing the risk of 
atherosclerotic plaques rupture in patients awaiting carotid endarterectomy. In this study, plaques 
from patients taking fish oil featured a net incorporation of n-3 PUFA into plaque lipids, and this 
correlated with a reduced macrophage infiltration and thicker fibrous caps compared with plaques 
from patients assuming sunflower oil-enriched control capsules. 
In recent years, supportive experimental evidence has indicated that plaque neovascularization and 
exacerbated release of metalloproteinases (MMP) by the activated endothelium and macrophages 
play a pathogenetic role in plaque progression and instabilization. Particularly, in the orchestration 
of angiogenesis, COX-2 activity seems to have a central role. Cell treatment with NS-398, an 
inhibitor of COX-2 activity, abolished such vascular organization. It is therefore plausible that DHA 
exerts an anti-angiogenic effect at least in part by reducing stimulated COX-2 expression. Moreover 
cell treatment with DHA for 48 h before stimulation resulted in a significant inhibition of MMP-9 
release, thus potentially having a plaque-stabilizing effect. 
 
V. Reduction of blood pressure 
N-3 PUFA seems also to exert antihypertensive effect acting on blood pressure. By a combined 
analysis of 36 randomized older trials, fish-oil intake (median dose 3.7 g/day EPA plus DHA) has 
been found to reduce systolic blood pressure by 2.1 mmHg and diastolic blood pressure by 
1.6 mmHg. These findings have been corroborated by those obtained in a large international cross-
sectional epidemiologic study conducted on 4680 middle age men and women, in which n-3 FA 
intake was found to be inversely related to blood pressure, both in hypertensive and in non-
hypertensive subjects. At least two mechanisms may account for this effect. Firstly, incorporation of 
EPA and DHA into membrane phospholipids was shown to increase systemic arterial compliance. 
Secondly, EPA and DHA seem to improve endothelial function by enhancing the release of NO. 
This effect seems to be due to the lipid and structural modification of caveolae, plasma membrane 
microdomains that act as regulators of endothelial nitric oxide synthase (eNOS) activity [20-23] 
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6. Catechins from tea. 
 
6.1 Structure, biosynthesis and occurrence in tea plants. 
 
Catechins belong to the group of compounds generically known as flavonoids, which have a 
C6-C3-C6 carbon structure and are composed of two aromatic rings, A and B (figure 31). 
Tea plant is known to contain seven kinds of 
major catechins and traces of various other catechin 
derivatives. Catechins could be divided into two 
classes: 
I) Free catechins:  
(-)-catechin,  
(-)-gallocatechin,  
(-)-epicatechin,  
(-)-epigallocatechin;  
II) Esterified or galloyl catechins: 
(-)-epicatechin gallate,  
(-)-epigallocatechin gallate,  
(-)-gallocatechin gallate.  
 
These catechins are present in all parts of the tea plant; 15–30% in the tea shoots, and there is also a 
high content in the second and third leaves2.  
The C6 (A) catechin ring is produced by the acetic–malonic acid pathway and C3-C6 (B) is 
sensitized by the shikimic–cinnamic acid pathway starting from the glucose pool. When 14C-acetic 
acid is supplied, metabolism occurs only at the A-ring of quercetin, and when 14C-shikimic acid or 
14C-t-cinnamic acid is supplied, 14C occurs at the C3-C6 structure. In this way the C6-C3-C6 
structure of flavanoid is synthesized with the decarboxylation of three molecules of acetic-malonyl-
CoA and cinnamic-coumaroyl-CoA. The first stable C6-C3-C6 compound is confirmed to be 
chalcone from which catechin is synthesized by way of flavanone. (_) Epigallocatechin is produced 
by hydroxylation of (_)- epicatechin. Then (_)-epicatechin gallate and (_)-epigallocatechin gallate 
are synthesized by esterification of catechins with gallic acid (2). It was confirmed that carbons in 
the N-ethyl group of theanine are incorporated into catechin, although this pathway of catechin 
synthesis seems to be a minor one.  
                                                            
2 In August, when the sun’s rays are the strongest, catechin content is the highest. 
Figure 31: Catechins structure. image from Lee et 
al. (2004) 
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The production of catechins in the tea plant increases on exposure to light and decreases in 
the shade. These phenomena are related to the activity of phenylalanine-ammonialyase, which is a 
key enzyme in the biosynthesis of catechin B ring. When the tea plant is covered (blocking out 
light), this enzyme activity decreases rapidly. The biosynthesis of catechin is also increased by a 
rise in temperature. Once catechin is synthesized, it is stored in the vacuole of the cell and hardly 
undergoes any metabolism or decomposition. 
According to the variety of tea plant, the catechin content varies. Green tea is rich in 
polyphenols, about 70% of which are catechins, and is the main dietary source of catechin 
gallatesand gallocatechins. In comparison, black tea contains about 30% of the catechins found in 
green tea and is mainly composed of complex condensation products such as thearubigins and 
theaflavins. Other dietary sources of catechins include red wine, grapes, apples and chocolate.  
EGCG is one of the most abundant green tea catechins, with a cup of green tea containing 
20–200 mg EGCG. It has also been suggested to be one of the most active compound in green tea, 
mediating most of the biological effects and accounting for 32% of the antioxidant potential. The 
remaining catechins include: (2)-epicatechin ((2)-EC), (2)-epigallocatechin (EGC) and epicatechin-
3-gallate (ECG), which provide 5–7, 9–12 and 9–12% of the antioxidant potential of green tea, 
respectively. Catechins are thought to be primarily responsible for the beneficial effects of green 
tea. [24, 25] 
 
6.2 Bioavailability and adsorption 
 
After oral administration green tea catechins are absorbed intestinally, predominately in the 
jejunum and ileum, with peak absorption occurring at 1.5–2.5 h after consumption. EGCG and ECG 
are thought to be mainly transported across the intestinal epithelial cell layer via paracellular 
diffusion. However, bioavailability is low due to instability under digestive conditions, poor 
absorption, and rapid metabolism and excretion, leading to only about 5% of consumed catechins 
appearing in the plasma. EGCG is the only known polyphenol to be mainly in the free form (77–
90%) in the plasma, whereas EGC and EC are mostly in the conjugated form (31 and 21% in the 
free form, respectively). The extensive metabolism in the intestine and liver leads to the formation 
of glucoronides, sulfides and methylated metabolites. This biotransformation alters the chemico-
physical properties of the catechins, such as the mass, charge and polarity, aiding the deactivation 
and rapid excretion of the biologically active compounds. 
Green tea catechins are methylated by the enzyme catechol-O-methyltransferase, glucuronidated 
by UDP-glucuronosyltransferases (UGT) and sulfadated by sulfotransferases (SULT). 
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Glucuronidation and sulfation can occur to previously methylated EGCG and vice versa, forming 
mixed metabolites.  
Green tea catechins have also been shown to undergo microbial degradation in the colon, 
forming compounds such as valerolactones, and phenolic and benzoic acids which may be absorbed 
or passed out in the feces. In comparison with the methylated, glucuronidated and sulfadated 
metabolites mentioned previously, studies have shown the valerolactones to appear in the blood and 
urine considerably later.  
The major products of EGCG metabolism are 4II-O-methyl-(-)-EGCG and 4I,4II-O-dimethyl-(-)-
EGCG (at high or low concentrations of  EGCG, respectively), (-)-5-(3I,4I,5 I -trihydroxyphenyl)-γ-
valerolactone and (-)-5-(3I,4I -dihydroxyphenyl)-γ-valerolactone and the respective sulfates and 
glucuronides. Also EGC and EC are metabolized in several products. 
In most cases, the biological activity of green tea catechin metabolites is limited compared with 
the parent form; however, a small selection of metabolites have been shown to have similar or in 
some cases higher activity than the parent compound. Lu et al. (2003) found EGCG-3I-glucuronide 
and EGCG-3II-glucuronide to have similar radical-scavenging ability compared with free EGCG. 
Exposure of human aortic endothelial cells to catechin metabolites extracted from the plasma of 
(+)-catechin-administered rats was found to inhibit monocytes adhesion when cells were pretreated 
with the cytokine IL-1b. The unconjugated form, (+)-catechin, had no such effect. [25-27] 
 
6.3 Mechanism of action 
 
Epidemiological evidence suggests that tea consumption lowers the risk of CVD. This 
protective effect is probably due to multiple mechanisms of action which are ascribed mainly to 
epigallocatechin gallate (EGCG), the main catechin in tea.  
EGCG is a potent inhibitor of lipid absorption, due to the formation of complexes with lipids 
and lipolytic enzymes which interfere with the luminal process of emulsification, hydrolysis, 
micellar solubilization, and subsequent uptake of lipids. EGCG intake is associated with lower 
plasma cholesterol level. Bursill et al (2006) demonstrated that this catechin regulates cholesterol 
metabolism in HepG2 cells via modulation of the conversion of sterol regulatory element binding 
protein-1 (SREBP-1) to its active form, and the increase of LDL receptor binding activity. In a 
study performed on animal models, green tea feeding reduced cholesterol and triglyceride plasma 
levels by 28 and 48%, respectively, and increased HDL cholesterol by 88%. 
EGCG and other catechins are also potent antioxidants. Pearson et al. (1998) demonstrated with 
human LDL and human aortic endothelial cells (ex vivo study) a 3.9% inhibition of LDL oxidation 
after 12 h incubation with 0.08 μg/ml green tea extract, and a 98% inhibition after incubation with 
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5 μg/ml. These concentrations are physiologically relevant and are achievable in plasma by normal 
dietary consumption of tea. 
EGCG is also reported to be a powerful anti-inflammatory agent. It directly inhibits neutrophil 
adhesion and suppresses chemokine production in the inflammatory site. Moreover EGCG inhibits 
the activity of the transcription factor NF-kB, so reducing the expression of target genes 
indispensable to the inflammatory process [28-33]. 
 
6.4 Green tea and cardiovascular diseases 
 
 Cardiovascular diseases (CVDs) are caused by many endogenous or exogenous factors such 
as cigarette smoking, diabetes mellitus, hypertension and hyperlipidemia. These factors can trigger 
an inflammatory response in vessels, the establishment of this inflammatory status, mediated in part 
by ROS, results in damage to vascular endothelial and smooth muscle cells. Endothelial 
dysfunction, characterized by pathological changes in endothelial cell anticoagulant, anti-
inflammatory and vasorelaxation properties, promotes recruitment of monocytes, macrophages, 
growth factors and cellular hypertrophy, which contribute to the formation of atherosclerotic 
plaques. ROS activity helps to drive many of these processes, but also altering transcription and 
signal transduction. Some important effects observed are: up-regulation of leukocyte adhesion 
molecules, increased apoptosis of endothelial cells, activation of matrix metalloproteinases, and 
altered vasomotor activity. These events mediate recruitment of inflammatory cells. Additionally, 
ROS level influences the accumulation and hypertrophy of vascular smooth muscle cells (VSMC) 
observed in atherosclerotic, restenotic lesions and hypertensive vascular diseases. ROS can also 
suppress growth and/or induce apoptosis. 
 The correlation between tea consumption and cardiovascular health has been extensively 
investigated. Experimental and clinical data underline the evidence that green tea consumption 
lowers the risk of cardiovascular diseases and mortality, and also cohort studies generally indicate 
the beneficial effects of green tea on CVDs mortality. These protective effects are probably due to 
multiple mechanisms of action of tea catechins.  
 EGCG is a potent inhibitor of lipid absorption. This catechin forms complexes with lipids 
and lipolytic enzymes, thereby interfering with the luminal process of emulsification, hydrolysis, 
micellar solubilization, and subsequent uptake of lipids. In a study performed on animals, green tea 
feeding reduced cholesterol and triglyceride plasma levels by 28 and 48%, respectively, and 
increased HDL cholesterol by 88%. These effects on lipid profile lower cardiovascular risk.   
LDL oxidation is inhibited by 3.9% after 12 h incubation with 0.08 ppm green tea extract, 
and by 98% after incubation with 5 ppm green tea extract. Interestingly, these concentrations, 
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particularly the first one, represent doses potentially achievable by natural intake. Two clinical trials 
substantiate these findings.  
 Another important aspect that characterize CVDs is atherogenesis, process dramatically 
influenced by chronic inflammation of the vessel wall, activation of the vascular endothelium, 
increased adhesion of mononuclear cells to the injured endothelial layer and their subsequent 
extravasation into the vessel wall. EGCG directly inhibits neutrophil adhesion and also suppresses 
chemokine production in the inflammatory site. Furthermore, some evidences indicate that EGCG 
can modulate adhesion-molecule expression. In addition, EGCG and ECG strongly induce apoptosis 
of monocytes, a cell type largely involved in atherogenesis, by dose-dependent activation of caspase 
8 and 9, and further downstream caspase 3. EGCG also inhibits the activity of the transcription 
factor NF-kB, reducing the expression of target genes indispensable to the inflammatory process. 
 In in vitro studies, catechins induced endothelium-dependent vasorelaxation via nitric oxide 
release from the endothelium. In other works emerged that green tea catechins directly enhances 
endothelial nitric oxide synthase (eNOS) activity by rapid phosphorylation and activation through 
phosphatidylinositol 3-kinase-dependent, cyclic adenosine monophosphate (cAMP)-dependent 
protein kinase, and Akt-dependent pathway. Nitric oxide (NO) is a reactive specie but is also the 
endothelial-derived relaxing factor which modulates vasodilatation essential for CV health. It has 
been demonstrated that under patho-physiological conditions such as hypoxia with subsequent 
reperfusion, when the circumstances allow the formation of substantial amounts of reactive oxygen 
species and NO, these molecules react avidly and RNS are generated, causing damage to cellular 
components. A recent study showed that the supplementation of moderate concentration of a green 
tea extract to the medium of cultured cardiomyocytes just before the induction of hypoxia and 
subsequent reoxygenation is able to prevent the increase of inducible NO synthase expression. This 
could reduce NO overproduction, allowing to hypothesize that GT components act not only on  
reactive oxygen species via an antioxidant mechanism, but also regulating NO synthesis.  
It must be considered that the bioavailability of potential antioxidants from plant foods is generally 
too low to have any substantial direct effect on reactive oxygen species. It has been postulated that 
the mechanism of action of polyphenols, even in very low concentrations, might entail their 
interaction with cell signaling and might influence gene expression, with the consequent modulation 
of several cell activities. The study by Danesi et al (2008) evidenced that a moderate GT 
concentration supplemented to cultured rat cardiomyocytes selectively activates the PPAR- β 
isoform. 
 Another issue involving catechins is their antithrombotic properties. Moreno et al (2004) in 
a humans study showed that the density of microvessels was increased in ruptured plaques and in 
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lesions with macrophage infiltration. The plaque base microvessel density appeared to be an 
independent marker for plaque rupture. Endothelial cells produce essential factors for angiogenesis. 
Tea compounds have been demonstrated to effectively impair growth factor signalling pathways and 
inhibit receptor tyrosine kinase activities, thereby affecting angiogenic processes in endothelial 
cells. 
[28, 29, 31-37] 
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7. Phytosterols 
 
7.1 Structure 
 
Phytosterols are plant-derived sterols that are structurally similar and functionally analogous 
to cholesterol in vertebrate animals. The chemical structure of common phytosterols is shown in 
figure 32. In many foods sitosterol is the most abundant form. 
 
 
Figure 32: Main phytosterols structure. Image from Ostlund et al (2002). 
 
Phytosterols are divided into two categories: 
I) Sterols or Δ5-sterols, possessing a double bond at position 5 
II) Stanols, with a 5α-reduction of that double bond  
These classes are reflected in the common names of the compounds. For example, sitosterol is 
structurally identical to sitostanol except for the double bond at position 5, and campesterol bears 
the same relationship to campestanol. Reduction of the double bond to give a β-hydrogen at 
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position 5 is a common intestinal bacterial degradation product of cholesterol and plant sterols but 
is not generally found in foods. [38] 
 
7.2 Biosynthesis and metabolism 
 
Plants and animals sterol biosynthesis and metabolism are quite different. Cholesterol is 
synthesized from acetate through the straight-chain compound squalene and then cyclized into 
many intermediate precursor sterols (§ 1.2.2), but the final product is most often nearly pure 
cholesterol, and only trace amounts of related precursors are found in humans. In plant phytosterols 
are also synthesized from acetate subunits through squalene, but the first cyclized product after 
squalene is the cycloarterol (compound unique of plant). Some foods, such as rice, contain 
cycloartenol or related compounds in significant amounts. Plants then produce a variety of final 
sterol products, and each species has a characteristic distribution of sterols3. Moreover there are 
modifications to the sterol nucleus at the level of the side chain.  
In animals most of the total body cholesterol is free, with a relatively small aggregate 
amount present as long-chain fatty acyl esters in plasma lipoproteins and specialized cells. Plants 
have a more diverse variety of derivatives at the 3-position.  
I) Long-chain fatty acyl esters4  
II) Ferrulate esters.  
III) Glycosylate derivatives.  
The complexity of phytosterols is increased further by steric asymmetry. Addition of alkyl 
groups in the side chain results in the substituted carbon becoming asymmetric. For example, 
soybeans contain two 24-methylcholesterol isomers, campesterol (24-α-configuration) and 
dihydrobrassicasterol (24-β-configuration). Generally the α-configuration is more common in 
higher plants, whereas the β-configuration predominates in algae. Stereochemistry has not generally 
been considered in human and animal studies of phytosterols. 
In foods three compounds account for most of the phytosterol mass:  
I) sitosterol (24-ethylcholesterol) 
II) campesterol (24-methylcholesterol) 
III) stigmasterol (Δ22-24-ethylcholesterol).  
                                                            
3 This characteristic distribution of sterols is sometimes used as a chemical fingerprint for the identification of food 
product sources 
4 Present in most plants and constitute over 50% of the total sterol in foods such as corn oil. 
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The structural similarity to cholesterol is striking, and it is difficult to separate cholesterol 
from phytosterols or different phytosterols from each other by physical methods unless powerful 
techniques such as high pressure liquid chromatography [38]. 
 
7.3 Occurrence in food 
 
All vegetable foods contain appreciable quantities of phytosterols. The most important natural 
sources of plant sterols in the human diet are oils and margarines, although they are also found in a 
range of seeds, legumes, vegetables and unrefined vegetable. Cereal products are a significant 
source of plant sterols, their contents, expressed on a fresh weight basis, being higher than in 
vegetables. 
Current food databases do not have comprehensive estimation of phytosterols content. Thus, 
they cannot be routinely calculated in test diets.  
Since the most concentrated source of phytosterols is vegetable oil, a person consuming 30 g/die 
of corn oil would receive 286 mg of phytosterols, an amount that has been shown to be active in 
reducing cholesterol absorption. An exception is palm oil, which is deficient in phytosterols after 
refining for western markets. Smaller unit amounts are found in nuts, breads, and whole vegetables, 
but these items also have larger portion sizes. Except for highly refined carbohydrates and animal 
products, nearly all foods contribute appreciably to phytosterols intake. The daily phytosterol 
consumption range is estimated to be in the range 167-437 mg/die, approximately the same as 
cholesterol intake.  
Stanols are present in un-hydrogenated vegetable oils and cereals. An estimate of stanol 
consumption can be obtained from fecal analyses because bacterial conversion of Δ5-sterols in the 
large bowel results in 5β-reduced rather than 5α-reduced metabolites. In subjects not receiving 
stanol treatment, stanol excretion has been reported to be ~24–29 mg/die. This suggests that stanols 
may comprise about 10% of dietary phytosterol intake. [38, 39] 
 
7.4 Adsorption 
 
Cholesterol absorption in normal subjects is in the range of 56.2±12.1%. Phytosterols 
traditionally have been considered to be non absorbable. In humans consuming solid food diets 
more than 90% of sitosterol is recovered in the stool, and sitosterol has been used as a non 
absorbable recovery standard in measurements of cholesterol balance and absorption. Despite this a 
small but definite absorption occurs. Several studies using radioactive sitosterol have reported that 
absorption is 0.6–7.5% of the administered amount. Percentage absorption varies inversely with the 
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dose, suggesting that a limitation in absorption exists at high intake levels. Campesterol absorption 
has been measured at 9.6% by losses during intestinal intubation and 16% from stool losses 
determined by mass spectrometry. Campestanol has been reported to be 12.5% absorbed by losses 
during intubation, and 5.5% absorbed by radioactive assay of plasma. The most desirable conditions 
for measuring phytosterol absorption involve the use of serum samples to establish unequivocal 
absorption into the systemic circulation. Recent works using these methods report the following 
generally lower values for percent absorption: sitosterol, 0.51%; campesterol, 1.9%; sitostanol, 
0.04; and campestanol, 0.16%. Taken together, these studies show that phytosterol absorption is 
quite low. Particularly, 5α-stanols are absorbed with about 10% of the efficiency of the 
corresponding Δ5-sterols. 
In humans serum, levels of sitosterol and campesterol are only 0.1–0.14% of the cholesterol 
concentration. When dietary Δ5-sterols are supplemented at 2–3 g/day, serum sitosterol and 
campesterol levels increase by 34–73%, with most values remaining in the normal range. The same 
dose of stanols reduces serum Δ5-sterol levels by 17–36%, presumably by inhibiting absorption. 
Baseline serum stanols were difficult to measure, with levels estimated at 0.003–0.004% of 
cholesterol.  
The same as cholesterol, phytosterols must be solubilized in micellar form for absorption. The 
sterol-laden micelle interacts with the intestinal brush border thereby facilitating the uptake of 
sterols by enterocytes. The precise molecular mechanisms for sterol absorption are not well defined 
but cholesterol and phytosterols absorption both require the Niemann-Pick C1 Like 1 Protein 
(NPC1L1). NPC1L1-deficient transgenic mice have virtually undetectable plasma phytosterols 
concentrations suggesting that NPC1L1 is the primary pathway for their absorption. Within the 
enterocyte, cholesterol is esterified by acyl cholesterol acyl transferase (ACAT2), packaged into 
chylomicrons at the basolateral membrane, and secreted into the lymphatic system for portage to the 
left subclavian vein. The intestine can secrete cholesterol back into the lumen of the intestine: 
unesterified cholesterol and  phytosterols are transported back into the intestinal lumen by a specific 
pump called the “sterolin pump” containing the ATP Binding Cassette (ABC) proteins, ABCG5 and 
ABCG8. Thus, ABCG5 and ABCG8 may selectively ‘pump’ sterols out of the intestinal cells as a 
first-line defense to dietary input, but in the fasting state, the liver can continually pump sterols 
(cholesterol and non cholesterol sterols) into bile and thus maintain a low non cholesterol sterol 
level in the body. In the fasting state, the intestine may also be able to reduce whole body sterol 
pools by continuing to pump sterols (presumably delivered to the intestinal enterocytes via the high-
density lipoprotein pathway) . 
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 Defective ABCG5 or ABCG8 genes generate the pathological condition of phytosterolemia5.  
Since ABCG5 and G8 not only regulate sterol absorption, but are also responsible for biliary 
excretion of phytosterols; consequently, the total body phytosterol pool in phytosterolemia is 
increased because of both increased absorption and decreased excretion [38, 40-42]. 
 
7.5 Safety of phytosterols supplementation 
 
A high intake of phytosterol could reduce not only cholesterol, but also fat-soluble vitamins 
and other vegetable-derived compounds adsorption. since these lipophilic materials are carried in 
plasma lipoproteins, most studies have normalized their plasma levels to those of lipids or 
cholesterol. In this way, in some studies serum α- and β-carotene level has been reported to be 
reduced by 11–22%, while other studies found only a small reduction without statistical 
significance. However, a correlation has been noted between estimated phytosterol-induced 
reduction in cholesterol absorption and decrease of circulating carotenes and lycopene. The most 
affected compounds are the non polar hydrocarbons α-carotene, β-carotene, and lycopene. Serum 
concentrations of 25-hydroxyvitamin D, retinol, and vitamin K are not reduced.  
One potential safety concern is the rare inherited disorder phytosterolemia. Phytosterolaemia 
or sitosterolaemia is a rare autosomal recessive condition caused by mutations on the ABCG5 and 
ABCG8 gut transporter proteins. This leads to accumulation of phytosterols in blood and tissues. 
Although increased absorption of phytosterols occurs in this illness and is an important clinical 
marker, it is possible that abnormal handling of cholesterol contributes most strongly to the 
resulting atherosclerosis. It is not clear what effect phytosterol feeding might have on sitosterolemic 
subjects [38, 43]. 
  
                                                            
5 Phytosterolemia is an autosomal recessive disease that occurs 1 in 5 million people. 
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8. Probiotics 
 
8.1 Colonic microbiota 
The human large intestine can be described as a complex microbial ecosystem where the 
community is in the range of 103 organisms, and in its diversity count over 400 different species. 
The behavior of colonies bacteria are affected by the physiology and architecture of the hindgut. 
The bacteria present have fluctuating activities in response to substrate availability, redox potential, 
pH, O2 tension and colon distribution. 
During birth, the gastrointestinal tract of the newborn is inoculated by the mother's vaginal 
and fecal flora. Initially a predominance of facultative anaerobic strains such as Escherichia coli or 
enterococci exists. These bacteria may therefore create an highly reduced environment that then 
allows the growth of strict anaerobes. After weaning a pattern that looks like the adult flora 
becomes to be established. Most human large intestinal microorganisms have a strictly anaerobic 
metabolism, and numbers of facultative anaerobes are many orders of magnitude lower than those 
of the obligate anaerobes. Because the native gut microflora are so well adapted to their 
environment, it is difficult for other organisms (including pathogens) to colonize in the lumen. This 
creates colonization resistance or non-specific disease resistance in the gut which acts as an 
important line of defense against pathogens. However disturbances in the normal intestinal 
microbial community structure can result in the proliferation of pathogens. 
  In this huge amount of bacteria, the numerically predominant anaerobes were Gram-negative 
rods of the genus Bacteroides. These microorganisms can constitute to 30% of the total fecal flora 
and as such can have an important impact on colony microbiological processes. Other numerically 
predominant groups are bifidobacteria (Gram-positive rods), eubacteria (Gram-positive rods), 
clostridia (Gram-positive rods), lactobacilli (Gram-positive rods) and Gram-positive. Other groups 
exist in lower proportions, including enterococci, coliforms, methanogens and dissimilatory sulfate-
reducing bacteria. 
Considering this wide range of bacterial species residing in the large gut, as well as the 
different growth substrates available, the colony microbial ecosystem harbors a multiplicity of 
nutritional patterns. A variety of different metabolic niches, bacterial habitats and interrelationships 
have arisen. The gut microflora exerts a considerable influence on host biochemistry including:  
• enzymatic activity of intestinal contents 
• short chain fatty acid (SCFA) production in the lumen 
• oxidation-reduction potential of luminal contents 
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• host physiology 
• host immunology 
• Modification of host-synthesized molecules 
In general, intestinal bacteria may be divided into species that exert either harmful or 
beneficial effects on the host (figure 33). Pathogenic effects include diarrhea, infections, liver 
damage, carcinogenesis and intestinal putrefaction; health-promoting effects may be caused by the 
inhibition of growth of harmful bacteria, stimulation of immune functions, lowering of gas 
distention problems, improved digestion and absorption of essential nutrients, and synthesis of 
vitamins. [44, 45] 
 
8.2 Probiotics 
R. Fuller in 1989 [46] gave the definition that well represent probiotics: “probiotics are live 
microbial food supplements, which benefit the health of consumers by maintaining, or improving 
their intestinal microbial balance”. In parallel the development of such compounds that are able to 
improve probiotic life, prebiotics, is fundamental. Gibson and Roberfroid in 1995 [44] defined 
prebiotic as “non-digestible food ingredient that beneficially affects the host by selectively 
Figure 33: Scheme of the composition and health effects of predominant human fecal bacteria.  
The bacteria are split into those groups that have harmful or pathogenic influences on human health, and health promoting function
are mentioned. Image from Gibson et al. 1994 
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stimulating the growth and/or activity of one or a limited number of bacteria in the colon, and thus 
improves host health” This non-viable food component moves to the colon and has a selective 
fermentation. Food ingredients classified as prebiotics must not be hydrolyzed or absorbed in the 
upper gastro intestinal tract, need to be a selective substrate for one or a limited number of colonic 
bacteria, must alter the microbiota in the colon to a healthier composition and should induce luminal 
or systematic effects that are beneficial to host health. 
A number of beneficial roles for probiotic strains have been reported or theorized. These 
benefits include: 
• Re-establishment of balanced intestinal microflora 
• Improving colonization resistance and/or prevention of diarrhea 
• Systemic reduction of serum cholesterol 
• Reduction of fecal enzymes, potential mutagens which may induce tumors 
• Metabolism of lactose and reduction of lactose intolerance 
• Enhancement of immune system response 
• Improved calcium absorption 
• Synthesis of vitamins and pre-digestion of proteins 
 
Due to their perceived health benefits probiotic bacteria have been increasingly included in food 
such as yoghurts and fermented milks during the past two decades. Most commonly they have been 
lactobacilli such as Lactobacillus acidophilus, and bifid bacteria. 
Before a probiotic can benefit human health it must accomplish several criteria: 
• It must have good technological properties to be manufactured and incorporated into 
food products without loose viability and functionality or creating unpleasant flavors or 
textures. 
• It must survive passage through the upper gastrointestinal tract and arrive alive at its site 
of action. 
• It must be able to function in the gut environment. 
• It must establish the effect of the probiotic strain on the intestinal microbiota and on the 
host. This includes not only positive health benefits, but also demonstration that 
probiotic strains do not have any deleterious effects. 
[44-49]  
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8.3 Cholesterol lowering effect of probiotics in human 
There is a large number of study reporting probiotic effects on serum cholesterol level in 
humans. It has been observed that whole-fat milk and skim milk consumption reduce serum cholesterol, 
while the same amount of milk fat, as butter intake, increase it. Yoghurt has also been shown to decrease 
serum cholesterol levels in humans, but several studies designed to evaluate the potential reduction of its 
levels by the consumption of certain cultured dairy products have given variable data and no solid 
conclusions. In most of these studies a decrease in serum cholesterol was only observed during the 
consumption of very high doses of fermented dairy products. Other investigators using more ‘normal’ 
doses of the fermented milk product failed to confirm such findings. It was suggested that the 
contradictory results obtained could be, at least in part, related to experimental design. Some of the 
factors addressed were lack of statistical power, use of inadequate sample sizes, failure to control 
nutrient intake and energy expenditure during the experiments and variations in the baseline levels of 
blood lipids. The intra-individual variation in blood cholesterol over a few months ranged from 5 to 
15%. Moreover differences in experimental design (type and quantity of the fermented milk product; 
age and sex distribution, and starting plasma cholesterol levels of the subjects studied; and length of 
study period) make direct comparisons difficult. Furthermore, more recent studies underline different 
effects that are ascribable to different probiotic used in fermented products. 
Agerbaek et al. in 1995 [50] reported that a fermented milk product (Gaio®), that is produced 
through the action of a bacterial culture containing a strain of Enterococcus faecium and two strains of 
Streptococcus thermophilus (CAUSIDO® culture), was effective in reducing plasma cholesterol at 
relatively modest levels of intake. The bacterial strains contained in this product were isolated from the 
intestinal flora of inhabitants of Abkhasia (Caucasus), a region reputed for the longevity of its people 
and where fermented milk is a major part of the diet.  Richelsen et al. [51] , using the same product in a  
six month trial, initially observed similar  resultsIn the follow up, , concentrations of Enterococcus 
faecium in the test product dropped, and  LDL-cholesterol level of treated subjects was similar to  
placebo. For this reason it was suggested that Enterococcus faecium plays a significant role in the 
potential beneficial effect of this fermented milk product.  
Larsen et al in 2000 [52] evaluated the effects of the Gaio® product and two alternative products 
on the serum cholesterol levels of overweight and obese subjects.  Five groups were randomly formed. 
One of the groups consumed the test Gaio®; two groups consumed two new yoghurts with different 
bacterial cultures (one was fermented with two strains of S. thermophilus and two strains of L. acido- 
philus, and the other with two strains of S. thermophilus and one strain of L. rhamnosus); the fourth 
group consumed placebo yoghurt. The last group was given two placebo tablets daily. When comparing 
all five treatment groups,  a significant decrease in LDL-cholesterol was reported in the Gaio® product 
group only (8.4%,P<0.05). The reason for the observed hypocholesterolemic effect was once again 
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proposed to be related to the CAUSIDO® bacterial culture, particularly E. faecium. Although the 
specific in vivo action of the strain remains to be investigated. 
 Rossi et al. [53] tested the ability of E. faecium, L. acidophilus, L. jugurti, S. thermophilus, and 
L. delbrueckii to decrease cholesterol in vitro and to grow in the presence of bile salts. The study 
showed that among the strains tested, E. faecium and the mixture of E. faecium plus L. acidophilus 
produced the greater cholesterol reduction in the medium after 24 h anaerobic incubation (53 and 65%, 
respectively). 
De Roos et al. [54], in a randomized, placebo-controlled parallel trial, attempted to evaluate 
whether the intake of Lactobacillus acidophilus strain L-1 lowered serum cholesterol levels in healthy 
men and women with normal to borderline high-cholesterol levels. The 78 subjects in this study 
consumed 500 ml of control yoghurt daily for 2 weeks. They were then randomly allocated to receive 
500 ml per day of either control yoghurt or yoghurt enriched with Lactobacillus acidophilus L-1 for 
another 6 weeks. No significant reduction of serum cholesterol levels in the subjects consuming the 
yoghurt enriched with L. acidophilus L-1 was observed after the trial.  
Schaarmann et al., 2001[55] aimed studying the interrelationship between the intake of probiotic 
yoghurt and the concentration of cholesterol fractions. In this study, 29 healthy women consumed 300 g 
per day of a probiotic yoghurt (Lactobacillus acidophilus and Bifidobacterium longum) after a period of 
eating standard yoghurt (Streptococcus thermophilus and Lactobacillus lactis). The volunteers were 
divided in a normocholesterolemic group (total cholesterol <250 mg/dL) and a hypercholesterolemic 
group (total cholesterol >250 mg/ dL). The experiment consisted of three periods (placebo, standard 
yoghurt, and probiotic yoghurt), each lasting for 51 days. A decrease in the concentration of LDL-
cholesterol and triacylglycerides after consumption of standard and probiotic yoghurts was reported. A 
larger decrease was observed after intake of the probiotic yoghurt when compared with the standard 
yoghurt in the hypercholesterolemic group, but this, however, was not significant. Inversely, a increase 
in the HDL cholesterol was observed with the probiotic yoghurt that resulted in a smaller atherogenic 
ratio (LDL/ HDL-cholesterol). No significant differences were observed when comparing the 
normocholesterolemic and the hypercholesterolemic groups.[50-56] 
 
8.4 Mechanism of action 
Existing evidence from human and animal studies suggests a moderate cholesterol lowering 
action of some fermented dairy products.  However, the potential mechanisms for this claimed 
effect remain to be clarified. 
Several in vitro experiments with lactobacilli and bifidobacteria evidenced the ability of some 
strains to assimilate cholesterol in the presence of bile acids. Gilliland et al  [57] in an in vitro study 
found that certain Lactobacillus acidophilus strains could remove cholesterol from a growth 
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medium only in the presence of bile and under anaerobic conditions. Because these conditions are 
expected to occur in the intestine, the authors concluded that this should enable the organisms to 
assimilate at least part of the cholesterol ingested in the diet, thus making it unavailable for 
absorption into the blood. 
To corroborate in vivo this in vitro findings, the same authors tested L. acidophilus RP32 
using young pigs6. Feeding of pigs with L. acidophilus RP32, selected for its ability to grow in the 
presence of bile and to remove cholesterol from a laboratory medium, significantly inhibited the 
increase in serum cholesterol when fed a high-lipid diet (P<0.05). The mechanism underlying this 
effect was referred to as cholesterol assimilation by the L. acidophilus strain. Other studies reported 
that L. acidophilus possesses a significantly greater cholesterol uptake ability than Streptococcus 
thermophilus. However, variations in the ability of cultures of yoghurt bacteria and bifidobacteria to 
assimilate cholesterol were observed. It has been suggested that the diverse results obtained in different 
human studies can be, at least in part, be due to the different bacterial strains used in fermentation. 
Viability of the ingested bacterial strains in the human gut, and the ability to colonize the small intestine 
(where most of the cholesterol absorption would take place), could ultimately be expected to be of key 
importance for this effect. 
Subsequent work done by Klaver and van der Meer (1993) [58] considered the mechanism of 
the proposed assimilation of cholesterol by Lactobacillus acidophilus and Bifidobacterium bifidum. 
Authors concluded that removal of cholesterol from the culture medium by L. acidophilus RP32 and 
other species was not due to bacterial uptake of cholesterol, but rather could relate to co-precipitation 
with de-conjugated bile salts in an acidic environment. De-conjugated bile acids are less soluble and less 
likely to be absorbed from the intestinal lumen than conjugated bile salts. Thus, de-conjugation of bile 
acids in the small intestine could result in a greater excretion of bile acids from the intestinal tract, 
especially as free bile acids are excreted more rapidly than their conjugated forms. Increased excretion 
of bile acids should result in lowered serum concentrations, which in turn would decrease the amount of 
bile acids reaching the liver for secretion back into the intestine through enterohepatic circulation. To 
replace the excreted bile acids, more would have to be synthesized from cholesterol in the liver. Thus, it 
has been suggested that in a steady state situation, de-conjugation of bile acids could lead to the 
reduction of serum cholesterol by increasing the formation of new bile acids or by reducing the 
absorption of cholesterol throughout the intestinal lumen. However, it remains unclear whether 
microbial bile de-conjugation properties are related to the hypocholesterolemic effects observed in vivo, 
because pH in the intestinal tract of humans is usually neutral to alkaline. 
                                                            
6 Pigs were used because their digestive system, distribution of coronary arteries, and atherosclerotic 
tendencies resemble those of humans. 
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Tahri et al. [59, 60] studied the hypothesis of the proposed assimilation or co-precipitation of 
cholesterol by Bifidobacterium species. They observed the existence of an intense binding between cell 
surface and cholesterol, which was considered as an uptake of cholesterol into the cells. This 
assimilation was dependent on cell growth and the presence of bile salts. They concluded that the 
observed removal of cholesterol from the broth could be attributed not only to the co-precipitation, but 
also to a conjugation. It still remains necessary to determine whether the requirement for bile salts is 
related to their detergent effect and if an inhibition of bile salt de-conjugation influences the assimilation 
of cholesterol. The same authors, in in vitro study in the absence of bacterial cells, observed that 
cholesterol was partially removed from the medium at pH values lower than 5.5 when de-conjugated 
bile salts were added. It was a transient phenomenon, and the precipitated cholesterol was re-dissolved 
when solutions were adjusted to pH 7. They concluded that resting cells of bifidobacteria do not interact 
with cholesterol, while growing cells of bifidobacteria  assimilate cholesterol in their cell membrane. No 
significant relationship was, however, noticed between cholesterol assimilation and the degree of bile 
salt de-conjugation by bifidobacteria, as previously reported for lactobacilli (Gilliland et al., 1985). It 
has been suggested that bile salts hydrolase activity might have a role in the mechanism of assimilation, 
as non de-conjugating bifidobacteria were not able to assimilate appreciable amounts of cholesterol even 
if conjugated or de-conjugated forms of bile salts were present in the growth medium. The authors 
concluded that this cholesterol assimilation model could explain the in vivo observed 
hypocholesterolemic effect. Further investigations are still needed to determine the mechanism of 
cholesterol assimilation and localization of the assimilated cholesterol in the cells. 
In  1997 Noh et al.[61] reported that cholesterol assimilated by L. acidophilus ATCC43121 was 
not metabolically degraded, as most of it was recovered with the cells. They observed that cells grown 
in the presence of cholesterol micelles and bile salts were more resistant to lysis by sonication. This 
could suggest a possible alteration of the cell wall or membrane by cholesterol.  
 Meei-YN Lin et al. [62] investigated the in vitro cholesterol reducing abilities of six L. 
acidophilus strains. A maximum cholesterol uptake of 57% was reported when L. acidophilus 
ATCC4356 was grown anaerobically for 24 h in a medium supplemented with bile acids . The authors 
concluded that the in vivo hypocholesterolemic effect of L. acidophilus cells was due to the direct 
assimilation by the cells and/or attachment of cholesterol to their surface. As previously mentioned, 
coprecipitation of cholesterol with decon-jugated bile acids, which occurs in vitro, is not likely to take 
place in vivo because pH of the small intestine is higher than 6.0. 
Lactic acid bacteria with active BSH, or cultured products containing them, were suggested . to 
lower serum cholesterol levels through an interaction with the host bile salt metabolism [63]. The 
proposed mechanism  is comparable to  cholestyramine treatment which, like other bile salt 
sequestrants, binds bile salts and prevents them from being reabsorbed. Thus, less bile salts would return 
to the liver, resulting in a loss of feedback inhibition of bile salt synthesis, and an increased conversion 
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of cholesterol to bile salts. This led the authors to suggest that the ingestion of lactic acid bacteria 
containing active BSH might be regarded as a ‘biological’ alternative to common medical or surgical 
interventions to treat hypercholesterolemia. 
Usman and Hosono [64, 65] focused on the binding abilities of the intact cells toward 
cholesterol. The authors found that all 28 strains of L. acidophilus were able to bind cholesterol, but the 
binding abilities varied widely. It was suggested that differences were related to chemical and structural 
properties of the bacterial cell wall peptidoglycans. In another study the same authors investigated the 
effect of a non-fermented milk supplemented with L. gasseri (SBT0270 and SBT0274), which  have 
previously been shown to exhibit high cholesterol- binding and taurocholate-deconjugating activities in 
vitro. The total and LDL-cholesterol levels were reported to be 42 and 64% lower, respectively, in the 
group given L. gasseri SBT0270 supplemented milk than in the milk-only group. Triglyceride levels 
decreased when rats were given milk and non-fermented milk supplemented with the bacterial strains in 
relation to the control group (water), while milk alone had no observed effect on total and LDL-
cholesterol. The authors attributed the observed hypocholesterolemic effect of L. gasseri SBT0270 to its 
ability to suppress the re-absorption of bile acids into the enterohepatic circulation (by de-conjugation), 
and to enhance the excretion of acidic steroids in feces. 
Probiotic bacteria, once resident in the human gut, ferment food-derived indigestible 
carbohydrates. This results in an increased production of short-chain fatty acids (SCFA). This has been 
suggested to cause a decrease in the systemic levels of blood lipids either by inhibiting hepatic 
cholesterol synthesis, or by redistributing cholesterol from plasma to the liver . The SCFA production in 
the large intestine has been reported to be 100 to 450 mmol/day, with relative proportions of acetate, 
propionate, and butyrate being about 60:20:15, depending on the substrate. Acetate in the serum seems 
to increase total cholesterol, while propionate increases blood glucose and tends to lower the 
hypocholesterolemic response caused by acetate by reducing its utilization by the liver for fatty acid and 
cholesterol synthesis. Indeed, a study by Wolever and colleagues [66] showed that serum acetate and 
propionate concentrations were related to serum lipid concentrations in both males and females, serum 
propionate being strongly negatively related to both total and LDL cholesterol (P < 0.001). However, 
sufficient propionate must be produced to offset the effects of acetate generation as a precursor for lipid 
synthesis. Therefore, depending on the proportion of fatty acids produced during bacterial fermentation, 
plasma cholesterol concentrations may be altered. Additionally, some bacteria may interfere with 
cholesterol absorption from the gut either by de-conjugating bile saltsor by directly assimilating 
cholesterol. A number of bacteria have been reported to hydrolyze conjugated bile acids, such as 
Bacteroides spp., bifidobacteria, fusobacteria, clostridia, lactobacilli, and streptococci. There is evidence 
that the gut flora not only hydrogenates, dehydrogenates, and oxidizes bile acids, but also cleaves side 
chains to yield steroids. In vivo, removal of cholesterol would occur because de-conjugated bile acids 
are not well absorbed by the gut mucosa and are excreted through the feces and urine. The excretion of 
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bile acids results in decreased enterohepatic recirculation and therefore more cholesterol, which is the 
precursor of bile acids, needs to be utilized for de novo bile acid synthesis. Moreover in vitro studies 
using different strains of L. acidophilus grown on media containing bile have shown that certain strains 
can modify cholesterol metabolism. Because the amount of bile in the medium did not exceed 
concentrations normally found in the intestine, it can be expected that this cholesterol assimilation 
would also occur in vivo. The uptake of cholesterol by bacteria would make it unavailable for absorption 
into the circulation. However, some work still needs to be undertaken in this field leading toward more 
conclusive clinical evaluations to understanding of the in vivo mechanisms of probiotic effect on blood 
lipids and to improvement of strain stability characteristics. Also, the in vitro ability to reduce 
cholesterol observed with some strains needs to be confirmed in mixed culture and mixed substrate 
environments [56-66] 
 
8.5 Food supplementation and safety 
In Europe, the European Food Safety Authority (EFSA), established and funded by the 
European Community as an independent agency in 2002, standardize food safety and the ability of 
regulatory authorities to fully protect consumers. In 2004 (13-14 December, Brussels, Belgium) 
EFSA defined the QPS: Qualified Presumption of Safety of Micro-organisms in Food and Feed 
[67]. 
The purpose of this document was to explore the possibility of introducing a system, similar in 
concept and purpose to the GRAS (Generally Recognised As Safe) [68] definition used in the USA, 
which could be applied to micro-organisms and eventually their products and to invite comments on 
its practicality. This claims do not look for reproducing the GRAS system but take account of the 
different social and regulatory climate present in Europe. This is necessary since issues of 
importance to Europe would not necessary influence a GRAS listing. An example of this would be 
the presence of acquired antibiotic resistance factors, considered highly undesirable in Europe but 
currently of lesser issue in the USA. 
QPS are defined as “an assumption based on reasonable evidence” and qualified to allow certain 
restrictions to apply. The scheme aims to have consistent generic safety assessment of micro-
organisms through the food chain without compromising safety standards. Individual evaluations 
would be limited to aspects particular to the organism, such as acquired antibiotic resistance 
determinants in lactic acid bacteria. QPS status would not apply to a micro-organism that 
commonly causes pathogenicity. A micro-organism would not necessarily be considered a potential 
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pathogen where there are infrequent reports of clinical isolates from severely ill people. Broadly the 
characteristics to be evaluated for QPS approval are: 
• Unambiguous identification at the claimed taxonomic level. 
• Relationship of taxonomic identity to existing or historic nomenclature. 
• Degree of familiarity with organism, based on weight of evidence. 
• Potential for pathogenicity to humans and animals. 
• The end use of the micro-organism. This will influence any qualifications imposed, 
depending on whether the organism is to be directly consumed; is a component of a food 
product not intended to enter the food chain, but which may adventitiously; or is used as 
a production strain in a product intended to be free of live organisms. 
Summarizing the concept, it is only when a probiotic strain has been unequivocally 
identified; characterized, screened and its mechanisms of action elucidated with scientific rigor; 
labeled accurately and truthfully; tested for safe and efficacious human use in randomized, blinded 
placebo-controlled clinical trials, ideally with independent verification; and undergone a risk-
benefit comparison with existing treatments that there will be evidence of sufficient quality to 
support the unjustified beneficial claims made to date for many proposed probiotics. [67-69] 
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EXPERIMENTAL STUDIES 
 
 
High serum cholesterol level is one of the major risk factor for cardiovascular diseases. 
Although different cholesterol lowering drugs exist, the possibility of nutritional interventions in the 
prevention and counteraction of hypercholesterolemia remains a very important issue. Beside an 
equilibrated and correct diet, different bioactive compounds could represent an additional strategy 
for reducing serum cholesterol, and therefore the incidence of cardiovascular diseases.  
During my PhD course I focused my attention on some of these bioactives, performing 
studies in cultured cells and experimental animals. Some of these studies were preliminary to the 
use of these compounds for lowering cholesterol. 
In the following chapter an overview of the performed experimental studies sorted by 
argument is reported. 
 
 
I. High within-sample variation in the expression of cholesterol metabolism and 
trafficking genes in human abdominal aortic aneurysm tissue precludes its use as a 
tissue culture model  
 
Note. The following study was carried out during my six month period abroad. It was 
performed at the Institute of Food Research IFR (Norwich, UK), and Norfolk and Norwich 
University Hospital NNUH (Norwich, UK) under the supervision of Prof. Paul A. Kroon. 
The aim of the investigation was to evaluate the potential of using cultured human 
abdominal aortic aneurysm tissue obtained during elective open surgery as a model to assess the 
vascular effects of bioactives.  
 
 
There is considerable interest in dietary bioactives such as n-3 polyunsaturated fatty acids 
and epigallocatechin-3-gallate that possess anti-hypercholesterolemic and anti-inflammatory 
activities. We investigated the potential of using cultured human abdominal aortic aneurysm (AAA) 
tissue obtained during elective open surgery as a model for assessing the vascular effects of 
bioactives. We quantified the mRNA levels for 5 genes involved in cholesterol metabolism and 
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trafficking. Inter-individual variation in gene expression of untreated tissue was extremely high (18, 
5-, 185-, 198-, and 317-fold for Srebp1, Srebp2, Ldlr, Acat2 and Hmgcr, respectively; n=4 patients). 
Within-patient variation in Srebp2 expression was also high (3-fold). The shortcomings of the tissue 
model precluded us from observing possible eicosapentaenoic acid, docosapentaenoic acid or 
epigallocatechin-3-gallate induced changes in gene expression. Human AAA tissue exhibits highly 
variable gene expression and is therefore not suitable as an in vitro model for evaluating the effects 
of xenobiotics on transcription.  
 
 
II.   Effect of n-3 LC-PUFA supplementation on the lipid environment: a HR-MAS NMR 
and GC study in cultured rat cardiomyocytes 
 
Note. N-3 polyunsaturated fatty acids are known to be involved in the prevention of 
cardiovascular diseases. However less is known on PUFA metabolic destiny and effects once inside 
the cell. This study aimed to elucidate the modifications occurring in the cell lipid environment after 
EPA and DHA supplementation. Investigation were carried out on cultured neonatal rat 
cardiomyocytes using high resolution magic angle spinning nuclear magnetic resonance technique 
in combination with gas chromatography. This research was carried out under the supervision of 
Prof. Vitaliano Tugnoli and Prof. Alessandra Bordoni, and was the result of an intense collaboration 
with The Department of Chemistry of the University of Modena and Reggio Emilia under the 
supervision of Prof. Luisa Schenetti and Prof. Adele Mucci. 
The manuscript has been accepted for publication in Lipids. 
 
It is well recognized that a high dietary intake of long chain polyunsaturated fatty acids (LC-
PUFA) has profound benefits on health and prevention of chronic diseases. Particularly, in recent 
years there has been a dramatic surge in interest on the health effects of n-3 LC-PUFA derived from 
fish, eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids. Notwithstanding, the metabolic 
destiny and the effects of these fatty acids once inside the cell has been seldom investigated in a 
global way. Using cultured neonatal rat cardiomyocytes as model system, we have investigated for 
the first time the modification occurring in the cell lipid environment after EPA and DHA 
supplementation by means of high resolution magic angle spinning nuclear magnetic resonance 
technique in combination with gas chromatography. 
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III. N-3 PUFA regulation of genes related to cholesterol metabolism is related to 
genotype 
 
Note. This in vivo investigation aimed to elucidate the effects of EPA and DHA 
supplementation in a rat model of metabolic syndrome. We focused on the modifications of hepatic 
gene expression after supplementation. The investigation was carried out using real time PCR as 
main technique. Experiments were done under the supervision of Prof. Alessandra Bordoni and 
Prof. Vitaliano Tugnoli. Some NMR analysis were also performed, in collaboration with the 
Department of Chemistry of the University of Modena and Reggio Emilia, under the supervision of 
Prof. Luisa Schenetti and Prof. Adele Mucci. 
 
Aim: To evaluate in liver the effect of EPA and DHA supplementation on the expression of genes 
related to cholesterol metabolism in two different strains of rat, SH and WK. 
Methods: 14 male WK rats and 14 male SH rats were used. SH rats are the most commonly used 
animal models for the metabolic syndrome, since they develop insulin resistance, hyper-
triglyceridemia, abdominal obesity, hypertension, and hypercholesterolemia 7 rats from each group 
received a control diet and 7 a diet enriched in n-3PUFA for 90 days. Plasma lipid profile, total lipid 
fatty acid composition in plasma and liver, and hepatic tissue cholesterol concentration were 
evaluated. The expression of Srebf-1, Srebf-2, Ldlr, Acat2, and Hmgcr was analysed by two step q-
PCR.  
Results: Dietary n-3 PUFA were absorbed, and incorporated in liver. In SH rats, the 
supplementation recovered the imbalanced blood parameters, lowering the atherogenic index. Gene 
expression analysis underlined that in control condition some genes were differently transcribed in 
the two strains, and PUFA molecular effects were different, according to the different genotype.  
Conclusions: genotype seems to influence the effects of n-3 PUFA at molecular level. Although 
further studies are needed, this observation could be useful while considering n-3 PUFA 
supplementation in humans with familial forms of hypercholesterolemia  
 
 
IV.  Phytosterols supplementation reduces metabolic activity and slows cell growth in 
cultured rat cardiomyocytes 
 
Note. Plant sterols are known to decrease cholesterol level, but they also inhibit the growth 
and development of tumours. Since these two effects are exerted at similar phytosterol 
 
Experimental studies 81 
concentrations, this work aimed to evidence possible adverse effects of phytosterols in non-
neoplastic cells. The study was carried out under the supervision of Prof. Alessandra Bordoni, in 
tight collaboration with Prof. Maria Fiorenza Caboni (Department of Food Sciences of the 
University of Bologna) and Prof. Andrea Pession (Department of Pediatrics Hematology and 
Oncology Unit “Lalla Seragnoli”, St. Orsola-Malpighi Hospital). 
This manuscript has been accepted for publication in British Journal of Nutrition, 
 
Phytosterols or plant sterols (PSs) are essential phytochemicals which have been shown to 
decrease serum total and LDL-cholesterol levels, and to inhibit the growth and development of 
tumours. PSs are poorly absorbed, but despite the low plasma concentration they can be 
incorporated into cell membranes, and their anti-neoplastic activity is accounted to the resulting 
interference of membrane composition and functionality. The similarity between the cholesterol-
lowering and anti-neoplastic PS effective doses deserves attention on the possible adverse effects 
even in non-neoplastic cells, but to date few studies have been addressed to the clarification of this 
important issue. In this study we supplemented primary, non-neoplastic neonatal rat cardiomyocytes 
with two different PS concentrations, both within the range of plasma concentration considered as 
effective for cholesterol-lowering. Cardiac cells were chosen as experimental model since the heart 
has been reported as the target organ for PS sub-chronic toxicity. Following supplementation a 
dose-dependent incorporation of PSs, and a decrease in cholesterol content were clearly evidenced. 
The replacement of cholesterol by PSs could have been the cause of the observed slowing down of 
cardiomyocyte growth and reduction in metabolic activity. The herein reported study is the first 
report on the effect of PSs in cardiac cells, and although it is difficult to translate the obtained 
results to the health of heart tissue, it raises the suspect that the long-term exposure to 
physiologically relevant PS concentrations is a potential hazard.  
 
 
V. Hypocholesterolemic effect of a new bifidobacteria mix on rat induced for 
hypercholesterolemia. 
 
Note. Probiotics are a large heterogeneous group of active non pharmacological compounds. Some 
strains seem to be able to decrease cholesterol absorption. Since different strains exert diverse 
outcomes on cholesterol metabolism, the aim of the following study was to evaluate the 
hypocholesterolemic effect of a probiotic mix on rat induced for hypercholesterolemia. This study 
was carried out under the supervisions of Prof. Alessandra Bordoni. The probiotic mix was a kind 
 
Experimental studies 82 
gift of Prof. Diego Matteuzzi (University of Bologna) and Prof. Maddalena Rossi (University of 
Modena). 
 
 
Aim. To evaluate the hypocholesterolemic effect of a probiotic mix (B. breve WC 0463, B. breve 
 WC 0420, and B. bifidum  WC 0417) on 30 days old male Wistar Kyoto rat nutritionally induced 
for hypercholesterolemia. 
Methods. After 15 day on 3% p/p cholesterol diet, total cholesterol, LDL-cholesterol, HDL-
cholesterol, atherogenic index, and triglyceride were evaluated in rats, evidencing a shift toward an 
atherogenic condition. Then rats were randomly divided into three groups, one fed a 1% 
hypercholesterolemic diet, one receiving the same diet plus the probiotics mix, and the third fed a 
standard diet. After further 30 days, total cholesterol, LDL-cholesterol, HDL-cholesterol, 
atherogenic index and triglyceride were evaluated.  
Results. The negative effects of a hypercholesterolemic diet were already evident after 15 days of 
treatment, and were reversed coming back to a standard diet. Treatment with the probiotic mix 
partially mitigated the effects of 1% hypercholesterolemic diet. Actually, administration of the 
probiotic mix reduced by 30% LDL-cholesterol, without affecting HDL-cholesterol. 
Conclusion. Our findings strength the hypothesized ability of bifidobacteria in reducing serum 
cholesterol level. In particular, the probiotic mix counteracted the effect of a high-cholesterol diet 
reducing LDL-cholesterol fraction by 30%.  The addition of suitable prebiotics could further 
enhance the observed effect.  
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I. High within-sample variation in the expression of 
cholesterol metabolism and trafficking genes in human 
abdominal aortic aneurysm tissue precludes its use as a 
tissue culture model1 
 
Elisa Boschettia,b, James R Baconb, Felicity Meyerc, Vitaliano Tugnolia, Alessandra Bordonid*, Paul 
A Kroonb* 
 
aDip. Biochimica "G. Moruzzi", University of Bologna, 48 via Irnerio, Bologna 40126, Italy. 
bInstitute of Food Research, Norwich Research Park, Norwich NR4 7UA, UK. 
cNorfolk and Norwich University Hospital NHS Foundation Trust, Norwich Research Park, 
Norwich NR4 7UY, UK. 
dDepartment of Food Sciences, University of Bologna, piazza Goidanich, 60 Cesena (FC) 47521 
Italy. 
 
Introduction  
 
Atherosclerotic cardiovascular disease (ACVD) is the leading global health problem as 
assessed by mortality [1]. Considerable research effort has focused on understanding the processes 
that lead to atherosclerotic plaque formation and growth, and also on interventions that can arrest, 
slow or reverse atherosclerosis. ACVD is understood to be a disorder of lipid accumulation and is 
also associated with inflammation [2]. Evidence from epidemiological and clinical trials, and from 
in vitro studies, indicates that certain diets and dietary components have the potential to inhibit 
atherosclerosis and reduce cardiovascular disease risk [3-5]. Some food bioactives, including 
flavonoids and n-3 polyunsaturated fatty acids (PUFAs), are recognized as both anti-
hypercholesterolemic and anti-inflammatory agents [3, 6-9]. The anti-inflammatory properties of 
epigallocatechingallate (EGCG) are well documented [10]. In addition, EGCG has been reported to 
                                                            
1  
Abbreviations: AAA: abdominal aortic aneurysm; Acat2: acyl-coenzyme A cholesterol transferase 
2; ACVD: atherosclerotic cardiovascular disease; DHA: docosahexaenoic acid; EGCG: 
epigallocatechingallate; EPA: eicosapentaenoic; Gapdh: glyceraldehyde phosphate dehydrogenase; 
HDL: high density lipoprotein; Hmgcr: hepatic 3-hydroxy-3-methyl-glutaryl-CoA reductase; LDH: 
lactate dehydrogenase; Ldlr: low-density lipoprotein receptor; PUFAs: poly unsaturated fatty acids; 
Srebp: sterol regulatory element binding proteins. 
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prevent lipid accumulation and alter lipoprotein levels in rats [11]. Eicosapentaenoic (EPA; C20 : 5 
n-3) and docosahexaenoic acid (DHA; C22 : 6 n-3), the main long chain n-3 poly unsaturated fatty 
acids (PUFAs), have been shown to lower serum triglycerides and total cholesterol levels, whilst 
increasing the levels of high density lipoprotein HDL-cholesterol (‘good cholesterol’) [12-14]. 
Furthermore, they are precursors of anti-inflammatory eicosanoids [15]. 
Due to the high incidence of ACVD globally, and the associated mortality, the identification 
of nutritional preventative strategies is crucial if the rate of the disease is to be controlled or 
reduced. Cultured cells or tissues are commonly used models for studying the effects and 
effectiveness of food components, and their mechanism of action. For the vasculature, cultured cell 
models are widely used (e.g. human umbilical vein endothelial cells, human umbilical aorta smooth 
muscle cells). However, vascular tissue models are rarely used, probably because of the lack of 
availability of suitable tissue. There are a number of reasons why cultured tissue models are more 
physiologically representative than single cell culture models. The main reason is that vascular 
tissues are complex and comprise multiple cell types (including endothelial cells, smooth muscle 
cells and macrophages) and an intercellular matrix that also performs important functions. The 
development of a cultured vascular tissue model would be a valuable experimental tool for 
exploring vascular responses to food components. 
In this report, we describe the culture of human aortic tissue obtained during elective open 
surgery with abdominal aortic aneurysm (AAA) patients, and experiments to test the possibility of 
using this tissue as an experimental model to investigate the effects of dietary components on 
certain vascular tissue functions. AAA aetiology involves dilation of all layers of the artery wall and 
is associated with inflammation [16, 17]. High plasma cholesterol concentrations have been 
associated with an increased risk of  AAA in large screening studies [18]. The aims were to (i) 
successfully culture AAA tissue, (ii) investigate within-patient and between-patient variation and 
develop an appropriate cultured tissue experimental design, (iii) determine the effects of EPA, 
DHA, and EGCG on the expression of various genes involved in cholesterol metabolism and 
trafficking. 
 
Materials and methods 
 
Materials 
5,8,11,14,17-Eicosapentaenoic acid (≥99%), cis-4,7,10,13,16,19-docosahexaenoic acid 
(≥98%), and Lactate dehydrogenase (LDH) based In Vitro Toxicology Assay Kit (TOX7) were 
purchased from Sigma Chemical (St. Louis, MO). EGCG was extracted from green tea by Dr Paul 
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Needs (Institute of Food Research, Norwich) and was shown to be ≥95% by HPLC. Medium 199 
was purchased from Invitrogen (Paisley, UK). RNA later, proteinase K, and RNase Mini Kits were 
purchased from QIAGEN (Crawley, UK), Taqman one-step RT-PCR Master Mix Reagent and 
predesigned TaqMan gene expression assays were purchased from Applied Biosystems (Foster 
City, USA). All other chemicals and solvents were of the highest analytical grade. 
 
Sampling and treatment 
Tissue samples, ranging in length from 3 to 7 cm, were collected from the Norfolk & 
Norwich University Hospital (NNUH) Human Tissue Bank according to local procedures and in 
accordance with international ethical guidelines on the use of human tissues in scientific research, 
and the Human Tissue Act (UK). The use of NNUH Human Tissue Bank tissue samples for 
research purposes had been approved by the Cambridge 1 Research Ethics Committee (REC 
Reference: 08/H0304/85) and the specific use of the tissue samples in this project was approved by 
the East Norfolk and Waveney Research 
Governance Committee, Norwich, UK 
[Proposal Ref: 2009HIST04S (91-06-09)]. 
Tissue samples were only used if the 
patient had provided informed consent for 
the spare resected AAA tissue to be used 
for scientific research purposes. Samples 
of aortic tissue were obtained from five 
patients undergoing surgery for open 
repair at the NNUH.  
The tissue sample obtained from each 
patient was cut into several pieces using 
sterile scissors, and subsequently each 
larger piece was cut into ~2 mm wide 
slices. Contiguous 2mm slices coming 
from the same larger piece of tissue were 
allocated to different wells in order to 
reduce the effects of tissue heterogeneity 
(figure 1). This process was repeated for 
each of the larger tissue pieces until each 
culture well contained several pieces of 
Figure 1. Scheme for sample preparation. Tissue was cut into
several pieces as indicated by the white dotted grid in panel a. Each
piece was subsequently cut into ~2 mm wide slices, as indicated by
the black dotted grid on panel b. Contiguous 2mm slices coming
from the same larger piece of tissue were allocated to different
wells on a stainless steel tissue grid support (panel c). This process
was repeated for each of the larger tissue pieces until each culture
well contained several pieces of aortic tissue from across the
original tissue sample. Atypical slices were discarded. 
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aortic tissue from across the original tissue sample. Atypical slices (e.g. exhibiting excessive 
calcification) were discarded. Tissue slices were placed on a stainless steel tissue grid support 
mounted on the bottom of a 6-well culture plate and cultured in GIBCO medium 199 containing 1% 
non essential amino acids, 2 mmol/L glutamine, 1 U/L penicillin, 1 g/L streptomycin and 5% fetal 
calf serum. The tissue was maintained overnight in a humidified cell culture incubator with 5% CO2 
at 37oC, then medium was removed and the different treatments were supplied in fresh media. EPA, 
DHA and EGCG stock solutions were prepared by dissolving the pure compound in 100% filtered 
ethanol. Equivalent concentrations of ethanol (<0.01% v/v) were added to not supplemented wells 
in order to control for potential vehicle interference. Bioactives were added to fetal bovine serum, 
and after 5 minutes incubation the medium was also added. For the tissue sample from each patient, 
5 different treatments were applied: (1) vehicle in control media, (2) 60 µM EPA, (3) 60 µM DHA, 
(4) 25 µM EGCG, (5) 25 µM EGCG + 60 µM EPA. After 24 h of incubation in the presence of the 
treatments, the tissue pieces were placed in 1.5 ml tubes containing RNA Later (1 ml), incubated at 
+4°C for 24h, and then frozen at -80°C. 
 
Assessment of tissue viability 
The relative number of cells surviving in an AAA tissue that had been prepared and 
maintained in culture in the manner described above was estimated using a lactate dehydrogenase 
(LDH) based In Vitro Toxicology Assay Kit (Sigma, TOX7). Untreated tissue samples were taken 
from culture at various time points, rapidly frozen on dry ice and stored at -80°C. Weighed pieces 
of frozen tissue (approx. 15 mg) were transferred to 1.5 ml tubes and dispersed in 300 µl kit LDH 
Assay Lysis Solution using a micro Ultra Turrax homogeniser. The homogenate was incubated at 
37°C for 30 min to complete cell lysis and then centrifuged at 13000 x g for 5 min. Aliquots of the 
supernatant were then assayed for LDH activity according to the kit manufacturer’s instructions and 
the resultant absorbance measured at 450 nm on an MRX-II 96-well plate reader (Dynex 
Technologies, Worthing, West Sussex, UK). LDH activity relative to tissue sampled at time zero 
was calculated. Tissue explants and the surface of cell culture dishes were also examined 
microscopically during culture to identify signs of cell proliferation. 
 
RNA extraction and quantification 
Total RNA was extracted from tissue using RNase Mini Kits. Weighed tissue (typically 
250 mg) from each treatment was cut into smaller pieces and homogenized in kit RLT buffer (2 ml) 
containing 1% β-mercaptoethanol using a PRO 400 homogenizer (Pro Scientific Inc, Oxford, USA). 
The homogenizer was rinsed with RNase-free water (4 ml). Proteinase K solution (65 µl ≡ 40 
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mAU) was added to the combined homogenate and washings and the mixture was incubated at 
55°C for 20 min. After centrifugation (5 min at 5000 x g), the supernatant was then processed 
according to the kit manufacturer’s instructions. RNA was eluted from RNase Mini columns using 
2 x 150 µl RNase-free water, quantified and assessed for purity on a nanodrop ND-1000 (Thermo 
Fisher Scientific Inc, Wilmington, USA). 
 
q-PCR analysis 
The protocol used was in accordance with the MIQE Guidelines: Minimum information for 
Publication of Quantitative Real-Time PCR Experiments [19]. All samples were prepared for q-
PCR in microamp optical 96-well plates in a total volume of 20µl per well using a CAS-1200 
automated PCR robot (Corbett Life Science, St. Neots, UK) with dedicated software. All reactions 
were carried out using Taqman One-step RT-PCR Master Mix Reagent on a Step-One-Plus real-
time PCR system with Step One Software v2.0. q-PCR conditions were as follows: 48°C 30 min; 1 
cycle of 95°C 20 min. 40 cycles: (95°C 15 sec; 60°C 1 min). TaqMan gene expression assays used 
were: sterol regulatory element binding proteins 1 and 2 Srebp1 (Hs00231674_m1), Srebp2 (Hs 
01081784_m1); acyl-coenzyme A cholesterol transferase Acat2 (Hs255067_m1); low-density 
lipoprotein receptor Ldlr (Hs00181192_m1); hepatic 3-hydroxy-3-methyl-glutaryl-CoA reductase 
Hmgcr (Hs 00168352_m1); Glyceraldehyde phosphate dehydrogenase Gapdh (Hs 99999905_m1), 
and beta-actin β-actin (Hs 9999993_m1). Data were analyzed using a standard curve generated by a 
serial dilution of total RNA from untreated tissue and then normalized against the expression of 
invariant endogenous control genes (GAPDH and β-actin).  
 
Results 
 
Culture of human AAA tissue 
The AAA tissue samples that were monitored for LDH activity showed only a small reduction in 
activity after 24h of culture (90.4±7.7%) compared to pre-cultured tissue. Tissue maintained in 
culture for longer periods still exhibited a high LDH activity, e.g. 60.7±4.8% after 4 days. In 
addition, microscopic observation of the cell culture dish revealed the appearance of clusters of 
loosely adherent new cells growing around the tissue explants for all the AAA tissue samples that 
were cultured, and it was also observed that the numbers of these cells increased with time. These 
results suggest that under the culture conditions used here the viability of the tissue is maintained 
and cell proliferation is stimulated. 
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Between patient variation in baseline (not treated) gene expression 
The variability of inter-individual gene expression was evaluated by comparing basal gene 
expression in not treated samples derived from the different patients. As shown in figure 2, the 
expression of all the selected genes appeared significantly different between patients for all 
examined genes (18-, 5-, 185-, 198-, and 317-fold for Srebp1, Srebp2, Ldlr, Acat2 and Hmgcr, 
respectively; n=4 patients; p<0.0001). 
 
 
Within patient variation in baseline (untreated) gene expression 
To test the possible existence of not only inter-, but also intra-individual variability in gene 
expression, six samples derived from the tissue of the same patient were evaluated for Srebp2 gene 
expression under basal conditions (no treatment) (Figure 3). The huge intra-individual variability 
observed (3-fold for Gapdh normalized data; n=6 samples analysed in triplicate; p<0.0001) was not 
related to technical problems, since technical replications on the same sample were almost identical. 
Figure 2: Inter-individual variability of basal gene expression in tissue derived from different patients. Basal expression
of Srebp1 (A), Srebp2 (B), Acat2 (C), Hmgcr (D) and Ldlr (E) was evaluated in untreated samples from 4 different
patients. Gene expression analysis was performed as reported in Methods. aGenes were normalized against Gapdh (∆cq)
and the average of all the not treated (NT) samples was used as calibrator (∆∆cq). Data are means +/- SD of three
technical replicates. Statistical analyses were by one way ANOVA (p<0.0001 for all genes). 
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Furthermore, normalization with two different reference genes, Gapdh and β-actin, generated a 
substantial change in the gene expression profiles. 
Effects of EPA, DHA and EGCG on gene expression 
The effect of the different treatments on gene expression was quantified for all the patient tissue 
samples. As shown in figure 4, none of the treatments caused significant differences in the mean 
expression of any of the 5 genes tested (compared to not treated samples). The high standard 
deviation values indicate that there is considerable variation in the measurements, which is 
consistent with the data in the two preceding subsections. 
 
Discussion  
 
Because the complexity of vascular tissue responses cannot be emulated in single cell 
culture models, the initial aim of the present study was to investigate the effect of three different 
bioactives, namely EGCG, EPA and DHA, on the expression of genes related to cholesterol 
metabolism (Srebp1, Srebp2, Acat2, Ldlr and Hmgcr), utilizing cultured explants of AAA as a 
model system. Absorbed bioactives are delivered to all tissues through the blood stream, and arterial 
vessels are directly in contact with the bioactives in the blood. Therefore, a cultured aortic tissue 
model would be expected to more closely replicate possible in vivo effects of bioactives, compared 
to a single cell-type culture model. 
 
Figure 3. Srebp2 gene expression in 6 untreated samples derived from the same patient. The quantification of Srebp2
transcripts was performed three times in each sample. a∆cq was compared against Gapdh (panel A) or β-actin (panel B),
then normalized against the average relative gene expression of Srebp2 in all the samples. Data are reported as mean +/-
SD. Statistical analysis was performed using one-way ANOVA (p<0.0001 in both comparisons). 
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Figure 4: Modulation of gene expression by tea catechins and n-3 PUFAs. Srebp1 (A), Srebp2 (B), Acat2 (C), Hmgcr 
(D) and Ldlr (E) expression is reported in not treated (NT, white bars) and treated samples (grey bars). aValue for each 
gene was obtained using ∆cq against Gapdh, and ∆∆cq was in comparison with the corresponding NT sample. Data are 
the means ± SD. Statistical analysis was performed using one-way ANOVA (n.s.). 
 
The main finding of this research was that there was substantial within-subject and between-
subject variation in gene expression. The within-subject variation in gene expression was high even 
though great care was taken to ensure that each culture well contained a representative set of tissue 
pieces from across the original tissue sample. In diseased tissue such as that of aneurytic aorta, it is 
not surprising that there is quite considerable within tissue variation in gene expression, but it was 
somewhat surprising that the effects of this variation could not be smoothed out by using multiple 
tissue pieces from across the original tissue sample. This observation likely means that there are 
small regions of the tissue in which genes are highly expressed, and other regions of the tissue in 
which gene expression is virtually absent. Normalization using two different reference genes 
resulted in different intra-sample profiles of srebp2 gene expression. Since reference genes can be 
differentially expressed in different cell types [20, 21], our data may be explained by the presence 
of different proportions of cell transcriptotypes in the different culture wells containing tissue slices 
from the same patient. This could be related to inflammatory cell infiltration [22]. Alternatively, a 
different Chol accumulation in the different areas of the lesion [23, 24] could have modulated the 
expression of genes related to Chol metabolism. It is well know that the sterol concentration 
regulates its own biosynthesis [25]. A previously published report has demonstrated that there can 
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be considerable heterogeneity in gene expression between cells isolated from the same piece of 
tissue. Trogan et al. [26] used laser capture micro-dissection to demonstrate considerable between 
cell variations in gene expression in macrophages isolated from atherosclerotic regions of 
apolipoprotein-E mice. 
The inter-sample variation described here (up to 317-fold for the 5 cholesterol metabolising 
and trafficking genes) was of a magnitude that was likely to seriously limit the potential utility of 
such a model for research purposes. High intra-subject and inter-subjects variations have been 
reported previously by Hennig et al. for samples from both Barrett’s mucosa and normal squamous 
epithelium [27]. 
Although we conducted experiments with cultured AAA tissue to examine the potential for the 
major tea catechin EGCG and fish oil n-3 PUFAs to modulate the expression of a set of genes 
involved in cholesterol metabolism and trafficking, we did not observe any significant changes in 
expression in response to the treatments. However, because the variability of expression of the 
target genes within and between tissues and subjects was shown to be very substantial, these data do 
not allow any conclusions to be drawn regarding the potential efficacy of EGCG, EPA or DHA to 
modulate the expression of these genes.  
 
Conclusions 
 
In conclusion, substantial within tissue variation in gene expression was observed in abdominal 
aortic aneurysm tissues obtained from patients who had undergone open surgery, and the magnitude 
of the variation precludes the use of such tissue in cultured tissue models for the purposes of 
investigating the effects of treatments on gene expression. 
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II. Effect of n-3 LC-PUFA supplementation on the lipid 
environment: a HR-MAS NMR and GC study in 
cultured rat cardiomyocytes 
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INTRODUCTION 
 
Cardiovascular diseases are responsible for significant morbidity and mortality throughout the 
world. It is well recognized that a significant dietary intake of polyunsaturated fatty acids (PUFA) 
has profound benefits on health and prevention of chronic disease states, although the overall 
responsible mechanism remains partially unclear [28, 29]. 
Supplementation with the main n-3 long chain polyunsaturated fatty acids (LC-PUFA), 
eicosapentaenoic acid (20:5n-3, EPA), and docosahexaenoic acid (22:6n-3, DHA) has been widely 
reported as protective for cardiovascular health, and fish oil feeding has been associated to reduced 
                                                            
2 Abbreviations: 1D: monodimensional; 2D: bidimensional; Ac: acetate; Ala: alanine; ARA: arachidonic 
acid; C: cholesterol; CE: cholesteryl esters; Cho: choline; ChoCC: choline-containing compound; COSY: 
COrrelation SpectroscopY; CPMG: Carr-Purcell-Meiboom-Gill; Cr: creatine; DHA: docosahexaenoic acid; 
DPAn-3: docosapentaenoic acid; EPA: eicosapentaenoic acid; Etn: ethanolamin; FA: fatty acid(s); FCS: fetal 
calf serum; FFA: unesterified fatty acids; GC: gas chromatography; Gln: glutamine; Glu: glutamate; Gly: 
glycine; GPC: glycerophosphocholine; HR-MAS: high resolution magic angle spinning; HS: horse serum; 
Lac: lactate; LB: lipid body(ies); LC-PUFA: long chain polyunsaturated fatty acid(s); Lys: lysine; MUFA: 
monounsaturated fatty acid(s); Myo: myo-inositol; NMR: nuclear magnetic resonance; PCho: 
phosphocholine; PEtn: phosphoethanolamine; PL: phospholipid(s); PtdCho: phosphatidylcholine; PUFA: 
polyunsaturated fatty acid(s); Scy: scyllo-inositol; TAG: triacylglycerol(s); Tau: taurine; TLC: thin layer 
chromatography; TOCSY: Total Correlation SpectroscopY; UDP: uridine diphosphate; α-CH of aminoacids 
(α-CH). 
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mortality in several studies [30-32]. Notwithstanding, the effects of these fatty acids (FA) on 
cardiac cell lipid environment are almost unknown. 
In this study we have coupled gas chromatography (GC) analysis and high-resolution magic-angle 
spinning (HR-MAS) nuclear magnetic resonance (NMR) spectroscopy to evidence the 
modifications occurring in the lipid environment and in the metabolic profile of cultured 
cardiomyocytes supplemented with n-3 PUFA. Chromatographic methods have become the 
standard for analyzing FA composition [33]. Particularly, GC is sensitive and specific for FA 
analysis, while HR-MAS NMR spectroscopy takes a picture of the whole metabolic profile 
detecting lipids, macromolecules, and small metabolites. Using HR-MAS NMR the sample can be 
analyzed directly without any manipulation, and many different compounds such as 
macromolecules, lipids, and small metabolites can be detected at the same time [34, 35]. The study 
of cellular metabolism using NMR spectroscopy has been successfully carried out for years in cell 
extracts solution, either hydrophilic or lipophilic. More recently, the development of HR-MAS 
techniques has made the direct analysis of cells increasingly preferred for metabonomic studies 
[36]. HR-MAS NMR spectroscopy is currently employed for the analysis of the biochemical profile 
of complex systems such as biofluids, biological tissues, or cells. In fact, it can provide the 
detection of many different metabolites, and information on the metabolic changes occurring in 
response to external stimuli, e.g. drug exposure, or disease [35]. To our knowledge, HR-MAS NMR 
investigations, alone or combined with GC analysis, involving cardiomyocytes are still virtually 
absent. In our opinion, they could offer baseline data for future investigation on the effects of FA 
supplementation to mammalian cells. 
 
MATERIALS AND METHODS 
 
Materials. FA, Ham F10 media, fetal calf serum (FCS), horse serum (HS), gentamicin, 
amphotericin B, 2′,7′-dichlorofluorescein were from Sigma (St. Louis, MO, USA). Hexane, diethyl 
ether, and formic acid were purchased from Carlo Erba (Milan, Italy). All other chemicals and 
solvents were of the highest analytical grade. 
Cardiomyocytes cell cultures. Primary cultures of neonatal rat cardiomyocytes were obtained from 
the ventricles of 2-4 day-old Wistar rats according to Yagev et al. [37]. Cells were seeded at the 
density of 1.5x106 cells/ml in 100-mm i.d. Petri dishes in Ham F10 nutrient mixture supplemented 
with 10% v/v FCS, 10% v/v HS, gentamicin (1%), amphotericin B (1%), and grown at 37°C, 5% 
CO2 and 95% humidity. The study protocol was approved by the Animal Care Committee of the 
University of Bologna (Italy) (prot. n. 58897-X/10). Forty-eight h after seeding, cardiomyocytes 
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were randomly divided in control and FA supplemented groups. EPA and DHA were dissolved in 
ethanol, added to FCS to allow binding to albumin, and supplemented at 60 µM concentration. 
Control medium was added with the same volume of ethanol (≤0.1% v/v) to avoid interference due 
to vehicle. Media were changed every 48 h, and cardiomyocytes were grown till complete 
confluence in a monolayer (day 8 from seeding). 
Cardiomyocytes FA composition. At confluence cardiomyocytes were washed three times with 
ice-cold phosphate buffered saline, scraped off, and cell total lipids were extracted according to 
Folch et al. [38]. Washings were analyzed by GC to ensure that supplemented FA had been 
completely removed and did not interfere with following analyses. Total cell lipids were separated 
by thin layer chromatography (TLC) using plates coated with silica gel G. Plates were developed in 
hexane/diethyl ether/formic acid (8:2:0.1 by vol). Spots were made visible under ultraviolet light by 
spraying with 2′,7′-dichlorofluorescein (0.2% w/v in ethanol), and identified by comparison with 
authentic co-chromatographed standards. Spots corresponding to the phospholipid (PL) and 
triacylglycerol (TAG) fractions were scraped off, extracted with methanol or dimethylether, 
respectively, and methylesterified according to Stoffel et al. [39]. Prior to methyl esterification, 
pentadecanoic acid was added as internal standard. FA composition (as methyl esters) was 
determined by GC (GC 8000, Fisons, Milan, Italy) using a capillary column (SP 2340, 0.2 µm film 
thickness) at a programmed temperature gradient (160-210°C, 8°C/min), as previously reported 
[40]. The gas chromatographic peaks were identified on the basis of their retention time ratios 
relative to methyl stearate and predetermined on authentic samples. Gas chromatographic traces and 
quantitative evaluations were obtained using a Chrom Card Software computing integrator (Thermo 
Electron Scientific, Milan, Italy). 
Nuclear Magnetic Resonance Spectroscopy. At confluence, after washing with ice-cold 
phosphate buffered saline, cells were scraped off in deuterated water. Fifty µl of the cell suspension 
were introduced in a 50 µl MAS zirconia rotor (4 mm OD), closed with a cylindrical insert to 
increase sample homogeneity, then transferred into the probe cooled to 4°C. 1H and 13C HR-MAS 
NMR spectra were recorded with a Bruker Avance 400 spectrometer operating at 400.13 and 
100.61 MHz, respectively. The instrument was equipped with a 1H,13C HR-MAS probe, which 
temperature was controlled by a Bruker Cooling Unit. The whole experiments were performed at 
4°C to prevent cell degradation processes [41]. Samples were spun at 4000 Hz. After an about 20 
min set up, three different types of monodimensional (1D) proton spectra were acquired by using: i) 
a composite pulse sequence (zgcppr) [42], with 1.5 s water-presaturation during relaxation delay, 8 
kHz spectral width, 32k data points, 32-64 scans; ii) a water-suppressed spin-echo Carr-Purcell-
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Meiboom-Gill (CPMG) sequence (cpmgpr) [43], with 1.5 s water presaturation during relaxation 
delay, 1 ms echo time (τ), and 360 ms total spin-spin relaxation delay (2nτ), 8 kHz spectral width, 
32k data points, 128 scans; and iii) a sequence for diffusion measurements based on stimulated echo 
and bipolar-gradient pulses (ledbpgp2s1d) [44] with big delta 200 ms, eddy current delay Te 5 ms, 
little delta 2*2 ms, sine-shaped gradient with 32 G/cm followed by a 200 μs delay for gradient 
recovery, 8 kHz spectral width, 8k data points, 256 scans. Two-dimensional (2D) 1H,1H-
COrrelation SpectroscopY (COSY) spectra [45, 46] were acquired using a standard pulse sequence 
(cosygpprqf) and 0.5 s water presaturation during relaxation delay, 8 kHz spectral width, 4k data 
points, 32 scans per increment, 256 increments. 2D 1H,1H-TOtal Correlation SpectroscopY 
(TOCSY) spectra [47, 48] were acquired using a standard pulse sequence (mlevphpr) and 0.5 s 
water-presaturation during relaxation delay, 100 ms mixing (spin-lock) time, 4 kHz spectral width, 
4k data points, 32 scans per increment, 128 increments. NMR spectra of specimens were analyzed 
using MestReC software (Mestrelab Research, Santiago de Compostela, Spain). A line-broadening 
apodization function of 5 Hz was applied to lead diffusion-edited HR-MAS 1H FIDs prior to 
Fourier transformation. NMR spectra were referenced with respect to FA terminal -CH3 signal at δ 
0.89 ppm, manually phased, and a Whittaker baseline estimator was applied to subtract the broad 
components of the baseline. 
Statistical analysis. Three batches for each type of samples (control, EPA supplemented and DHA 
supplemented cardiomyocytes) derived from three independent cell cultures were analyzed. 
Statistical analysis was performed by the Student’s t test comparing control and LC-PUFA 
supplemented cells. 
 
RESULTS 
 
HR-MAS NMR. The metabolic pattern of un-supplemented, control cardiomyocytes can be 
derived by the analysis of the spectra shown in figure 1. The first spectrum (figure 1a) is a 
conventional presaturated 1D spectrum detecting lipids, macromolecules, and small metabolite 
contribution. Figure 1b shows the spectrum obtained using a CPMG spin-echo sequence. This 
allows to separate signals according to their different T2, and to enhance the resonance of small 
metabolites with respect to macromolecules. The small metabolites are labeled in figure 1b: alanine 
(Ala), choline-containing compounds (ChoCC), creatine (Cr), glutamate (Glu), glycine (Gly), myo-
inositol (Myo), phosphoethanolamine (PEtn), scyllo-inositol (Scy), taurine (Tau), ; α-CH of 
amminoacid (α-CH). The diffusion-edited spectrum (figure 1c) displays broad resonances arising 
 
Experimental studies 96 
from macromolecules. Particularly, mobile FA chains [signals at 0.89 ppm (-CH3), 1.33 ppm 
 
Figure 1. Representative ex vivo HR-MAS 1H NMR spectra of neonatal rat cardiomyocytes: water-presaturated pulse 
sequence with composite pulse (a), CPMG spectrum (b), and diffusion-edited spectrum (c).  
The mayor metabolites are labeled: alanine (Ala), choline-containing compounds (ChoCC), creatine (Cr), glutamate 
(Glu), glycine (Gly), phosphoethanolamine (PEtn), scyllo- (Scy) and myo-inositol (Myo), taurine (Tau), α-CH of 
aminoacids (α -CH). Lipid components are labeled: 1, -CH3; 3, acyl chain methylene- (CH2)n; 5, CH2C=C; N(CH3)3+, 
signal for PL components. 
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(CH2)n, and 2.03 ppm CH2C=C], and phosphatidylcholine (PtdCho) [signal at 3.26 ppm N(CH3)3+] 
are clearly detectable. Membrane PL do not contribute significantly to the NMR signals due to their 
low mobility and short relaxation times. Control cardiomyocytes 1H HR-MAS NMR spectra were 
used for the comparison with spectra obtained from cells supplemented with EPA and DHA. 
In figure 2 the conventional water-presaturated 1H spectra of control (2a), EPA supplemented (2b), 
and DHA supplemented (2c) cardiomyocytes are reported. In the spectra of n-3 LC-PUFA 
supplemented cardiomyocytes it is possible to recognize the characteristic signals from unsaturated 
FA. The resonances of FA chains are identified as: 1, methyls (-CH3) at 0.89 ppm (saturated FA 
chains), and 2, -CH3 at 0.96 ppm (n-3 EPA, and DHA); 3, acyl chain methylenes (CH2)n (1.33 
ppm); 4, CH2-C-CO (1.58 ppm); 5, CH2C=C (2.02 ppm); 6, CH2CO other than DHA (2.25 ppm) 
and 7, CH2CO of DHA, (2.33 ppm ); 8, =C-CH2-C= (2.78 ppm); 9, -CH=CH-(5.33 ppm) [49-51]. 
Signals at 2.02 ppm are assigned to methylene protons of the CH2-CH=CH moiety of both 
monounsaturated FA (MUFA) and PUFA, while the signal at 2.78 ppm is characteristic of PUFA 
[49, 50]. Both MUFA and PUFA are also identified by the signals at 5.33 ppm, due to the protons 
of the -CH=CH- moiety. 
The comparison of 1H NMR spectra of supplemented and control samples shows that the PUFA 
signals are dominant in EPA and DHA supplemented cardiomyocyte spectra, whereas they are 
almost absent in those of control cells. Moreover, the signal at 2.33 ppm, characteristic of DHA 
CH2-CO and CH2-C-CO protons, permits the distinction between DHA and EPA supplemented 
samples. 
In figure 3 the 1H HR-MAS NMR diffusion-edited spectra of control (3a), EPA supplemented (3b), 
and DHA supplemented (3c) cardiomyocytes are reported. According to literature, lipid 
components are identified as above. Signals 10 and 11, due to bonded glycerol (4.10 and 4.30 ppm) 
are clearly detected, especially in the case of DHA supplemented cells. 
The comparison of these spectra shows an increase of signals coming from mobile lipids in PUFA 
supplemented cells with respect to the unsupplemented ones. Low PL signals (particularly that of 
N(CH3)3+ at 3.26 ppm) are present, together with macromolecules broad components, in the control 
cell spectrum (see figure 3a). In supplemented cells, these signals are obscured by the high intensity 
of signals from PUFA, mainly bonded to glycerol in TAG. Signals from CH2 of bonded glycerol in 
TAG are clearly seen at 4.30 and 4.10 ppm (see figure 3, signal 10, 11), whereas the CH resonance 
at 5.26 ppm is overlapped by the CH=CH protons of FA chains. Signals attributable to cholesterol 
(C) or cholesteryl esters (CE), the most characteristic of which is that of 18-CH3, at about 0.7 ppm, 
are not detected. 
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Figure 2. Water-presaturated ex vivo HR-MAS 1H NMR spectra of control (a), EPA (b), and DHA (c) supplemented 
cardiomyocytes.  
Lipid components are labeled as in the previous figure and: 2, DHA and EPA -CH3; 4, CH2-C-CO; 6, CH2CO other than 
DHA; 7, CH2CO and CH2-C-CO of DHA; 8, =C-CH2-C=; 9, CH=CH. 
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Figure 3. 1H HR-MAS NMR diffusion-edited spectra from control (a), EPA (b), and DHA (c) supplemented 
cardiomyocytes.  
Lipid components are labeled as in previous figures and: 10 and 11, bonded glycerol. 
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The evaluation of the variation of the mobile lipid components can be obtained by the integration of 
the resonances present in HR-MAS led diffusion-edited spectra (figure 4). Supplemented 
cardiomyocytes show a general increase of lipid signals, particularly unsaturated FA, which are 
almost absent in control cells (lack of signals at 2.78 ppm and 5.33 ppm). Instead, the PL fraction 
(N(CH3)3+ signal at 3.26 ppm) does not seem significantly affected by supplementation (see figure 
3). In EPA and DHA supplemented cardiomyocytes glycerol bonded signals (at 4.10 and 4.30 ppm), 
absent in control cells, are detected, indicating that NMR-visible FA are involved in TAG. The 
comparison between theoretical (6:4) and experimental (7.4:4) TAG integral ratio between the 
CH2CO (2.25 ppm) and glycerol (4.30 and 4.10 ppm) signals in EPA supplemented cell spectra 
points to the presence of almost completely glycerol-esterified FA chains, and a slight excess of 
unesterified FA (FFA). The same approach, if applied to DHA samples, is less straightforward. In 
this case two signals, at 2.33 and at 2.25 ppm, derive from CH2CO protons (DHA and other FA, 
respectively), and the former receives also a contribution from CH2-C-CO protons of DHA. 
Moreover, the signal at 2.25 ppm accounts for about 25-30% of the total integral (2.25+2.33). The 
theoretical ratio between the integrals of the signals at 2.25+2.33 ppm and that of glycerol (4.30 and 
4.10 ppm) is 12:4 in the case of glycerol-triesterified with DHA (signal at 2.25 ppm absent) and 6:4 
in the case of glycerol-triesterified with FA other than DHA (signal at 2.33 ppm absent). On these 
basis, in DHA supplemented cells we calculate a [DHA/(FA other than DHA)] ratio of about 3:2 
and a theoretical ratio of (12x0.6+6x0.4)= 9.6:4 for FA involved in TAG. This compares well with 
the experimental value of 10.1:4, and indicates that the NMR visible lipid signals are due to almost 
completely glycerol-esterified FA chains also in DHA supplemented cells. 
 
Figure 4. Relative amount from HR-MAS diffusion edited spectra of lipid components from control, EPA, and DHA 
supplemented cardiomyocytes.  
X axis represents ppm, and Y-axis intensity; the spectra are scaled respect to -CH3. Data are reported as means ± SEM. 
Lipid components are labeled: 1, -CH3 (0.89 + 0.96 ppm); 2, -CH3 from EPA and DHA (0.96 ppm); 3, acyl chain 
methylene- (CH2)n; 4, CH2-C-CO; 5, CH2C=C; 6, CH2CO (2.25 ppm); 7, CH2CO and CH2-C-CO from DHA (2.33 
ppm); 8, =C-CH2-C=; 9, CH=CH; 10 and 11, bonded glycerol (4.10 and 4.30 ppm).  
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Figure 5 reports the CPMG HR-MAS 1H NMR spectra of control (5a), EPA (5b) and DHA (5c) 
supplemented cardiomyocytes. In the spectra some residual signals from EPA and DHA are present, 
indicating that some protons in PUFA chains are characterized by long transverse relaxation times 
T2. Hence the chains are not only slowly diffusing (as appears from diffusion edited spectra), but 
also free to rotate. This situation is usually indicative of the presence of lipid bodies (LB) in the cell 
[49, 50, 52]. As above reported, the NMR data show that these lipids are essentially constituted by 
mobile TAG.  
The analysis of the CPMG spectra shows that supplementations do not have relevant effects on the 
small metabolites (polyols, osmolites, and aminoacids) profile. They were assigned by direct 
inspection of 1D and 2D spectra (COSY and TOCSY spectra, here not reported), and by 
comparison with literature data [53, 54] The main metabolites detected by HR-MAS NMR in 
cardiomyocytes are ethanol, lactate (Lac), Ala, acetate (Ac), Glu, Cr, Tau, Gly, choline (Cho), 
ethanolamine (Etn) phosphocholine (PCho), glycerophosphocholine (GPC), Sci and Myo, PEtn, 
uridine-diphosphate (UDP), adenine, trace of glutamine (Gln), and lysine (Lys). 
GC. In the PL fraction (figure 6a), EPA supplementation to cardiomyocytes leads to an 
enhancement of the relative molar content of both EPA itself and its metabolic elongation derivative 
docosapentaenoic acid (22:5n-3, DPA) [28]. No further conversion of n-3 DPA to DHA is detected. 
Following DHA supplementation, the relative molar content of this FA increases, without any 
appreciable retroconversion to DPA or EPA. The increased incorporation of n-3 PUFA is 
accomplished to a decrease in palmitoleic (16:1n-7), oleic (18:1n-9), and arachidonic acid (20:4n-6, 
ARA) relative molar contents. 
In the TAG fraction (figure 6b), EPA is not incorporated as itself but after conversion in its 
derivative DPA [55], while DHA is incorporated without any further metabolization. In both cases, 
a concomitant decrease in the relative molar content of saturated FA and ARA is detected. 
The total amount of FA esterified in the PL fraction is slightly lower in DHA supplemented cells 
than in controls (figure 7a). On the contrary, the low amount of FA esterified in the TAG fraction of 
control cells significantly increases after EPA and DHA supplementation, as shown in figure 7b. 
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Figure 5. 1H CPMG ex vivo HR-MAS 1H NMR spectra of control (a), EPA (b), and DHA (c) supplemented 
cardiomyocytes.  
The major metabolites are labeled as in previous figures and: choline (Cho), ethanolamine (Etn), 
glycerophosphocholine (GPC), lactate (Lac), phosphocholine (PCho). 
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Figure 6. Fatty acids composition of PL (a) and TAG (b) 
derived control, EPA, and DHA supplemented 
cardiomyocytes. 
Data are expressed as moles/100 moles and are means ± SD 
of at least three independent cell cultures. Statistical analysis 
was by the Student’s t test comparing control and n-3 LC-
PUFA supplemented cells: # P<0.05; ° P<0.01; * P<0.001 
 
Figure 7. Acyl content of PL (a) and TAG (b) derived from 
control, EPA, and DHA supplemented cells. 
Data are expressed as µg/plate and are means ± SD from at 
least three independent cell cultures. Statistical analysis was 
by the Student’s t test comparing control and n-3 LC-PUFA 
supplemented cells: # P<0.05; ° P<0.01; * P<0.001. 
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DISCUSSION 
Cells contain a considerable amount of polar lipids, PL and C, and neutral lipids such as TAG and 
CE. Taken together, these account for roughly 4-16% of total and some 20-50% of dry cell mass 
[56]. Although NMR is considered a universal detector, lipid 1H NMR resonances are not always 
observed in tissues that are rich in C and PL. This directly implies that 1H NMR visible lipids must 
have unique structural and biochemical properties that set them apart from the bulk of tissue lipids. 
This apparent paradox is resolved by considering the physical basis of NMR, which underscores the 
importance of sufficient molecular mobility in the immediate chemical environment for a given 
molecule to become detectable by NMR [52]. Lipid resonances must arise from the isotropically 
tumbling, relatively non restricted molecules. Since it is known that LC-PUFA mainly incorporate 
into membrane PL, the use of NMR alone does not allow a complete overview of the lipid 
environment. For this reason, we coupled GC analysis to NMR. As expected, signal related to PL is 
very low in NMR analysis, regardless the experimental condition, whereas GC analysis, besides 
detecting PL, shows that EPA and DHA supplementation causes a wide modification of PL FA 
composition. In several studies, the biological effects of n-3 LC-PUFA have been ascribed to the 
incorporation of these FA into PL in cellular membranes, where they may alter membrane fluidity 
and functionality, and may affect cellular eicosanoid synthesis [57-60]. According to GC data, EPA 
and DHA are actively incorporated in the PL fraction displacing ARA, which relative molar content 
is reduced by more than 50%. It is conceivable that the modifications occurred in PL after EPA and 
DHA supplementation could cause important changes not only in membrane structure, but also in 
membrane and cell functionality. The total amount of FA esterified in PL is decreased in 
supplemented cardiomyocytes, particularly in DHA supplemented ones (Figure 7a). The larger 
packing free volume associated with LC-PUFA-rich membranes could explain in part the reduction 
of the acyl content in the PL fraction. In fact, in saturated or monounsaturated membranes the acyl 
chains pack quite uniformly, while in membranes containing DHA the packing is distorted by the 
steric restrictions associated with a higher surface area of the FA [61]. As an alternative, EPA and 
DHA could have triggered a remodeling mechanism causing an increase in lyso-PL. Actually, DHA 
and EPA have been shown to alter cell membranes increasing the activation of phospholipase A2 
[62]. 
The most important difference between control and n-3 LC-PUFA supplemented cardiomyocytes 
highlighted by HR-MAS NMR spectroscopy is the increase of signals coming from mobile lipids, 
identified as TAG. Regarding TAG, two alternative sources for 1H NMR visible mobile lipid 
resonances have been proposed, i.e. membrane-associated globular microdomains [63, 64] and 
intracellular LB [65, 66]. Many in vitro cell studies and in vivo diffusion measurements have 
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suggested the importance of LB as contributors to 1H NMR detectable lipid resonances [52, 65-67]. 
It is therefore conceivable that the observed increase of NMR-visible TAG in supplemented cells is 
associated to an enhanced presence of LB, as already reported for human cardiomyocytes [68]. The 
observed increase of mobile TGs could represent a metabolic response to n-3 LC- PUFA 
supplementation, which leads to an increased lipid storage. The increase in the total amount of FA 
incorporated in TAG, as well as the higher relative molar content of n-3 LC-PUFA in this fraction 
after supplementation, is confirmed by GC. Our data are in agreement with Finstad et al. [69], who 
evidenced in monocytic U937-1 cells an increase in TAG content after treatment with 60 μM EPA. 
This TAG increase was accompanied by the accumulation of LB. 
The second hypothesis has been considered the more probable in the last years [70, 71]. The 
sequestration of mobile lipids in LB provides a deposit of stored energy that can be accessed in a 
regulated fashion according to metabolic need [72]. In particular, the myocardium stores FA, the 
major energy substrate for normal heart function, as TAG in LB [73]. 
Incorporation of n-3 LC-PUFA into TAG-rich LB could also be the basis for a yet unknown 
mechanism important for cell regulation. First, the storage of FA in LB may function to protect the 
cells from exposure to high concentrations of FFA. Secondly, a TAG pool rich in LC-PUFA may be 
an important reservoir for signal molecules. Finstad et al. [69] suggested that EPA, DPA and DHA, 
when liberated from an intracellular storage pool, affect intracellular signal transduction systems 
differently than when released from cellular PL. Furthermore, LC-PUFA stored as TAG in LB 
could be used for membrane PL synthesis. In the heart, the synthesis of PL to ensure membrane 
homeostasis is a priority that warrants the membrane depolarization that triggers cardiac contraction 
[73]. It is also possible that n-3 LC-PUFA stored in TAG may influence cardiomyocytes gene 
expression via PPAR-dependent signal pathways. We have already demonstrated that incubation of 
with 60 μM EPA and DHA alters the expression of different genes [74]. 
The accumulation of LB has been correlated with the reduction in cell number, inhibition of 
proliferation and induction of apoptosis in monocytic U937-1 cells [69]. In a previous study, 
supplementing neonatal rat cardiomyocytes with the same EPA and DHA concentration, we 
observed a modest increase in cell growth and no significant alteration in cell cycle distribution. 
Furthermore, n-3 LC-PUFA supplementation significantly protected cardiomyocytes from apoptosis 
[74]. The different cell type used in these studies can explain the different results, underlining that 
cell response to LC-PUFA supplementation can be deeply different. 
The signal from C or CE is not detected in cardiomyocyte NMR spectra, probably due to their low 
mobility. Similarly, the TLC spot corresponding to CE was hardly detectable, regardless the 
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supplementation. This is in agreement with Finstad et al. [75] who, supplementing different cell 
lines with labeled EPA, evidenced that only the 1% of the FA was recovered in the CE fraction. 
Regarding the small molecules, the HR-MAS NMR metabolic characterization of cardiomyocytes 
exhibits only negligible variations of the metabolic profile among differently treated cells. Indeed, 
the metabolome of unsupplemented and supplemented cells is characterized by the same small 
metabolites (mainly Ala, Lac, Ac, Glu, Cr, Tau, Gly, Cho, PCho, GPC, Sci, Myo, PEtn, Gln, UDP, 
adenine and Lys) in almost the same relative ratios. N-3 LC-PUFA supplementation to neonatal rat 
cardiomyocytes causes a huge variation in the cell lipid environment, but a negligible variation in 
the metabolome. 
In conclusion, the simultaneous use of 1H HR-MAS NMR spectroscopy and GC permits to derive 
information on the cell lipidome and metabolome. This work shows the complementary potential of 
these techniques. Furthermore, in our knowledge it is the first report on changes in the lipid 
components of cardiomyocytes after n-3 LC-PUFA supplementation. The understanding of the 
modification of the lipid environment represents a further step towards the clarification of n-3 LC-
PUFA role in cardiovascular disease prevention. 
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III. N-3 PUFA regulation of genes related to cholesterol 
metabolism is related to genotype 
 
INTRODUCTION 
Although cholesterol (Chol) is essential for membrane structure and as precursors of 
hormones, vitamin D, bile acids and other bioactive molecules [76], it is perceived as dangerous 
since its increased total plasma concentration is an important risk factor for cardiovascular diseases 
(CVDs) [77]. Human Chol concentration mainly depends on de novo endogenous biosynthesis and 
on dietary intake, with a ratio estimated as ~70:30 [78]. Endogenous synthesis is subject to 
feedback control by hepatic 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-CoAR) activity, 
the rate-limiting enzyme in Chol biosynthesis that catalyzes the formation of mevalonate from 
HMG-CoA [79]. The exogenous supply is mainly controlled by the modulation of the low-density 
lipoprotein receptor (LDLr) [80], which mediates the clearance of Chol and cholesteryl ester-
containing low-density lipoprotein (LDL) particles from the blood [81]. 
Prevention trials using statins have demonstrated that lowering Chol results in a substantial 
decreased risk of CVD events [82]. Statins are widely used for reducing hypercholesterolemia 
although their side effects have been largely demonstrated [83, 84]. It would be therefore crucial to 
identify nutritional agents able to reduce cholesterolaemia, and to accomplish them to a low-Chol 
diet for an effective cholesterol-lowering nutritional strategy. 
The feedback control of HMG-CoAR and LDLr occurs through regulation of gene 
transcription or by regulation of protein level through translation or degradation [85]. Both Hmgcr 
and Ldlr encoding genes exhibit the sterol response element (SRE) sequence, and are recognized as 
SREBP-regulated genes [86, 87]. The sterol regulatory element binding proteins (SREBPs) are 
helix-loop-helix transcription factors involved in the transcription of gene related to Chol and lipid 
biosynthesis. Three members of the SREBP family have been described in several mammalian 
species: SREBP-1a and 1c produced from a single gene (Srebf-1) located on human chromosome 
17p11.2, and SREBP-2 from a separate gene (Srebf-2) located on human chromosome 22q13. 
SREBP-1a and SREBP-2 increase the expression of genes involved in Chol synthesis, and SREBP-
1c of genes related to fatty acid (FA) and triglyceride (TG) synthesis [88]. The endoplasmic 
reticulum (ER) houses the precursor of SREBP and associated proteins, the cholesterol-sensor 
protein SCAP (SREBP Cleavage Activating Protein) and the ER retention protein, Insig [89]. Chol 
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biosynthetic enzymes, such as HMG-CoAR, also reside in the ER [90] along with the Chol 
etherifying enzyme acyl-CoA: cholesterol acyltransferase (ACAT) [91] Excess cellular Chol is 
converted to cholesteryl esters (CE) by ACAT-2 or is removed from  cell by cellular Chol efflux at 
the plasma membrane [92]. Sterol-sensing domains are present in several membrane proteins, 
including HMG-CoAR, ACAT, and the SREBP cleavage–activating protein [92]. 
Polyunsaturated fatty acids (PUFAs) are among nutritional candidates for lipid synthesis 
regulation. Fish oil, rich in n-3 PUFAs, has proven to lower serum levels of triglycerides (TG), 
Chol, free fatty acids, and to elevate high-density lipoprotein cholesterol (HDL-chol) [12-14]. It has 
been suggested that some of the beneficial effects of n-3 PUFA are due to changes in membrane 
fatty acid composition and subsequent alterations in hormone signalling. However, fatty acids, their 
CoA derivatives and their metabolites are able to regulate gene expression, up-regulating the 
expression of genes encoding proteins involved in fatty acid oxidation while simultaneously down-
regulating genes encoding proteins of lipid synthesis [93]. 
In this study we have evaluated in rats the modulation of genes related to Chol homeostasis 
by a 3 month administration of a diet enriched inn n-3 PUFA. In particular we have evaluated the 
expression of genes encoding for SREBP-1, SREBP-2, HMG-CoAR, LDLR and ACAT2 in the 
liver.  
We used SH rats since they are the most commonly used animal models for the metabolic 
syndrome (MS) [94]. Actually, SH rats develop insulin resistance, hyper-triglyceridemia, abdominal 
obesity, hypertension, and hypercholesterolemia [95]. It is reported that naturally occurring 
variation in the gene encoding the SREBP-1 isoforms might contribute to inherited variation in lipid 
metabolism in the SH versus other strains of rats [96]. We also used Wistar Kyoto (WK) rats as 
control. 
To evaluate the effect of the different diets on lipemia, as well the incorporation of the 
supplemented PUFA, plasma lipid profile and total lipid fatty acid composition in plasma and liver 
were also determined in all rats. To evaluate possible modification of cholesterol content in liver, 
nuclear resonance spectroscopy (NMR) analysis was performed on this organ. 
Our findings confirm that dietary n-3 PUFA are absorbed, and incorporated in hepatic tissue.  
In SH animals PUFA supplementation recovered the imbalanced plasma lipids status. At molecular 
level, n-3 PUFA exerted effects in both strains, but in a different way, evidencing the importance of 
genotype in the mechanisms of n-3 PUFA cholesterol lowering action.  
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MATERIALS AND METHODS 
Materials 
Diets were from Mucedola (Milan, Italy). Chloroform and n-hexane were from Carlo Erba SpA Co. 
(Milan, Italy). Methanol, potassium chloride, sodium sulphate anidre, TRIS borate EDTA buffer, 
Chloroform-d 99.8 atom % D, and Methanolic- chloridric acid 3N were purchased from Sigma 
Chemical Co. (Milan, Italy). 25 bp and 1 Kb Plus DNA Ladder, SYBR Safe DNA gel stain 
10,000X in DMSO, and Ultra Pure Agarose were from Invitrogen (Paisley, UK). Lipoprotein 
measurements commercial kits were from (Roche Diagnostics SpA, Milan, Italy). QIAshredder, 
RNeasy mini kit, Quantitect reverse transcription kit, QuantiTect SYBR Green PCR Kit, and 
premade primers Quanti Tect Primer Assay 200: Srebf-1 (QT00432684); Srebf-2 (QT00403305); 
Acat-2 (QT00412461); Ldlr (QT00177744); Hmgcr (QT00182861); Gapdh (QT00199633) were 
from Qiagen (Hilden, Germany). β actin was a custom primer purchased from IDT, Integrated DNA 
Technologies (San Diego, California) 
 
Methods 
Animals and diet. N-3 PUFA solution used for diet preparation contained eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA) as ethyl esters, in the ratio 0.9:1.5. N-3 PUFA solution 
was added in appropriate amounts (0.1% w/w) to control diet during its preparation. Protein, lipid 
and carbohydrate content of control diet were in the normal range of adequacy for rats (g/100 g 
diet): proteins about 21g; lipids about 8g; carbohydrates about 61.5g, and contained appropriate 
amounts of vitamins and other minerals. 
14 male WK rats and 14 male SH rats, aged 14 weeks, were used. Animals were housed in 
individual cages under strictly controlled conditions of temperature (20 ± 2 °C) and humidity (60–
70%), with a 12-hour dark-light cycle, and were weighed each week. Water was provided ad 
libitum. After a 15 day period of acclimatation at control diet, both WK and SH rats were randomly 
divided into two groups, one fed the control diet (WK-St and SH-St) and the other fed the PUFA 
supplemented diet (WK-PUFA and SH-PUFA). . After 90 days of dietary treatment, rats were 
weighted, anesthetized and killed. Blood samples were collected in heparinised test tubes, and livers 
were quickly excised and frozen at -80°C in RNA Later.  
Plasma was obtained by centrifugation at 800 X g for 5 min. Then samples were stored -20°C until 
analysis. 
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The Animal Care Committee of the University of Bologna approved the study 
 
Lipid profile and fatty acid composition. The lipid profile (plasma triglycerides, total and HDL-
cholesterol) was analysed using enzymatic and colorimetric methods with commercial kits (Roche 
Diagnostics SpA, Milano, Italy) according to manufacturer. The concentrations were determined 
spectrophotometrically using a Hitachi 911 auto analyser. Low-density lipoproteins (LDL-chol) 
were estimated indirectly by using formula: (LDL-chol)=TG-(HDL-chol)-(TG/5) [97, 98] 
Atherogenic index was calculated using the following formula: Atherogenic index= [TG-(HDL-
chol)]/HDL-chol. 
Total lipid fatty acid composition was determined on plasma and liver by gas chromatographic 
analysis. Whole lipids were extracted from 300μl plasma or 0,3 g hepatic tissue  according to Folch 
et al. [38]. Fatty acid methyl esters were prepared from all samples according to Stoffel et al.[39].  
Methyl esters dissolved in n-hexane were gas chromatographed on a Carlo Erba model 4160 
(Milan, Italy) equipped with a capillary column (30 m×0.25 mm i.d.) filled with a thermo stable 
stationary phase (SP 2340, 0.10–0.15 μm film thickness), at a programmed temperature (160–210 
°C, with a 8 °C/min gradient), with He as carrier gas at a flow rate of 2 ml/min as previously 
reported [40, 99]. Gas chromatographic traces and quantitative evaluations were obtained using a 
Chrom Card Software (Thermo Electron Scientific, Milan, Italy) computing integrator. 
Statistical analysis was by the Student's t-test [100]. 
 
Liver cholesterol concentration. Total lipids were extracted from 1 g liver according to Folch et al. 
[38]. The solvent was then dried under nitrogen, and the lipid fraction resuspended in deuterated 
chloroform. Cholesterol concentration was evaluated by High Resolution Magic Angle Spinning 
(HR-MAS) NMR. 1D 1H HR-MAS spectra were recorded with a Bruker Avance400 spectrometer 
equipped with a 1H/13C inverse probe operating at 400.13 and 100.61 MHz, respectively. In the 1H 
NMR spectra, free Chol signal was evidenced at 0.65ppm and 1,01ppm, while cholesteryl ester 
signals were not detectable (figure 1). Since retinol (signal at 1.13ppm ) was present in the same 
amount in both experimental diets, we could assume its liver concentration as a constant. Therefore 
retinol concentration was used for free cholesterol signal normalization. 
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Statistical analysis of NMR data was by the 
Students’t test. 
RNA extraction, retro-transcription and gene 
expression analysis. 30 mg of hepatic tissue were 
mechanically disrupted by sterile scissors and 
homogenized using QIAshredder (Qiagen, Hilden, 
Germany) according to manufacturer.  RNA was 
extracted using RNeasy mini kit (Qiagen, Hilden, 
Germany) and elution was done in a final volume 
of 50  μl.  Samples integrity were assessed by 
nanodrop nd-100. All used samples had absorbance 
A 260/280 in the range of purity. 
Retro transcription was performed on 200ng of 
extracted RNA in a 20μl  total reaction volume 
using Quantitect reverse transcription kit (Qiagen, 
Hilden, Germany) as follow. Samples were 
incubated 2 minute 42°C with gDNA Wipeout 
Buffer to eliminate possible genomic DNA contamination. After this samples were quickly put on 
ice and reverse transcription mix were added as shown by manufacturer. Optimized blend of oligo-
dT and random primers dissolved in RNAse free water supplied by the kit were used as primers. 
Mix contains also RNAse inhibitors. Reaction conditions were as follow: 15 min 45°C, 3 min 95°C 
and 5 min 4°C. Obtained cDNA were quickly stored at -20°C. Relative gene expression analysis 
was performed on 6000 Rotor gene  (Corbett, Sydney, Australia) by two step real-time q-PCR 
assays using SYBR® Green detection (Qiagen: QuantiTect SYBR® Green PCR Kit). Amplification 
was done in a 25 μl final volume including 1 μl of cDNA as template. The PCR Master Mix was 
prepared according to Qiagen protocol and amplification conditions were as follows: 15 min at 
95 °C followed by 45 cycles (94 °C for 15 s, 55 °C for 30 s, and 72 °C for 30 s). Melt curve were 
obtained every time 15sec at 95°C. Amplicons length were assessed using 2% agarose gel 
electrophoresis using SYBR green 1X Invitrogen (Paisley, UK). The primer pairs used were 
(Qiagen: Quanti Tect Primer Assay 200). The sequences are confidential and available data are 
reported in table 1. All primer set were bioinformatically validated by QIAGEN. Actin-β primer 
was a custom primer: Forward: GGGAAATCGTGCGTGACATT (20 bp) Reverse: 
GCGGCAGTGGCCATCTC (17 bp). Amplicon length was 76 bp on the recognized sequence 
Figure 1: HR-MAS spectra of hepatic tissue from WK
and SH rats fed the different diets.  
 A) WK-CT  B) WK PUFA C) SH-CT; D)SH PUFA 
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NM_031144. Primer specificity was evaluated using melt curve that showed unique specific peak in 
all cases. Q-PCR validation was carried out by standard curve. Reaction efficiency and R value 
were in the range of 80-100% and 0,99 respectively, for all examined genes. 
Three expression technical replicate was performed on RT duplicate. Seven biological repeats for 
each experimental group were used. Relative quantification of the mRNA levels of all genes in 
exam was determined using the Rotor-gene 6000 software 1.7 comparative quantification analysis, 
in which reaction efficiency is calculated on each reaction tube. All samples used had >85% 
efficiency.  
 
Table 1: Qiagen Quanti Tect Primer available information.  
For each employed gene, gene code, amplicon length, recognised sequence on gene bank, between exons amplicon 
position are reported. 
 
Srebf-1 primer is between exons 6 and 7, so can recognize both the isoform –a, and -c, but SREBP-
1c is the predominant SREBP-1 isoform in the liver [101], so our findings are ascribed to this 
isoform. 
GAPDH was chosen as reference gene since it is reported that fish oil supplementation has no effect 
on its expression [102]. Actin‐β was previously used in gene expression study involving PUFA 
supplementation by Caplan et al. and by Prasad et al. [103, 104]. 
 Statistical analysis of gene expression data was performed by REST 2009 software in Rotor Gene 
(RG)  Mode that use Taylor’s series to find statistical differences, as shown by Pfaffl et al. [105]. 
Gene expression was normalized on the reference genes glyceraldehyde-3-phosphate-
Gene QIAGEN code Amplicon length Recognized sequence Between exons position 
Srebf-1 QT00432684 82 
XM_213329 
XM_001075680 
6-7 
Srebf-2 QT00403305 86 XM_216989 8-9 
Acat-2 QT00412461 72 NM_001006995 8-9 
Ldlr QT00177744 111 NM_175762 3-4 
Hmgcr QT00182861 87 NM_013134 10-11 
Gapdh QT00199633 149 NM_017008 1-3 
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dehydrogenase (GAPDH) and actin‐β. All sample groups were referred to WK standard diet rat 
calibrator group. 
 
RESULTS 
 
Plasma lipid profile 
The lipid profile of WK and SH rats fed the different diets are reported in table 2. 
Comparing control diet fed groups, total cholesterol, HDL-chol and TG were lower in SH than in 
WK rats, while LDL-chol was higher. In both PUFA fed groups, total cholesterol and triglyceride 
were significantly lower than in the corresponding control. In SH rats the LDL fraction was also 
reduced by PUFA. While HDL fraction was not affected. As a result, the atherogenic index higher 
in control SH than in control WK rats, was normalized by the PUFA diet 
Table 2: Plasma lipid profile in WK and SH rats fed the different diet. 
Data are means +/- SD of 7 animals per group. Statistical analysis was by the one way ANOVA using Tukey’s as post 
test. Similar superscript letters indicate statistical significance (at least p<0.05) 
 
Plasma fatty acid composition  
The fatty acid composition of plasma total lipid is reported in figure 2A. EPA (20:5n-3) and DHA 
(22:6 n-3) concentration increased in both PUFA-fed groups, evidencing the absorption of the 
supplemented fatty acids. In WK rats this increase was accomplished to a decrease in linoleic acid 
(18:2 n-6, LA) content, while in SH ones to a decrease in arachidonic acid (20:4 n-6, AA) content.  
Parameter (mg/dl) WK-CT WK-PUFA SH-CT SH-PUFA 
TOT-chol 107.60 ± 2.70a,b,c 88.40 ± 2.30a,d 91.60 ± 4.83 b,e 73.40 ± 3.65c,d,e 
HDL-chol 41.80 ± 2.49a,b 37.20 ± 2.28c 26.00 ± 3.74a,c 31.20 ± 5.85b 
LDL-chol 26.24 ± 6.19a 25.48 ± 3.04b 41.48 ± 9.57a,b,c 23.88 ± 6.14c 
TG 197.80± 14.20a,b,c 128.60 ± 12.44a,d 120.60 ± 12.50b,e 91.60 ± 11.28c,d,e 
Atherogenic index 1.44 ± 0.29a 1.38 ± 0.14b 2.59 ± 0.60a,b,c 1.41 ± 0.41c 
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Dietary EPA and DHA were also incorporated in the hepatic tissue (figure 2B), mainly at the 
expense of AA. 
 
 
Figure 2. Plasma (A) and liver (B) total lipid fatty acid composition in WK and SH rats fed the different diets. 
Data are means +/- SD of 7 animals per group. Statistical analysis was by the Students’t test. Similar superscript letters 
indicate statistical significance (at least p<0.05).  
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NMR free hepatic cholesterol 
revelation. 
In control condition, free cholesterol 
content (Figure 3) was higher in the 
liver of  SH than WK rats. N-3 PUFA 
enriched diet increased liver 
cholesterol concentration in WK 
animals only. 
 
Gene expression analysis.  
In rats fed the control diet no 
differences were observed in both 
Srebf-1 and Srebf-2 gene expression 
(figure 4 A and B respectively). PUFA 
treatment down regulated Srebf-1 
expression in SH animal only, without any effect on Srebf-2. 
Figure 4. Srebf-1 (A) and Srebf-2 (B) gene expression in the liver of WK and SH rats fed the different diets. 
Data are median +/- standard error. Significant differences were evaluated with Taylor’s series statistical analysis.  
Similar superscript letters indicate statistical significance (at least p<0,05). 
 
Figure 3. Free cholesterol concentration in liver of WK and SH rats
fed the different diets. 
Cholesterol is reported as the ratio between the intensity of cholesterol
and retinol signals. Data are means +/- SD of 7 animals per group.
Statistical analysis was by the Students’ t test . Similar superscript
letters indicate statistical significance (at least p<0.05).  
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  No difference was observed in Hmgcr expression between WK and SH animals fed the 
control diet (figure 5A).  PUFA treatment down-regulated Hmgcr expression in both groups. 
In control condition, Ldlr gene expression (figure 5B) appeared up-regulated in SH rats. The 
n-3 PUFA enriched diet decreased Ldlr expression in SH animals, without any effect in WK ones. 
Acat-2 gene expression (figure 5C) appeared up-regulated in control SH rats compared to 
the corresponding WK. The n-3 PUFA rich diet further increased Acat-2 expression in SH animals, 
without any effect in WK ones. 
 
Figure 5. Hmgcr (A), Ldlr (B), and Acat-2 (C) gene expression in the liver of WK and SH rats fed the different diets  
Data are median +/- standard error.Significant differences were evaluated with Taylor’s series statistical analysis.  
Similar superscript letters indicate statistical significance (at least p<0.05). 
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DISCUSSION 
 
PUFA play a key role in membrane composition and function, in cell signaling, and in the 
control of gene expression. A very high omega-6/omega-3 ratio, as in today’s Western diet, could 
promote the onset of many diseases, including CVD. On the contrary, increased levels of n-3 PUFA, 
and a lower omega-6/omega-3 ratio, appear to exert protective  effects [106]. Understanding how 
dietary lipids influence chronic diseases is complicated by the fact that they exert many 
physiological roles. Dietary fats are substrates for energy metabolism, membrane formation and 
signaling molecules. Furthermore, PUFAs also regulate gene expression.  
The main aim of this study was to evidence in liver the effect of EPA and DHA 
supplementation on the expression of genes related to cholesterol metabolism. We compared the 
effect of a PUFA-rich diet in control rats and in SH rats, which are commonly used as animal model 
for the metabolic syndrome. 
As indicated by plasma and liver fatty acid composition, the supplemented fatty acids were 
absorbed, and incorporated in liver. The liver plays a central role in whole body lipid metabolism, 
and responds rapidly to changes in dietary fat composition [107]. The incorporation of dietary EPA 
and DHA mainly at the expense of AA reflects the metabolic competition between PUFA families, 
as previously reported by H. Mu et al. and Simopoulos et al. [108, 109].  
According to Aziz et al. [110], control diet fed SH animals did not show high blood level of 
total cholesterol. However their HDL-chol level was lower and LDL-chol higher than WK animals, 
resulting in a higher atherogenic index. Therefore SH rats can be considered a good model to assess 
imbalanced cholesterol metabolism. N-3 PUFA supplementation normalized the imbalanced blood 
parameter, lowering the atherogenic index and confirming the positive effect of n-3 PUFA on LDL 
and HDL-cholesterol levels. 
Gene expression analysis underlined that in control condition some genes are differently transcribed 
in WK and SH animals. Furthermore, the response to the dietary treatment appeared different in the 
two groups of rats.  
SREBP-1 is a master regulator of lipid biosynthesis, and it is reported that naturally occurring 
variation in the gene encoding the SREBP-1 isoforms might contribute to inherited variation in lipid 
metabolism in the SH versus other strains of rats [96]. We did not observe a different Srebf-1 
expression between WK and SH rats fed the control diet, but after PUFA supplementation Srebf-1 
expression level decreased in SH rats only. This is consistent with the observed reduction in plasma 
TG level.  
 
Experimental studies 118 
PUFA supplementation decreased plasma TG level also in WK rats, although no modifications 
occurred in Srebf-1 expression. Other mechanisms, i.e. a different proteolytic cleavage of SREBP-1 
to its nuclear active form, might be involved in n-3 PUFA TG lowering effects. Actually, the 
activating cleavage of SREBP is inhibited by n-3 PUFA [111-113]. N-3 PUFA are suppressors of 
SREBP-1 nuclear abundance [114], but their effect on Srebf-1 mRNA is still controversial. The 
different PUFA concentration used may explain in part the discrepancies in literature. Nakatani et 
al. [115] evidenced that EPA and DHA reduce the amount of mature active SREBP-1 in a dose 
dependent manner. At low concentration SREBP-1 proteolytic cascade is inhibited, while at high 
concentration a decrease of Srebf-1 mRNA is also observed.  
Our data seem to indicate that not only PUFA dose, but also the constitutive expression of the 
Srebf-1 gene could influence the effect of PUFA supplementation. SH rats harbor a valine-to-
methionine substitution in the COOH terminal portion of the SREBP-1 protein that is not present in 
44 other strains of laboratory rats [96]. This reflects SNPs in the Srebf-1 gene, which could also be 
related to a different response to PUFA supplementation.   
Furthermore, it is reported that SH rats have increased fasting levels of insulin [116], and insulin 
stimulates the transcription of SREBP-1c [117]. A diet enriched in n-3 PUFA significantly lowers 
insulinemia [118], so it is conceivable that in PUFA fed SH rats a reduction in insulin level had 
contributed to the decrease in srebf-1 expression.  
In addition, plasma TG level can be also reduced by the inhibition of TG secretion via VLDL [119], 
and possibly by accelerating VLDL and chylomicron degradation by lipoprotein lipase (LPL) [120]. 
In humans, n-3 PUFA increase LPL plasma activity and gene expression [121]. Further studies are 
needed to clarify the effect of n-3 PUFA on plasma TG level in both WK and SH animals. .  
Concerning Srebf-2 expression, we did not observe any differences due to PUFA 
supplementation. Xu et al. [102] reported that PUFA suppress the in vivo proteolytic release of 
SREBP-1 and -2, although the effect on SREBP-2 is transient.  To date, no evidences about n-3 
PUFA effects on Srebf-2 mRNA abundance are reported in literature. Since in this study the 
expression of Hmgcr,  Ldlr , and Acat-2, which are all regulated by SREBP-2, was affected by n-3 
PUFA, our data seem to confirm a post-transcriptional regulation of SREBP-2 by EPA and DHA. 
HMGCR is one of the key enzymes that regulate endogenous cholesterol production. Hmgcr 
DNA sequence encode SRE responsive element, so is strongly regulated by nuclear SREBP2 [122]. 
In both WK and SH rats Hmgcr gene expression was down-regulated by PUFA treatment. This data 
are consistent with the decrease in plasma cholesterol level due to treatment.  
Control diet fed SH rats evidenced an Ldlr up-regulation coupled with high LDL-chol level. 
This underlines the imbalance in lipid processing that characterizes SH rats. In PUFA fed SH 
 
Experimental studies 119 
animals Ldlr mRNA was similar to corresponding WK. As for Hmgcr, this could be ascribed to a 
reduction in SREBP-2 post-transcriptional activation.  
Another justification could emerge analyzing the relationship between Ldlr activity and 
cholesterol esterification. This topic has been largely discussed.  
It has been suggested that dietary fatty acids and cholesterol regulate hepatic LDL receptor 
activity via cholesteryl ester and free cholesterol regulatory pools [123]. These regulatory pools are 
affected by the activity of ACAT, the rate-limiting enzyme of cholesterol esterification.  The 
increase in hepatic cholesteryl ester is negatively correlated with LDL receptor activity in hamsters 
[124]. Moreover, human interventional studies underline that ACAT inhibitors cause a significant 
elevation in LDL cholesterol [125, 126].  
In our study, Acat-2 expression was up-regulated in SH rats at control diet, and the PUFA 
diet further enhanced the expression of this gene. We can therefore hypothesize an increased 
cholesteryl ester concentration in the liver of SH animals, contributing to the observed decrease in 
plasma LDL level. Unfortunately, in our conditions NMR analysis was unable to detect cholesteryl 
esters.  This could be due to overlapping signals or to a low concentration of cholesteryl esters 
compared to the other lipids fractions. Further studies are therefore needed to clarify this issue. 
The results on cholesterol esterification need further elucidation. in our condition.  
In conclusion, in this study we evidenced that SH rats are characterized by a deep imbalance 
in lipid metabolism, which is related to a different expression of genes implied in cholesterol 
metabolism. N-3 PUFA supplementation recovered the impaired blood parameters observed in SH 
animals, confirming the positive effect of these fatty acids. It is worth noting that the molecular 
effects of n-3 PUFA were different in WK and SK rats. Although further studies are needed, this 
observation could be useful while considering n-3 PUFA supplementation in humans with familial 
forms of hypercholesterolemia.   
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Introduction 
Phytosterols or plant sterols (PSs) are minor constituents and essential phytochemicals that 
are present in plant foods such as nuts, peanuts, sesame seeds, soybean seeds, and grains as well as 
their products. The most common PSs in foods are sitosterol (SS), campesterol, and stigmasterol, 
representing about 50-65, 10-40, and 0-35% of the total phytosterol fraction, respectively[127]. PSs 
are well known cholesterol-lowering agents[128], and several theories have been proposed to 
explain their action[129]. Unlike cholesterol, PSs are poorly absorbed, and the small absorbed 
amount is actively re-excreted in bile, resulting in low serum levels of these sterol molecules. 
                                                            
3  List of abbreviation: 19-OH: 19-hydroxycholesterol; ACAT: acyl-CoA:cholesterol 
acyltransferase; GC/MS: coupled system gas chromatography/mass spectrometry; IS: internal 
standard; LDH: lactate dehydrogenase; MTT: 3-(4,5-dimethyldiazol-2-yl)-2,5-diphenyltetrazolium 
bromide; PI: propidium iodide; POP: oxidised phytosterol; PS: phytosterol; SPE: solid phase 
extraction; SS: sitosterol; TMS: trimethylsilyl. 
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Notwithstanding the low plasma concentration, due to their similarities to cholesterol, PSs can be 
incorporated into cell membranes and affect its composition and functionality[130]. 
Beside the cholesterol-lowering effect, PSs have been shown to inhibit the growth and 
development of tumours[131] at concentration levels within the physiological human blood range. 
Normal PS blood concentration in humans is about 10-15 µM and it doubles when a vegetarian or a 
PS-rich diet is consumed[132, 133]. Although to date clinical studies have demonstrated no obvious 
side effects of dietary PSs, apart from a reduction of carotenoid blood level[134], the similarity 
between anti-neoplastic and cholesterol-lowering concentrations deserves attention. Few studies 
have been addressed to the effect of PSs on non-neoplastic cells. Awad et al.[132] showed in an in 
vitro study that SS inhibited smooth muscle cell proliferation. Rubis et al.[135] evidenced SS strong 
cytotoxic properties at very low concentration (2 µM) in human abdominal aorta endothelial cells. 
These effects, keeping a balance in proliferation and apoptosis of endothelial cells, have been 
considered positive in atherosclerosis prevention[136]. Notwithstanding, they further rise concerns 
about the possibility of PS detrimental effects on other non-neoplastic cell types, and therefore on 
their long-term use as nutritional hypolipidaemic agents.  
To further clarify this important issue, in this study we have evaluated the effect of the 
supplementation of a mixture of soybean-derived PSs, in which the main component was SS, using 
primary cultures of neonatal rat cardiomyocytes as a model of non-neoplastic cells. We choose 
primary cultures of cardiomyocytes for two main reasons. First, we wanted to avoid the use of 
immortalised cell lines derived from neoplastic cells. Second, the heart is considered the target 
organ for PS subchronic toxicity[137]. Due to the recommendation of high PS intake for long time 
in primary and secondary cardiovascular prevention[138], the clarification of PS effect on cardiac 
cells is extremely important. We supplemented cardiomyocytes with two different PS 
concentrations, both within the range of plasma concentration considered effective for cholesterol-
lowering[139]. To exclude that the observed effects, if any, could be accounted to phytosterol 
oxidation products (POPs), which are negatively perceived in terms of health[140], POP content in 
the PS mixture used for supplementation was also determined. 
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Experimental methods 
Materials  
Horse serum, foetal calf serum, Ham F10, and other biochemicals were from Sigma-Aldrich 
(St. Louis, MO, USA), as well as the PS mixture (derived from soybean) used for supplementing 
cells. Chemicals and solvents, unless specified, were of analytical grade and purchased from Carlo 
Erba Reagenti (Rodano, Italy), Merck (Darmstadt, Germany) and Sigma-Aldrich (St. Louis, MO, 
USA). Dihydrocholesterol (assay: 94.8%) employed as internal standard for the quantification of 
phytosterols, and campesterol, stigmasterol and sitosterol used for the identification of PS 
compounds, were from Sigma-Aldrich. 19-hydroxycholesterol (19-OH) from Steroloids (Newport, 
RI, USA) was employed as internal standard to quantify POPs in the phytosterol mixture adopted 
for cell supplementation. Deionised water was obtained from a water purification system Elix 10 
from Millipore (Bedford, CT, USA). 
 
Methods 
Quantification of PSs and POPs in the PS mixture. 10 mg of the soybean PS mixture powder 
employed for cell supplementation were dissolved in 10 mL n-hexane/i-propanol 4:1 (v/v). 0.2 mg 
of dihydrocholesterol in n-hexane/i-propanol 4:1 v/v (c = 1.9 mg/mL) were added as internal 
standard to 1 mL of the PS solution. After silylation performed according to Sweeley et al.[141] and 
the addition of 4 mL of n-hexane, samples were centrifuged at 1000⋅g for 3 min. One μL of the 
resulting solution was analysed using a GC/MS apparatus mod. GCMS-QP2010 Plus (Shimadzu, 
Tokyo, Japan). Gas chromatographic conditions were as follows: injector temperature: 310°C; oven 
temperature from 265 to 310°C at 0.80°C/min, finally held at 310°C for 10 min; gas carrier 
(helium) velocity: 30.0 cm/sec. The separation was carried out on a fused silica capillary column 
Zebron ZB-5 (30 m × 0.25 i.d., 0.25 f.t.) coated with 95%-dimethyl-5%-diphenyl-polysiloxane 
(Phenomenex, Torrance, CA). Instrumental conditions employed for MS detector were as follows: 
acquisition mode: total ion current; ion source temperature: 230°C; interface temperature: 210°C; 
detector voltage: 0.95 kV; scan range from 40 to 600 m/z; scan speed: 1250; solvent delay time: 10 
min. Data were filed and processed by the software GCMSsolution ver. 2.50 SU1 from Shimadzu. 
PS identification was achieved by comparing peak mass spectra with those obtained from a standard 
mixture containing campesterol, stigmasterol, and SS and with the data reported by Pelillo et 
al.[142]. Quantification of identified PSs was done relative to dihydrocholesterol. 
To evaluate the content of POPs in the soybean PS mixture, 10 µg of 19-OH in n-hexane/i-
propanol 4:1 (v/v) was added as internal standard (c = 0.1 mg/mL) to 3 mL of the aforementioned 
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PS solution in n-hexane/i-propanol. After drying and the addition of 1 mL of n-hexane/ethyl acetate 
95:5 (v/v), POPs were purified by solid phase extraction[143] using aminopropyl bonded phase 
cartridges (STRATA NH2, 500 mg stationary phase, 3 mL reservoir volume) from Phenomenex. To 
evaluate the recovery of procedure, 9 µg of dihydrocholesterol in n-hexane/i-propanol 4:1 v/v (c = 
0.07 mg/mL) were added to the POP containing fraction, which was then silylated[141], and 
centrifuged at 1000⋅g for 3 min after the addition of 300 μL of n-hexane. One μL of the resulting 
solution was analysed by GC/MS under the same conditions as formerly reported. POPs were 
identified by comparing the peak mass spectra with those reported by Dutta[144]. Quantification of 
identified POPs was done relative to 19-OH. 
 
Cell culture.  
Heart cells were obtained from the ventricles of 2-4 d-old Wistar rats as reported[145]. The study 
was approved by the Ethical Committee for Animal Care of the University of Bologna (Italy) (prot. 
n. 58897-X/10). Apart from cell growth determination, due to technical reason, cells were seeded at 
1 x 106 cells/mL concentration. Twenty four h after seeding (T0) cardiomyocytes were divided at 
random in control, grown in control medium (Ham F10 plus 10% foetal calf serum plus 10% horse 
serum), and supplemented, grown in the same medium supplemented with PSs (3 or 6 µg/mL). PS 
stock solution (600 µg/mL) was prepared dissolving the mother solution (derived from soybean and 
containing 45% SS, 35% campesterol, and 5% stigmasterol, as determined) in 100% ethanol. 
Control cells received a similar amount of ethanol (<0.01% v/v) to avoid interference due to the 
vehicle. Media were changed every 2 d, the last change being 48 h before the experiment. Before 
each determination, at each time point, viable cells were counted by trypan blue dye exclusion. On 
day 6 (T144) control cardiomyocytes were at complete confluence, as assessed by cell counting and 
by protein determination with the method of Bradford[146]. 
 
Cell count: trypan blue exclusion test. 
 Trypan blue exclusion test was performed by adding 25 μL of 0.1% trypan blue solution to 100 μL 
of cells suspended in PBS. The cells that excluded the dye were counted on a haemocytometer as 
described[147]. 
 
Identification and quantification of PSs in cardiomyocytes by GC/MS.  
On day 6 (T144), cells were washed three times in PBS, and scraped off in cold n-
hexane/isopropanol (4:1 v/v). Phytosterols were recovered from lipids after a cold 
saponification[148], using hydrocholesterol as internal standard. Before GC/MS analysis, the 
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trimethylsilyl (TMS) derivatives of PSs were obtained as reported by Sweeley et al.[141]. One µL 
of the derivatised sample was analysed under the same conditions as reported above. PS 
identification was achieved by comparing peak mass spectra with a standard mixture containing 
campesterol, stigmasterol, and sitosterol and with the data reported by Pelillo et al.[142]. 
Quantification of identified phytosterols was done relative to dihydrocholesterol. 
 
Cytotoxicity. 
 According to the cytotoxicity assay techniques, cytotoxicity was evaluated as cell metabolic 
activity using the 3-(4,5-dimethyldiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric 
assay[149]. At T144, after a washing with 0.9% NaCl, 1 mL of MTT reagent diluted in RPMI-1640 
medium modified without phenol red (1 mg/mL) was added to each dish, and the cell cultures were 
incubated for 3 h at 37°C. After removal of the medium, the cells were lysed with isopropanol for 
15-20 min. Formazan production, which is proportional to cell vitality, was determined 
spectrophotometrically at 560 nm.  
 
Cell growth curve 
Cells were seeded in 24-well plates at a concentration of 2 x 105/well. Two-four replicates were 
performed for each time point. Viable cells were counted each day for the following 6 days (T0, 
T24, T48, T96, T120, and T144). 
Cell cycle. Cells were seeded in duplicate in 6-well plates. At each time point (T0, T12, T24, T48, 
T72, T96, and T144) cardiomyocytes were washed with PBS, harvested and resuspended in 500 µL 
of a solution (0.1% sodium citrate, 0.1% Triton X-100 in PBS) containing PI 50 µg/mL, as 
described[150]. Cell cycle analysis was performed by cytofluorimetric detection of DNA content 
with a FACS Calibur Cytometer (Becton Dickinson, Mansfield, MA, USA) after staining with PI. 
Apoptosis. 
 Cells were plated in duplicate in a 6-well plate. At each time point (T0, T12, T24, T48, T72, T96, 
and T144), after counting for viable cells, cell number was normalised to 5 x 105, and apoptosis was 
verified using two different methods. In the first one (propidium iodide uptake) cells were washed 
with PBS, harvested and resuspended in 500 µL of propidium iodide (PI) buffer[150]. PI-stained 
cells were analysed by flow cytometry as described above; apoptotic cells were counted as the 
percentage of sub-G1 cells. In the second one (Annexin-V binding) cells were washed with PBS, 
harvested and resuspended in 100 µL of Annexin-V-Fluos and PI-labelling solution (Roche, 
Penzberg, Germany) for 15 minutes. The stained cells were analysed by flow cytometry with a 
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FACS Calibur Cytometer (Becton Dickinson, Mansfield, MA, USA); apoptotic cells were counted 
as the percentage of Annexin-V-positive, PI-negative cells. 
 
Cell membrane damage: lactate dehydrogenase (LDH) release in media. 
Cells were seeded in duplicate in 6-well plates. To evaluate the possible damage to cell membrane 
integrity, the release of the LDH enzyme in the media was determined. At each time point (T24, 
T48, T96, and T144) LDH activity in the media was determined spectrophotometrically by 
measuring NADH levels at 340 nm[151]. 
Statistical Analysis.  
The reported data are the means of at least three samples obtained from independent cell cultures. 
Statistical analysis was carried out by one-way ANOVA using Tukey’s as post test.  
 
Results 
The composition of the supplemented PS solution was analysed prior to experiments and is 
reported in figure 1. The total POP content in the PS mixture was low (0.124 ± 0.012 g/100 g) and 
the amount of single POPs identified is shown in figure 2. As regards the performance of the 
analytical methods herein employed, the determination of PSs after cold saponification ensured a 
good reproducibility, with a relative standard deviation associated to total phytosterol amount which 
was usually less than 5%. POP purification in cell feeding mixture by solid phase extraction (SPE) 
showed a high recovery percentage (85.9 ± 1.5%) and an acceptable reproducibility (≈9%) as 
concerns the amount of total oxidised sterols detected. 
Figure 1: Gas chromatographic trace of trimethylsilyl (TMS) ethers of sterols contained in the PS mixture. Peak
identification: IS, internal standard (cholestane); 1, cholesterol; 2, brassicasterol; 3, campesterol; 4,
campestanol; 5, stigmasterol; 6, stigmastanol; 7, clerosterol; 8, sitosterol; 9, sitostanol; 10, avenasterol; 11,
fucosterol; 12, Δ7-sitosterol. For analytical conditions see Methods. 
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Incorporation of supplemented PSs by cardiomyocytes was verified at T144. On that day, 
control cardiomyocytes were at complete confluence, as determined by microscopy. To evaluate if 
PS supplemented cardiomyocytes also reached confluence at T144, cells were counted and protein 
content was determined, evidencing no differences among groups (table 1). As shown in figure 3, 
cardiomyocytes actively incorporated the supplemented PSs, in a dose-dependent manner (r2 = 
0.92). 
  
Figure 2. Gas chromatographic trace of trimethylsilyl (TMS) ethers of phytosterol oxidation products (POPs) 
purified from the PS mixture. Peak identification: IS1, dihydrocholesterol; IS2, 19-hydroxy cholesterol; 1, 7α-
hydroxy campesterol; 2, 7α-hydroxy stigmasterol; 3, 7α-hydroxy sitosterol; 4, sitotrienol; 5, 7β-hydroxy sitosterol; 
6, 7-ketocampesterol; 7, 7-ketostigamsterol; 8, 7-ketositosterol. Peaks marked with an asterisk were non-oxidised 
sterols. Other peaks were not identified. For analytical conditions see Methods. 
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Treatment 
Cell number (cells/dish) Protein content (mg/dish) 
Mean SD Mean SD 
Control 5,158,333 914,429 0.98 0.02 
PS 3 µg/mL 5,637,500 2,203,974 1.05 0.05 
PS 6 µg/mL 5,197,500 1,255,998 0.99 0.06 
 
 
Table 1. Cell number and protein content at T144 in the different experimental conditions. Data are mean value and 
standard deviations of at least three samples obtained from independent cell cultures. No differences in cell number and 
protein among the different experimental conditions were determined by the one-way ANOVA analysis. 
 
 
 
 
 
 
 
 
 
 
 
Cholesterol content significantly decreased in PS supplemented cardiomyocytes compared 
to controls, with no difference between the two supplemented groups. According to the composition 
of the supplemented PS solution, SS appeared to be the most incorporated one, followed by 
campesterol and stigmasterol (figure 4). Figure 5 illustrates the different chromatographic traces of 
PSs extracted from cardiomyocytes grown in non-supplemented and supplemented media. 
  
Figure 3. Total PS and cholesterol content of unsupplemented and supplemented cardiomyocytes. PS and cholesterol
concentration was determined as described in Methods. Results are expressed as µg/dish and are means of at least three
samples obtained from independent cell cultures, with standard deviations represented by vertical bars. Statistical
analysis was by the one-way ANOVA (PSs: p<0.001; cholesterol p<0.01) using Tukey’s as post test (PSs: control vs. 3
µg/mL p<0.001; control vs. 6 µg/mL p<0.001; 3 µg/mL vs. 6 µg/mL p<0.001. Cholesterol: control vs. 3 µg/mL p<0.05;
control vs. 6 µg/mL p<0.01; 3 µg/mL vs. 6 µg/mL n.s.). 
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Figure 4. Distribution of the different PSs in unsupplemented and supplemented cardiomyocytes. PS incorporation was 
determined as described in Methods. Results are expressed as µg/dish and are means of at least three samples obtained 
from independent cell cultures, with standard deviations represented by vertical bars. Statistical analysis was by the one-
way ANOVA (campesterol p<0.001; stigmasterol p<0.001; sitosterol p<0.001; avenasterol p<0.01) using Tukey’s as
post test for evaluating differences between the two PS concentrations used (campesterol p<0.001; stigmasterol p<0.01;
sitosterol p<0.001). 
Figure 5. Gas chromatographic traces of trimethylsilyl 
(TMS) ethers of sterols recovered from the lipid 
fraction of unsupplemented and PS supplemented 
cardiomyocytes. Cardiomyocytes were grown in 
unsupplemented (trace A), 3 µg/mL PS supplemented 
(trace B) and 6 µg/mL PS (trace C) supplemented 
media. Peak identification: IS, internal standard 
(cholestane), 1, cholesterol; 2, campesterol; 3, 
campestanol; 4, stigmasterol; 5, stigmastanol; 6, 
clerosterol; 7, sitosterol; 8, sitostanol; 9, avenasterol. 
For analytical conditions see Methods 
 
Experimental studies 129 
To verify the possible interference between the observed PS incorporation and 
cardiomyocyte metabolic activity, the MTT assay was also performed at T144. MTT conversion to 
formazan appeared reduced in supplemented cardiomyocytes compared to controls, independent of 
PS concentration in the media (figure 6). 
 
 
  
Figure 6. Metabolic activity in unsupplemented and
PS supplemented cardiomyocytes. MTT conversion to
formazan, as a measure of metabolic activity, was
determined as reported in Methods and expressed as
percentage of value obtained in unsupplemented cells
(assigned as 100%). Data are means of at least three
samples obtained from independent cell cultures, with
standard deviations represented by vertical bars.
Statistical analysis as by the one-way ANOVA
(p<0.001) using Tukey’s as post test (control vs. 3
µg/mL p<0.001; control vs. 6 µg/mL p<0.001; 3
µg/mL vs. 6 µg/mL n.s.). 
Figure 7. Apoptotic effects of PS supplementation evaluated using Annexin-V at different time points. Data are means of
at least three samples obtained from independent cell cultures, with standard deviations represented by vertical bars. No
differences in the number of apoptotic cells were detected among groups at any time point by the one-way ANOVA.  
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The pro- or anti-apoptotic effects of PSs were investigated using two different independent 
methods, Annexin-V (figure 7) and propidium iodide uptake (data not shown). Both methods 
evidenced no differences in the number of apoptotic cells at any time point. LDH release in the 
media was also evaluated, and no differences were detected among groups at any time point (data 
not shown). 
Regarding the cell cycle, the distribution of cell populations was similar in both control and 
PS supplemented cells (figure 8), but significant differences were observed in the growth curve.  
Performing this analysis, for technical reason cells were seeded at a lower concentration to prevent 
them from reaching confluence in an early stage, therefore hiding possible differences in cell 
growth. As evidenced in figure 9, supplemented cardiomyocytes grew more slowly than controls. 
Figure 8. Cell cycle distribution in control and PS
supplemented cardiomyocytes at different time points.
The bar graph shows the distribution of cells among the
different phases of the cell cycle: G0/G1 phase -
quiescent cells, S phase - DNA replicating cells, and
G2/M phase - cells with two full complements of DNA
or at mitotic phase. Data are means of at least three
samples obtained from independent cell cultures, with
standard deviations represented by vertical bars. No
differences in the cell cycle distribution were detected
among groups at any time point by the one-way
ANOVA.  
Figure 9. Cell growth analysis in unsupplemented and PS
supplemented cardiomyocytes. Cell growth analysis was
performed as reported in Methods, and cells counted at
different time points. Data are means of at least three
samples obtained from independent cell cultures, with
standard deviations represented by vertical bars. Statistical
analysis was by the one-way ANOVA (T144 p<0.05). 
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Discussion 
  
In neoplastic cells, PS anti-proliferative activity is accounted to their incorporation in cell 
membrane[152], but the effects of PS incorporation in normal cells have been described in few 
studies, and never in cardiac cells. In the herein reported study, following supplementation, a dose-
dependent incorporation of PSs by cardiomyocytes was clearly evidenced. It was accompanied by a 
decrease in cholesterol content. The replacement of cholesterol by PSs could have caused the 
observed slowing down of cell growth and the reduction in metabolic activity, which could rely on 
PS increase, cholesterol decrease, or both. High sterol concentration within the cells is cytotoxic, 
and the enzyme acyl-CoA:cholesterol acyltransferase (ACAT) represents one of the most important 
mechanisms for reducing excess sterols, preventing cytotoxicity[153, 154]. Previous works showed 
that PSs are relatively poor substrates for ACAT[155, 156]. According to our results, Melchert et 
al.[157] evidenced that the decrease of cell cholesterol content, due to the inhibition of cholesterol 
synthesis by statins, reduces growth and MTT reduction in cardiac myocytes, without significant 
changes in propidium iodide staining. Furthermore, replacement by PSs of cholesterol molecules 
increases ion permeability [158] and modifies the activity of enzymes such as Na+, K+-ATPase[159] 
in biomembranes. 
Another possible explanation of the presented results could be related to PS oxidation. 
Although POPs were present in low amount in the PS mixture used for cell supplementation, PS 
oxidation processes could take place in cells in vitro, producing not only harmful epoxy forms but 
also generating free radicals[135]. In this light, PS negative effects could be also dependent on POP 
production and POP scavenging capacity in different cell types. Further studies are in progress to 
clarify this point.  
Although it has been reported that SS induces apoptosis in cancer cells through caspase 
activation[160], we did not observed apoptosis in cardiomyocytes. Recently Bao et al.[161] 
evidenced that SS did not activate the caspase-dependent pathway in non-neoplastic macrophages. 
The observed death of these cells was caspase-independent, involving necroptosis and autophagy, 
and was induced by SS concentration higher than those used in the present study.  
The lower MTT conversion observed in PS supplemented cells suggests that the study 
compounds more efficiently target cell metabolism, including cytochrome activity, than membrane 
integrity. This is in agreement with our data on LDH release. The reduction of MTT into formazan 
pigment predominantly depends upon mitochondrial reductase activity, and is also correlated with 
the mitochondrial metabolic capacity[162]. Mitochondrial metabolism provides the heart with very 
high amount of ATP per day[163], and the importance of intermediary metabolism to sustain the 
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function of the heart has long been appreciated. The decrease of MTT reduction activity in PS 
supplemented cardiomyocytes suggests that cardiac energy metabolism is switched from β-
oxidation of fatty acid to glycolysis[164], and Taegtmeyer [165] has proposed that metabolic 
changes often antedate functional contractile changes in the heart. The reduced cell metabolic 
activity could also explain the results obtained on cell growth curve. 
 
 
Conclusions 
 
The herein reported study is the first report on the effect of PSs in cardiac cells, and 
although PS supplementation appeared less deleterious than in neoplastic cells our results deserve 
important consideration. It is important to note that we grew cardiomyocytes in PS supplemented 
media, so reproducing more closely the in vivo situation when consuming a PS-rich diet. In other 
studies higher PS concentrations were supplemented to cells for a short time period. Although at 
present it is difficult to translate the obtained results to the health of heart tissue, the slowed cardiac 
cell growth and metabolic activity could represent a potential hazard. As already suggested by 
Lizard[166], and in the light of our data further investigations are needed to evaluate the biological 
impact of long-term exposure to physiologically relevant PS concentrations in humans, due to their 
wide use in the prevention and treatment of hypercholesterolaemia.  
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V. Hypocholesterolemic effect of a new bifidobacteria mix 
on rat induced for hypercholesterolemia. 
 
INTRODUCTION 
The association between cardiovascular disease (CVD) and elevated serum cholesterol 
(chol) was established more than 50 years ago. Since then CVD has been considered a preventable 
health hazard. In spite of this, lifetime risk for CVD remains high and it continues to be an 
important health problem [167]. When LDL cholesterol (LDL-chol) levels are too high, chol tends 
to slowly accumulate in the artery inner wall, encouraging the development of atherosclerosis [168-
171].  
Approximately 25% of cholesterol within the human body derives from the diet, while about 
75% is endogenously synthesized [172]. The human diet provides ~400 mg of cholesterol, but only 
50% is absorbed in the intestine. The liver secretes ~1 g cholesterol daily [173]. Cholesterol 
absorption efficiency and absorbed dietary cholesterol significantly regulate cholesterol synthesis 
and elimination. These factors are important determinants of within-population variation in the 
serum levels of total, LDL, and HDL cholesterol (HDL-chol) [174].  
Therapeutic interventions with lipid-lowering drugs (statins, fibrates) act by reducing levels 
of total cholesterol (TOT-chol) and LDL-chol, and by increasing HDL-chol levels [175, 176]. Like 
other drugs,  they may have side effects [177], and should be assumed for a very long period or 
during the whole life. For this reason the development of new non-pharmacological approaches to 
reduce the absorption of cholesterol, interacting with steps that regulate the digestion and absorption 
of dietary lipids could be a very important topic. 
Probiotics are accounted among active non pharmacological compounds able to low 
cholesterol absorption. Probiotics are live microbial food supplements, which benefit the health of 
consumers by maintaining or improving their intestinal microbial balance [178]. In recent years 
many researchers have demonstrated that gut microflora can exert positive effects in several 
pathological conditions such as heart diseases, pseudomembranose colitis, lactase deficiency and 
many others [179]. Microflora composition could be affected by improving the presence of some 
species introducing specific probiotic strains by diet. Different strains have different ability to 
colonize and persist in the gut. This is tightly linked to the specific rate of growth, division, 
interaction with other strains, and presence/quality of substrate to be fermented [180, 181]. 
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Probiotics are a very heterogeneous group of bacteria that account for a large specie- 
specific number of effects. Some strains are known to exert, more than other, positive outcome 
against cholesterol accumulation with a mechanism not always completely understood. Different 
strains, and also different strains combination, exert diverse effects [182-185]. 
Among species, Bifidobacteria seems to be particularly effective against cholesterol 
adsorption. For exempla, Bifidobacterium longum exhibited a more significant effect in lowering 
serum total cholesterol than a mixed colture of Streptococcus thermophilus and Lactobacillus 
delbrueckii both in rats and humans [186].  
Bifidobacteria have been shown to constitute 95% of the total gut bacterial population in 
healthy breast-fed newborns. The content decreases in the adult, although it remains relatively 
stable representing 3–6% of the fecal flora, until advanced age when the population of 
bifidobacteria appears to decline [187, 188]. Preparations containing bifidobacteria are safe, 
commonly used and well tolerated. Two mechanisms are purposed to explain the 
hypocholesterolemic effect: 
a. co-precipitation with bile salt [189] 
b. microbial uptake and co-precipitation of cholesterol by bacteria [190, 191]. 
Different Bifidobacterium strains have different effectiveness in cholesterol control [192, 
193], this leading to focus on the search of more efficient strain combinations.  
The aim of this study was to evaluate in rats the effectiveness of a Bifidobacteria mix in 
reducing cholesterol. The mix contained three different strains of Bifidobacterium, namely B. 
breve (WC 0463), B. breve (WC 0420), and B. bifidum (WC 0417). 
The experiment was carried out on Wistar Kyoto rats. During the first part of the study, 
hypercholesterolemia was induced in rats by means of a cholesterol-enriched diet. After 15 days, 
rats were divided into three groups:  
1. hypercholesterolemic diet 1% plus probiotics mix (i-chol 1%+mix) 
2. hypercholesterolemic diet 1% alone (i-chol 1%) 
3. standard diet (st-diet). 
The probiotic mix was administered to rats by gastric gavage, in an amount providing 
0,33x109 cfu/die of each strain. 
Blood was taken at the beginning of the study (T0), after the hypercholesterolemic period 
(T15), and at the end of the treatment (T45). The following parameters were measured on serum: 
TOT-, LDL-, HDL-chol, triglyceride (TG) level, and the atherogenic index were calculated. Results 
obtained indicated that the treatment with the Bifidobacterium mix partially counteracts the effects 
of the hypercholesterolemic diet. 
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MATERIALS AND METHODS 
 
Materials 
Cholesterol/ Cholesteryl Ester Quantification Kit; HDL and LDL/VLDL Cholesterol Quantification 
Kit; and Triglyceride Quantification Kit were purchased by BioVision Inc. (CA, U.S.A.); Phosphate 
Buffered Saline were from Lonza Walkersville Inc (Maryland, U.S.A.). 
The probiotic mix was a kind gift of Prof. Diego Matteuzzi (University of Bologna) and Prof. 
Maddalena Rossi (University of Modena). 
 
Methods 
Diets: Diets were prepared by Mucedola (Milano, Italy) according to Reeves et al.[194]. To obtain 
the hypercholesterolemic diets, 1% or 3% cholesterol were added to the standard diet AIN-93M.  
 
Animals: 24 male, 30 day old Wistar-Kyoto rats were used. Animals were housed in individual 
cages under strictly controlled conditions of temperature (20 ± 2 °C) and humidity (60–70%), with 
a 12-hour dark-light cycle. Food and water were provided ad libitum. During the whole experiment 
rat were weighted weekly and food consumption was evaluated daily. 
Before starting the experimental period, each animal was weighed and rats statistically different 
from the average were discarded and substituted. After a 5 day of acclimatation at standard diet, 
followed by 12h fasting, rats were weighted and blood samples were collected from the retro orbital 
plexus (T0). 
During the following 15 day animals were fed a 3% hypercholesterolemic diet (AIN-93M diet + 3% 
chol). At the end of this period, after 12h fasting, rats were weighted and blood samples were 
collected from the retro orbital plexus (T15). Animals were randomly divided into three groups of 8 
rats, each receiving the following diets: 
1. AIN-93M + 1% chol hypercholesterolemic diet plus probiotics mix (i-chol 1%+mix) 
2. AIN-93M + 1% chol hypercholesterolemic diet alone (i-chol 1%) 
3. AIN-93M standard diet (st-diet) 
The probiotic mix was administered to rats by gastric gavage, in an amount providing 0,33x109 
cfu/die of each strain in isotonic water. A similar amount of water was administered by gastric 
gavage to rats not receiving the probiotic mix. 
After 30 days, subsequent to 12h fasting, rats were weighted, sacrificed and blood samples 
were collected (T45). Immediately after withdrawal, serum was isolated by natural blood 
sedimentation and frozen -20°C. 
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The study was approved by the Ethical Committee for Animal Welfare of the University of 
Bologna. 
 
Biochemical measurements 
Total cholesterol evaluation: Cholesterol/ Cholesteryl Ester Quantification Kit (BioVision Inc., CA, 
U.S.A.) was used. Reaction mix was prepared adding cholesterol esterase, cholesterol oxidase and 
DMSO eluted probe according to manufacturer. Cholesterol esterase was used to hydrolyze 
cholesterol esters into free cholesterol. Cholesterol is oxidized by cholesterol oxidase to yield 
hydrogen peroxide (H2O2). The probe purchased in the kit reacts with H2O2 to produce resorufin, a 
colored substrate that is directly proportional to cholesterol content and is relievable 
spectrophotometrically at λ=570 nm. 
In a 96 multi-well plate, 2µl of serum were mixed with 48 µl cholesterol assay buffer. A 
calibration curve was obtained in the same multi-well plate using different concentrations of pure 
cholesterol. Then 50 µl reaction mix were added to each well. After 1h incubation at 37°C in the 
dark, samples were read at λ=570 nm using a spectrophotometer Infinite M200 multi plate reader 
TECAN (Männedorf, Switzerland). All values were corrected from background, and cholesterol 
concentration in wells containing the samples was calculated by comparison with the generated 
standard curve. 
Cholesterol concentration in the samples was calculated as  
C =A / V (µg/µl)  
Where: C= chol concentration in the sample; A = cholesterol in the well (µg); V = sample 
volume in the well (µl) 
 
LDL- HDL-cholesterol evaluation. The HDL and LDL/VLDL Cholesterol Quantification Kit 
(BioVision Inc., CA, U.S.A.) was used. HDL and LDL/VLDL separation was obtained mixing 
100µl Precipitation Buffer to 100µl serum. After 10 minutes incubation samples were centrifuged 
10 minutes at 2000 x g. The supernatant, representing HDL fraction, was removed and collected in 
a new tube. The resulting pellet, representing the LDL fraction, was re-suspended in 200µl PBS.  
Analysis was performed as described above for total cholesterol evaluation. Sample wells 
preparation were done adding 18µl LDL fraction to 32 µl assay buffer or 15 µl HDL fraction to 35 
µl assay buffer. After 1h incubation at 37°C in the dark, samples were read at λ=570 nm using a 
spectrophotometer Infinite M200 multi plate reader TECAN (Männedorf, Switzerland).  
All values were corrected from background.  LDL-chol, and HDL-chol concentration in 
wells containing the samples were calculated by comparison with the generated standard curve.  
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LDL- and HDL-chol concentrations in the samples were calculated as  
C =A / V (µg/µl)  
Where: C= concentration in the sample; A = concentration in the well (µg); V = sample 
volume in the well (µl) 
 
TG content evaluation. The Triglyceride Quantification Kit (BioVision Inc., CA, U.S.A.) 
was used. TG are converted to free fatty acids and glycerol by lipase enzyme. The glycerol is then 
oxidized to generate a product which reacts with the probe to generate a substrate relievable at λ = 
570 nm. Reaction mix was prepared adding Triglyceride Assay Buffer, Triglyceride Enzyme Mix 
and DMSO eluted probe according to manufacturer. In a 96 multi-well plate, 5µl serum were mixed 
with 45 µl cholesterol assay buffer. A calibration curve was obtained in the same multi-well plate 
using different concentrations of pure Triglyceride Standard. 2 μl of lipase was added to each 
standard and sample well, mixed, and incubated 20 min at room temperature to convert triglyceride 
to glycerol and fatty acid. 50 µl reaction mix were then added to each well. After 50 minutes 
incubation at room temperature in the dark, samples were read  at λ=570 nm using a 
spectrophotometer Infinite M200 multi plate reader TECAN (Männedorf, 
Switzerland). All values were corrected for background, and TG concentration in sample wells were 
calculated by comparison with the calibration curve. TG concentration in the samples was 
calculated as 
C = Ts / Sv (mM) 
Where Ts is TG concentration in the sample well (nmol) and Sv is the sample volume in the 
well (μl). 
 
Statistical analysis. Data are reported as means ± SD. Statistical analysis was done by the one way 
ANOVA with Tuckey as post test and by the Students’ t test. 
 
RESULTS 
 
Rat body weight was monitored during the whole trial, and was compared to an external 
control group of rats of the same age, fed a standard diet and  grown in the same condition (ext-ctr) 
(figure 1). Although no significant differences were detected between experimental rats and 
external controls, experimental rats gained weight with an irregular pattern. This finding was 
consistent with the measured food consumption, which showed significant differences between rats. 
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Since during the first phase of the trial all rats received the same hypercholesterolemic diet, 
all animals were considered together. Serum TOT-, LDL-, and HDL-chol, and TG at T0 and T15 
were compared, as reported in table 1, as well as the HDL/LDL ratio (atherogenic index). The diet 
induced a significant increase in LDL-chol (p<0.01) with an even more significant decrease in 
HDL-chol (p<0.001). The decrease in TOT-chol, which is was also significant, was the 
consequence of the strong decrease in HDL fraction. The HDL / LDL ratio (normal value >3) was 
greatly reduced at T15. A significant decrease in TG level was also count at T15. 
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Figure 1: Change in rat body weight gain during the trial. 
Data are means +/- SD. Statistical analysis was carried out using the one way ANOVA with Tuckey as post test (n.s.).  
 
 T0 T15 
TOT-chol (mg/dl) 99.33 ± 10.03 45.46 ± 6.51* 
LDL-chol (mg/dl) 18.52 ± 1.07 22.31 ± 3.86° 
HDL-chol (mg/dl) 65.22 ± 3.10 21.85 ± 4.50* 
TG (μmol/dl) 67,80 ± 13,12 6.64 ± 1,29* 
HDL/LDL 3.54 ± 0.25 1.00 ± 0.22* 
 
Table 2: Serum TOT-, LDL-, HDL-chol, TG level, and HDL/LDL ratio at T0 and T15. 
Data are means +/- SD. Statistical analysis was by the Students’ t test: ° p<0.01; * p<0.001. 
 
To verify if different food consumption and weight gain occurred during 
hypercholesterolemia induction could be related to differences in blood parameters, rats were 
divided into 3 subgroups according to weight gain: 
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W1: weight gain 60-70 g  
W2: weight gain 70-80 g  
W3: weight gain 80-90 g  
At T0 no significant differences in TOT-chol, LDL-chol, HDL-chol, and TG levels were detected 
among the weight groups. At T15, TOT-chol and TG decreased and LDL-chol increased in all 
weight groups, without any significant differences among the groups. On the contrary, although a 
decrease in HDL-chol was observed in all weight groups, it appeared greater in animals expressing 
the lower weight gain (figure 2).  
 
Figure 2: Serum TOT-, LDL-, HDL-chol and TG levels in rats grouped according to body weight gain. 
(a) TOT-chol; (b) LDL-chol; (c) HDL-chol, and (d) TG serum levels in W1, W2 e W3 groups at T0 and T15. Data are 
reported as means ± DS. Statistical analysis was carried out using the one way ANOVA comparing the three weight 
groups at the same time point. The Student’s t test was used to compare the same weight group at T0 and T15: * 
p<0.01, ** p<0.001. 
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Treatment effects: 
 
Modifications in serum LDL- and HDL-chol level, and in HDL/LDL ratio during the whole 
experiment, as well as their level at T45, are shown in Figure 3.  
Comparing T15 and T45, LDL-chol did not change in rat fed the hypercholesterolemic diet, 
while it decreased in rats fed the same diet but receiving the probiotic mix. An even higher 
reduction was observed in the standard diet fed group. In this group, HDL-chol significantly 
increased at T45, coming back to T0 level. In the other two groups a further significant decrease in 
HDL-chol was observed. The HDL / LDL ratio significantly increased in rats fed the standard diet 
rises significantly, reaching higher values than those observed at T0. No modification between T15 
and T45 were observed in the other two groups. 
Modification in TOT-chol level during the whole experiment and at T45 (figure 4) were 
consistent with the modifications observed in LDL and HDL fractions. 
 
Figure 3:  Serum LDL-chol, HDL-chol, and HDL/LDL ratio in rats fed the different diets. 
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(a) LDL-chol; (b) HDL-chol, and (c) HDL/LDL ratio Data are reported as mean ± SD. At T45, statistical analysis was 
carried out using the one way ANOVA with Tuckey as post test. Similar superscript letters indicate statistical 
significance (at least p<0.05).  
 
 
Figure 4 Serum TOT-chol in rats fed the different diets. 
Data are reported as means ± SD. At T45, statistical analysis was carried out using the one way ANOVA with Tuckey 
as post test. Similar superscript letters indicate statistical significance (at least p<0.05).  
  
TG levels increased at T45, without any significant difference among the dietary groups 
(figure 5). 
 
 
Figure 5: Serum TG (μmol/dl) in rats fed the different diets. 
Data are reported as mean ± SD. At T45 statistical analysis was carried out using the one way ANOVA with Tuckey as 
post test (n.s.) 
 
DISCUSSION 
 
The first part of this study (T0-T15)was devoted to the dietary induction of  
hypercholesterolemia induction in normal Wistar rats. Since it is demonstrated that rats have a good 
resistance to hypercolesterolemia [195], and extreme  dietary protocol are required to induce it, we 
used a diet containing a high cholesterol amount (3%).  
The 3% hypercholesterolemic diet caused significant changes in lipemia toward a 
pathological condition, increasing LDL-chol and decreasing HDL-chol. The HDL/LDL ratio 
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(atherogenic index), commonly utilized as an index of cardiovascular risk [196], was strongly 
affected. TOT-chol level diminished at T15. TOT-chol is mostly the sum of LDL- and HDL-chol, 
plus a small amount related to other lipoproteins. Therefore, it is clear that the HDL-chol huge 
decline caused the reduction in TOT-chol level.  
A reduction in HDL-chol after a strong hypercholesterolemic diet was also observed in rats 
by Mahley and  Holcombe [195]. In New Zealand white rabbits, the decrease in HDL-chol observed 
after a 1% hypercholesterolemic diet was linked to the oxidative stress induced by a severe 
cholesterol-rich diet [197]. Further studies are in progress to verify if the 3% hypercholesterolemic 
diet used in the present study could have induced an oxidative stress.  
The decrease in serum TG after the hypercholesterolemic diet could be explained by the 
composition of the AIN-93M diet. This diet contains ~40 g fat / kg diet, mainly mono- and 
polyunsaturated, and ~50 g fiber / kg diet are also present. The high content of unsaturated fat 
[198]and fiber [199] could explain the observed huge decrease in serum TG level. 
During the first phase of the study (T0-T15), food intake and body weight gain was not 
homogeneous among experimental rats, although their mean body weight gain was similar to the 
external control. It is conceivable that the high cholesterol content modified the texture, the flavor 
and the taste of the pellet, so influencing food intake in some animals.  
In order to evaluate the possible influence of food intake on chol and TG levels, rats were 
divided according to body weight gain, which reflects food intake. Among the measured 
parameters, only HDL-chol was affected by food intake, its decrease being lower in rats with the 
lower body weight gain.  
At T45, rats turned to a standard diet showed a trend to normality. Compared to T15, LDL 
chol was strongly reduced in standard diet fed rats, while it was unchanged in animals maintained 
on a hypercholesterolemic diet. In rats also receiving the probiotic mix LDL-chol was 30% lower 
than in the hypercholesterolemic diet alone group. 
At T45, HDL-chol further decreased in animals fed the hypercholesterolemic diet, regardless 
the administration of the probiotic mix. The standard diet raised HDL-chol level, which came back 
to T0 values. As a consequence, the HDL/LDL ratio significantly increased, doubling value at T0. 
On the contrary, it remained low in rats receiving hypercholesterolemic diet, without differences 
related to the treatment with probiotic. TOT-chol level were consistent with LDL+HDL chol 
summation.  
The observed absence of any effect of probiotic on HDL-chol level is in agreement with 
Endo et al. [200]. Similarly, no modification of HDL-chol level was observed in male albino 
hypercholesterolemic rats after supplementation of Bifidobacteria, although LDL-chol was reduced 
 
Experimental studies 143 
by 56.3% [201]. On the contrary, B. longum BL1 increased HDL-chol and decreased TOT-chol and 
LDL-chol in humans [186].  In women, a mix of L. acidophilus 145 and B. longum 913 in the 
presence of 1% oligofructose was effective in HDL-chol reduction, without affecting LDL fraction. 
[202].  
Akalin et al.[203] evaluated the in vivo effect of yoghurt made from milk inoculated with S. 
thermophilus and L. acidophilus, showing a significant decrease in LDL-chol but no effect on both 
HDL-chol and TG. Also in our study, no effect related to the probiotic mix were evidenced on TG 
level. On the contrary, Nguyen et al.[204] evidenced a 10% decrease in TG serum level in 
hypercholesterolemic mice treated with Lactobacillus plantarum PH04. 
Strain genotype and strain combination appear therefore the crucial point for setting an 
effective cholesterol lowering mix. Different Authors indicate Bifidobacteria as the best choice, 
particularly when different strains are mixed [205-207].  
However, the number of living cells administered per day represents another crucial point. 
Number of bacteria ingested, and their permanence in the gut is essential. Prebiotics largely affect 
probiotics effects and residence [208]. In the present study prebiotics were not administered, but 
this could be a good chance for enhancing the effect of the probiotic mix.  
In conclusion, our data support the hypothesized ability of bifidobacteria in reducing 
cholesterol. In particular, our probiotic mix composed by B. breve WC 0463, B. breve  WC 0420, 
and B. bifidum  WC 0417 reduced LDL-chol fraction by 30% in the presence of a 
hypercholesterolemic diet. Although the mix did not affect serum HDL-chol and TG level, as 
reported in many other studies, it improved one of the main cardiovascular risk. It is known that 
different probiotics bacterial strains possess different effectiveness on hypercholesterolemia, and it 
is crucial to find effective strain combinations. Our findings suggest that the Bifidobacteria mix 
used in this study could be a good coadjuvant in the treatment of hypercolesterolemia, even in 
subjects consuming high cholesterol diet. Humans interventional studies are anyway needed to 
confirm our encouraging findings. A future perspective could also be to find out suitable prebiotics 
able to enhance the observed probiotic effect. 
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FINAL CONSIDERATIONS 
 
Lipids cover a central role in cell life. Changes in the organization of membrane fatty acids 
can exert profound effects on cellular functions such as signal transduction and membrane 
trafficking. Modification of lipid metabolism due to genetic alterations or environmental effects 
(such as diet) can lead to disease development.  
Cholesterol is one of the most important regulators of lipid organization, and mammals have 
developed sophisticated and tight regulated mechanisms to maintain cellular cholesterol levels in 
membranes within a narrow range. When these homeostatic mechanisms are overwhelmed, 
outcomes or progression of pathological conditions under cardiovascular system are facilitate.  
Cardiovascular diseases (CVD) are a group of pathological condition affecting both heart 
and blood vessels. CVD includes coronary heart disease (i.e. heart attacks), cerebro-vascular disease 
(i.e. stroke), raised blood pressure (i.e. hypertension), peripheral artery disease, rheumatic heart 
disease, congenital heart disease and heart failure.  
A real representative in vitro model for CVD does not really exist. Cell lines or primary 
cultures are suitable to elucidate the basic molecular mechanism of the biological process, but 
cannot mimic the physiological multifactorial states that occur in a whole organism. Many in vivo 
models have been proposed. However it is difficult to quantify how closely one animal model 
should imitate the human syndrome. Human ex vivo explants are not so easy to obtain in term of 
number of samples and amount of tissue. Interventional studies usually stand for only the last step 
of investigations. These evidences underline the importance to find representative models to 
investigate on CVD treatments outcomes. 
CVD has been strongly linked to an excessive dietary intake of saturated fatty acids and 
cholesterol, over production of endogenous cholesterol, and chronic inflammation due to oxidative 
stress. The combination of these conditions causes accumulation and oxidation of plasma low-
density lipoprotein cholesterol, vascular inflammation, and endothelial dysfunction.  
Therapeutic interventions with lipid-lowering drugs (i.e. statins) act by reducing levels of 
total cholesterol and LDL-chol, and by increasing HDL-chol levels. Like all drugs, they may have 
side effects, and should be assumed for a very long period or during the whole life. For this reason 
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the development of new non-pharmacological approaches to reduce the endogenous cholesterol 
production and absorption could be a very important issue. 
 Many nutritional compounds can act on cholesterol absorption, metabolism, and 
biosynthesis. There is a large amount of evidence suggesting that a high consumption of fruits, 
vegetables and fish can help reduce the risk of CVD. Certain phytochemicals, including flavonoids 
and phytosterols are the food components to which the protective effect is ascribed. A considerable 
amount of epidemiological data suggests that phytochemicals contained in plant derived foods are 
able to reduce the risk of age-related chronic illness such as CVD. The initial ideas about how these 
compounds provide protection following ingestion centered upon their direct antioxidant activity. 
Now it appears clear that phytochemicals act not only as direct anti-oxidants but also through more 
subtle routes such as interaction with cell signaling pathways, or modulation of gene expression. 
Simultaneously, in recent years many researchers have demonstrated that gut microflora can exert 
positive effects in CVD development and treatment. Probiotics are accounted among active non 
pharmacological compounds able to low cholesterol absorption. 
Improve our knowledge concerning mechanisms involved in cholesterol regulation and 
adsorption is essential to battle the CVD development and consequences. Essential in this topic is to 
find even better representative models clever to imitate the human pathological condition.  
For this reason we have tried to set up a new experimental model using abdominal aortic 
aneurysm tissues obtained from patients who had undergone open surgery. Cultured tissue models 
are more physiologically representative than single cell culture. The development of a cultured 
vascular tissue model would be a valuable experimental tool for exploring vascular responses to 
food components. However considerable inter- and intra- tissue variations in the expression of 
different genes was observed. The magnitude of these variation precludes the use of such tissue as 
experimental model for the investigation of the effects of bioactives in the modulation of gene 
expression. 
Using other in vitro and in vivo models we have tested bioactives of different origin for their 
ability to modulate cholesterol absorption and metabolism. In particular, we have tested EPA and 
DHA from fish oil,  phytosterols from plants, and probiotics. 
Regarding n-3 PUFA, using cultured neonatal rat cardiomyocytes as in vitro model system, 
we investigated the modification occurring in the cell lipid environment after EPA and DHA 
supplementation by means of high resolution magic angle spinning nuclear magnetic resonance 
technique in combination with gas chromatography. Then, using SH rats, we evidenced that dietary 
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EPA and DHA are able to improve lipemia, lowering the atherogenic index. This was related to a 
molecular effect of n-3 PUFA, which appeared different in SH rats compared to control rats. 
 
 Phytosterols were tested in primary cultures of neonatal rat cardiomyocytes. Our first aim 
was to exclude any possible deleterious effect of phytosterol supplementation. Cardiac cells were 
chosen as experimental model since the heart has been reported as the target organ for PS sub-
chronic toxicity. A dose-dependent incorporation of PSs and a decrease in cholesterol content were 
clearly evidenced. The replacement of cholesterol by PSs could have been the cause of the observed 
slowing down of cardiomyocyte growth and reduction in metabolic activity. Our findings raise the 
suspect that the long-term exposure to physiologically relevant PS concentrations is a potential 
hazard. Our future perspective is to better elucidate is a molecular mechanism is part of the well 
known cholesterol lowering effect of phytosterols. For this reason we have started to test changes in 
gene expression induced by several phytosterol on the same in vitro model.  
 
We used Wistar Kyoto rat nutritionally induced for hypercholesterolemia as in vivo models 
to assess the hypocholesterolemic effect of a new probiotic mix composed by: B. breve WC 0463, 
B. breve  WC 0420, and B. bifidum  WC 0417. Our findings strength the hypothesized ability of 
bifidobacteria in reducing serum cholesterol level. In particular, the probiotic mix counteracted the 
effect of a high-cholesterol diet reducing LDL-cholesterol fraction by 30%. 
Although the herein reported studies are far from being conclusive, they could represent a 
further step in the recognition of the effects and mechanisms of action of different bioactives 
commonly used for cholesterol lowering.  
To find active biological compounds, elucidating their mechanism of action, is crucial for 
the identification of the suitable combinations of molecules able to promote health. Keeping in 
mind that a single bioactive cannot exert the same effect of a pharmacological drug, an overall 
nutritional strategy could be able to prevent the onset of diseases, therefore avoiding 
pharmacological therapy. 
 
